<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">1964</journal-id><journal-id journal-id-type="pmc-domain">intjoncol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-title-group><journal-title>International Journal of Oncology</journal-title></journal-title-group><issn pub-type="ppub">1019-6439</issn><issn pub-type="epub">1791-2423</issn><publisher><publisher-name>Spandidos Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11173371</article-id><article-id pub-id-type="pmcid-ver">PMC11173371.1</article-id><article-id pub-id-type="pmcaid">11173371</article-id><article-id pub-id-type="pmcaiid">11173371</article-id><article-id pub-id-type="pmid">38847236</article-id><article-id pub-id-type="doi">10.3892/ijo.2024.5660</article-id><article-id pub-id-type="publisher-id">ijo-65-01-05660</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Glutathione-degrading enzymes in the complex landscape of tumors (Review)</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="T">Tianyi</given-names></name><xref rid="af1-ijo-65-01-05660" ref-type="aff">1</xref><xref rid="af2-ijo-65-01-05660" ref-type="aff">2</xref><xref rid="fn1-ijo-65-01-05660" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yao</surname><given-names initials="C">Chongjie</given-names></name><xref rid="af2-ijo-65-01-05660" ref-type="aff">2</xref><xref rid="af3-ijo-65-01-05660" ref-type="aff">3</xref><xref rid="fn1-ijo-65-01-05660" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="X">Xu</given-names></name><xref rid="af2-ijo-65-01-05660" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="S">Shimin</given-names></name><xref rid="af2-ijo-65-01-05660" ref-type="aff">2</xref><xref rid="af4-ijo-65-01-05660" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qi</surname><given-names initials="L">Li</given-names></name><xref rid="af5-ijo-65-01-05660" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="S">Shiguo</given-names></name><xref rid="af6-ijo-65-01-05660" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="C">Chen</given-names></name><xref rid="af2-ijo-65-01-05660" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hu</surname><given-names initials="D">Dan</given-names></name><xref rid="af2-ijo-65-01-05660" ref-type="aff">2</xref><xref rid="c2-ijo-65-01-05660" ref-type="corresp"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Shen</surname><given-names initials="W">Weidong</given-names></name><xref rid="af1-ijo-65-01-05660" ref-type="aff">1</xref><xref rid="c1-ijo-65-01-05660" ref-type="corresp"/></contrib></contrib-group><aff id="af1-ijo-65-01-05660">
<label>1</label>Department of Acupuncture, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China;</aff><aff id="af2-ijo-65-01-05660">
<label>2</label>School of Acupuncture-moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China;</aff><aff id="af3-ijo-65-01-05660">
<label>3</label>Department of Rehabilitation, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China;</aff><aff id="af4-ijo-65-01-05660">
<label>4</label>Shanghai Research Institute of Acupuncture and Meridian, Shanghai 200030, P.R. China;</aff><aff id="af5-ijo-65-01-05660">
<label>5</label>Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China;</aff><aff id="af6-ijo-65-01-05660">
<label>6</label>School of Basic Medical Sciences, Center for Traditional Chinese Medicine and Immunology Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China</aff><author-notes><corresp id="c1-ijo-65-01-05660">Correspondence to: Professor Weidong Shen, Department of Acupuncture, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Shanghai 201203, P.R. China, E-mail: <email>shenweidong1018@163.com</email></corresp><corresp id="c2-ijo-65-01-05660">Professor Dan Hu, School of Acupuncture-moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, P.R. China, E-mail: <email>273013745@qq.com</email></corresp><fn id="fn1-ijo-65-01-05660" fn-type="equal"><label>*</label><p>Contributed equally</p></fn></author-notes><pub-date pub-type="collection"><month>7</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>03</day><month>6</month><year>2024</year></pub-date><volume>65</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">464345</issue-id><elocation-id>72</elocation-id><history><date date-type="received"><day>30</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>4</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>06</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>13</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-22 12:25:26.333"><day>22</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright: &#169; 2024 Zhang et al.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijo-65-01-05660.pdf"/><abstract><p>Glutathione (GSH)-degrading enzymes are essential for starting the first stages of GSH degradation. These enzymes include extracellular &#947;-glutamyl transpeptidase (GGT) and intracellular GSH-specific &#947;-glutamylcyclotransferase 1 (ChaC1) and 2. These enzymes are essential for cellular activities, such as immune response, differentiation, proliferation, homeostasis regulation and programmed cell death. Tumor tissue frequently exhibits abnormal expression of GSH-degrading enzymes, which has a key impact on the development and spread of malignancies. The present review summarizes gene and protein structure, catalytic activity and regulation of GSH-degrading enzymes, their vital roles in tumor development (including regulation of oxidative and endoplasmic reticulum stress, control of programmed cell death, promotion of inflammation and tumorigenesis and modulation of drug resistance in tumor cells) and potential role as diagnostic biomarkers and therapeutic targets.</p></abstract><kwd-group><title>Key words</title><kwd>GSH degrading enzyme</kwd><kwd>GGT</kwd><kwd>ChaC1</kwd><kwd>tumor</kwd></kwd-group><funding-group><award-group><funding-source>Shanghai Style TCM Inheritance and Innovation Team Building</funding-source><award-id>2021LPTD-004</award-id></award-group><award-group><funding-source>Natural Science Foundation of Shanghai</funding-source><award-id>19ZR1457500</award-id><award-id>19ZR1460800</award-id><award-id>18ZR1440300</award-id></award-group><award-group><funding-source>Research Project of Shanghai Health Commission</funding-source><award-id>202140348</award-id></award-group><funding-statement>The present study was supported by the Shanghai Style TCM Inheritance and Innovation Team Building Project (grant no. 2021LPTD-004), Natural Science Foundation of Shanghai (grant nos. 19ZR1457500, 19ZR1460800 and 18ZR1440300) and Research Project of Shanghai Health Commission (grant no. 202140348).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>Glutathione (GSH), also known as &#947;-glutamylcysteylglycine, is the most common small molecular weight thiol molecule generated in living cells (<xref rid="b1-ijo-65-01-05660" ref-type="bibr">1</xref>). It is extensively present in all eukaryotes and is particularly concentrated in the liver. GSH manifests in two forms, mercaptan reduction (GSH) and disulfide oxidation (GSSG). GSH is the more common form, with a concentration &gt;100 times higher than that of GSSG (<xref rid="b2-ijo-65-01-05660" ref-type="bibr">2</xref>). Synthesized from glutamic acid, cysteine, and glycine, GSH serves a pivotal role in the pathway using niacinamide adenine dinucleotide to establish a reducing environment key for cellular function. A previous study (<xref rid="b3-ijo-65-01-05660" ref-type="bibr">3</xref>) underscored the crucial involvement of GSH in diverse cellular processes, including immunological function, cell proliferation, differentiation and programmed cell death. As a regulator agent in key signal transduction pathways, GSH is involved in maintaining cellular homeostasis. The dysregulation of GSH expression strongly correlates with onset and progression of numerous types of disease, including tumors (<xref rid="b4-ijo-65-01-05660" ref-type="bibr">4</xref>), liver disease (<xref rid="b5-ijo-65-01-05660" ref-type="bibr">5</xref>), diabetes (<xref rid="b6-ijo-65-01-05660" ref-type="bibr">6</xref>) and neurodegenerative disease (<xref rid="b7-ijo-65-01-05660" ref-type="bibr">7</xref>,<xref rid="b8-ijo-65-01-05660" ref-type="bibr">8</xref>). Tumor cells require elevated GSH levels to combat reactive oxygen species (ROS) and detoxify carcinogens. Thus, decreasing intracellular GSH renders tumor cells more susceptible to oxidative stress and chemotherapeutic drugs (<xref rid="b9-ijo-65-01-05660" ref-type="bibr">9</xref>).</p><p>While existing studies (<xref rid="b2-ijo-65-01-05660" ref-type="bibr">2</xref>,<xref rid="b4-ijo-65-01-05660" ref-type="bibr">4</xref>) predominantly focused on the anabolic aspects of GSH metabolism, the catabolic process of GSH has received limited attention (<xref rid="b10-ijo-65-01-05660" ref-type="bibr">10</xref>,<xref rid="b11-ijo-65-01-05660" ref-type="bibr">11</xref>). Previously, the cytoplasm was hypothesized to have no role in GSH catabolism. However, the identification of novel GSH degradation pathways in the cytosol (<xref rid="b12-ijo-65-01-05660" ref-type="bibr">12</xref>,<xref rid="b13-ijo-65-01-05660" ref-type="bibr">13</xref>) underscores the importance of exploring GSH degradation. GSH-degrading enzymes are essential for maintaining GSH homeostasis in cells. Dysregulation of these enzymes significantly impacts GSH homeostasis, leading to pathological changes. Such dysregulation is frequently observed in tumor tissue and has been shown to play an essential role in tumor development (<xref rid="b14-ijo-65-01-05660" ref-type="bibr">14</xref>,<xref rid="b15-ijo-65-01-05660" ref-type="bibr">15</xref>). Since different GSH-degrading enzymes are oriented to either intracellular or extracellular GSH pools, intracellular degrading enzymes directly decrease intracellular levels of GSH. By contrast, extracellular degrading enzyme produces cysteine, providing an additional rate-limiting amino acid for resynthesis of intracellular GSH (<xref rid="b16-ijo-65-01-05660" ref-type="bibr">16</xref>). Therefore, different GSH-degrading enzymes exhibit different effects on cancer, either promoting or suppressing it, and their specific functions varies according to the type of tissue and tumor. In addition, the levels of GSH degradation products glutamic acid, cysteine and glycine serve as growth factors, proliferation stimulators and signal transducers of tumor cells (<xref rid="b17-ijo-65-01-05660" ref-type="bibr">17</xref>,<xref rid="b18-ijo-65-01-05660" ref-type="bibr">18</xref>). Thus, understanding of GSH-degrading enzymes and their roles in cancer is imperative for developing more effective therapeutic interventions.</p><p>The present review summarizes the crucial role of enzymes in GSH degradation in tumors, as well as their potential as biomarkers and targets for tumor therapy and their potential directions for clinical translation in tumor therapies.</p></sec><sec sec-type="other"><title>2. Extracellular and intracellular GSH-degrading enzymes</title><p>Initiation steps in the mammalian GSH degradation pathway fall into two categories, intracellular and extracellular degradation (<xref rid="f1-ijo-65-01-05660" ref-type="fig">Fig. 1</xref>) (<xref rid="b10-ijo-65-01-05660" ref-type="bibr">10</xref>). The first category is classical GSH degradation, which commences with extracellular enzyme &#947;-glutamyl transpeptidase (GGT) (<xref rid="b11-ijo-65-01-05660" ref-type="bibr">11</xref>). Intracellular GSH is released into the extracellular space via multidrug-resistant protein 1-mediated transporter (<xref rid="b19-ijo-65-01-05660" ref-type="bibr">19</xref>). Once outside the cell, GSH is hydrolyzed to Cys-Gly and glutamate by plasma membrane-bound GGT, marking the initial step in extracellular GSH degradation. Discoveries in the cytoplasmic cation transport regulator homolog (ChaC) family of &#947;-glutamylcyclotransferases have expanded the understanding of GSH degradation (<xref rid="b12-ijo-65-01-05660" ref-type="bibr">12</xref>,<xref rid="b13-ijo-65-01-05660" ref-type="bibr">13</xref>). This family, including ChaC1 and ChaC2, directly breaks down GSH within the cell into Cys-Gly and 5-oxoproline (<xref rid="b11-ijo-65-01-05660" ref-type="bibr">11</xref>,<xref rid="b20-ijo-65-01-05660" ref-type="bibr">20</xref>).</p><sec><title>GGT: Classical perspective</title><p>GGT, a core component of the &#947;-glutamyl cycle (<xref rid="b21-ijo-65-01-05660" ref-type="bibr">21</xref>), has long been associated with GSH degradation, predating the discovery of the ChaC family. Initially considered the sole enzyme capable of degrading GSH, GGT hydrolyzes the &#947;-glutamyl bond of extracellular reduced and oxidized GSH (<xref rid="b22-ijo-65-01-05660" ref-type="bibr">22</xref>). This results in cleaved glutamate, cysteine and glycine while facilitating the transfer of &#947;-glutamyl moiety of GSH to either water (hydrolysis) or substrates such as peptides (transpeptidation). Consequently, GGT is classified as a bisubstrate enzyme (<xref rid="b23-ijo-65-01-05660" ref-type="bibr">23</xref>).</p><p>GGT is a glycosylated heterodimer protein formed by the non-covalent combination of a heavy chain subunit (relative molecular mass, 50,000-62,000) and a light chain subunit (relative molecular mass 22,000-30,000; <xref rid="f2-ijo-65-01-05660" ref-type="fig">Fig. 2</xref>) (<xref rid="b24-ijo-65-01-05660" ref-type="bibr">24</xref>). The human GGT family members are synthesized and cleaved by an autocatalytic processing reaction. They have a conserved 'sandwich-like' three-dimensional domain with four layers of &#945;&#946;&#946;&#945; folds (<xref rid="b23-ijo-65-01-05660" ref-type="bibr">23</xref>). The catalytic site of GGT consists of two successive regions: Well-characterized donor site, specifying the substrates to which donor &#947;-glutamyl groups bind, and the acceptor site, about which little is currently known regarding the involved residues (<xref rid="b24-ijo-65-01-05660" ref-type="bibr">24</xref>).</p><p>Anchored in the plasma membrane by the N-terminus of the heavy chain across the membrane segment, GGT protein, under physiological conditions, is typically confined to the plasma membrane. It is distributed on the apical surface of epithelial and endothelial cells in glands and lumens. A unique characteristic of GGT is that it is located on the extracellular surface of mammalian cells with a catalytic active site oriented to the extracellular environment (<xref rid="b11-ijo-65-01-05660" ref-type="bibr">11</xref>). The kidney expresses GGT at the highest levels, while notable expression is also found in bile canaliculi of hepatocytes, ducts within the pancreas, the apical surface of the intestinal epithelium and the luminal surface epithelium of many reproductive organs (<xref rid="b25-ijo-65-01-05660" ref-type="bibr">25</xref>).</p></sec><sec><title>GGT gene family and proteins</title><p>A GGT gene family exists in the human genome (<xref rid="tI-ijo-65-01-05660" ref-type="table">Table I</xref>), suggesting that regulating GGT activity may be associated with activating different GGT genes rather than identifying distinct gene loci (<xref rid="b26-ijo-65-01-05660" ref-type="bibr">26</xref>).</p><p>The human genome sequence contains 13 GGT homologs, the most active of which is GGT. The GGT gene was first discovered on human chromosome 22 at q11.1-q11.2 (<xref rid="b27-ijo-65-01-05660" ref-type="bibr">27</xref>), although it was also subsequently discovered on additional autosomes (<xref rid="b26-ijo-65-01-05660" ref-type="bibr">26</xref>). In addition, two homologs, GGTLC1 (previously GGTL6, GGTLA4) and GGTLC2, which may only encode the light-chain portion of GGT, as well as at least three other homologs, exhibit activity: GGT5 (formerly GGL, GGTLA1/GGT-rel), GGT6 (formerly rat GGT6 homologous) and GGT7 (formerly GGTL3, GGT4) (<xref rid="b28-ijo-65-01-05660" ref-type="bibr">28</xref>). While GGT5 and GGT1 share 40% of the amino acid sequence (<xref rid="b22-ijo-65-01-05660" ref-type="bibr">22</xref>), GGT5 is not as active in hydrolyzing GSH, GSSG and leukotriene C4 as GGT1 is (<xref rid="b29-ijo-65-01-05660" ref-type="bibr">29</xref>). Despite the absence of verified protein-coding activity, GGT6 and GGT7 exhibit aberrant expression in conditions such as tumors (<xref rid="b30-ijo-65-01-05660" ref-type="bibr">30</xref>-<xref rid="b32-ijo-65-01-05660" ref-type="bibr">32</xref>) and pancreatic disease (<xref rid="b33-ijo-65-01-05660" ref-type="bibr">33</xref>). Furthermore, proteins expressed by the human GGT2 gene share 94% of the amino acid sequence encoded by GGT1 (<xref rid="b34-ijo-65-01-05660" ref-type="bibr">34</xref>), even though GGT2 only encodes inactive pro-peptides. GGT2 also exhibits abnormal expression in tumors (<xref rid="b30-ijo-65-01-05660" ref-type="bibr">30</xref>) and upregulating GGT2 can overcome H<sub>2</sub>O<sub>2</sub>-induced apoptosis (<xref rid="b35-ijo-65-01-05660" ref-type="bibr">35</xref>). These findings suggest that GGTs play potential roles in disease physiology and pathology.</p></sec><sec><title>Catalytic activity of GGT</title><p>As a member of the N-terminal nucleophilic hydrolase superfamily (Ntn), GGT uses a highly conserved catalytic mechanism. An N-terminal Thr residue is essential for substrate priming in human GGT (<xref rid="b22-ijo-65-01-05660" ref-type="bibr">22</xref>), with the substrate binding site featuring a key Thr side chain. This facilitates conversion of the &#947;-glutamyl bond of GSH into an acyl bond, releasing Cys-Gly and glutamate (<xref rid="b11-ijo-65-01-05660" ref-type="bibr">11</xref>).</p></sec><sec><title>GGT gene expression</title><p>While the human GGT gene is not fully characterized, evidence suggests its existence in multiple copies within the human genome (<xref rid="b36-ijo-65-01-05660" ref-type="bibr">36</xref>). As GGT mRNAs share a common coding sequence and have 59 untranslated regions (UTRs), its structural complexity is evident (<xref rid="b37-ijo-65-01-05660" ref-type="bibr">37</xref>). Understanding of the human GGT promoter remains limited (<xref rid="b38-ijo-65-01-05660" ref-type="bibr">38</xref>).</p><p>A number of promoters control human GGT transcription, and the resulting transcripts undergo selective splicing in untranslated regions and coding sequences (<xref rid="b37-ijo-65-01-05660" ref-type="bibr">37</xref>). The initiation of GGT mRNA transcription involves cis-reactive elements, including the cis-regulatory element (TRE) and the binding element for activator protein 1 (AP-1) (<xref rid="b38-ijo-65-01-05660" ref-type="bibr">38</xref>). TRE, also known as 12-O-tetracylacylphobolol 13 acetic acid reactive element, incorporates binding sites for activating protein 2 (AP-2) and specific protein 1 (Sp1; <xref rid="f3-ijo-65-01-05660" ref-type="fig">Fig. 3</xref>).</p><p>A study (<xref rid="b39-ijo-65-01-05660" ref-type="bibr">39</xref>) on HeLa cells highlighted that phorbol 12-myric acid 13-acetic acid enhance the expression of human GGT, pinpointing its binding site at the AP-1 binding site 2,214/2,225 nucleotides upstream from the transcription start site. More research is necessary to understand the transcriptional mechanism of the human GGT gene and promoters.</p><p>Although rat and human GGT promoters may have similar structures, the human promoter is more complex. As the rat GGT gene is single-copy, replicating unique genes after species transfer between rats and humans likely results in multiple human GGT genes (<xref rid="b40-ijo-65-01-05660" ref-type="bibr">40</xref>). Therefore, rat GGT may provide insight into human GGT expression and regulation.</p><p>In rats, GGT expression is controlled by a tandem P1-P5 promoter, facilitated by variable splicing. This yields transcripts sharing the same coding region and diverse 5'-UTRs (<xref rid="b38-ijo-65-01-05660" ref-type="bibr">38</xref>). These unique promoters have high tissue stage-specificity (<xref rid="b38-ijo-65-01-05660" ref-type="bibr">38</xref>).</p></sec><sec><title>GGT regulation</title><p>Upregulation of GGT activity is primarily dependent on the Ras protein and its downstream effectors, which include extracellular signal-regulated kinase 1/2 (ERK1/2), p38 mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/AKT and c-Jun N-terminal kinase (JNK) signaling pathways (<xref rid="f3-ijo-65-01-05660" ref-type="fig">Fig. 3</xref>) (<xref rid="b41-ijo-65-01-05660" ref-type="bibr">41</xref>). The Ras protein is a key regulator of signaling pathways key for normal cell proliferation. Malignant phenotype of tumor cells is caused by the Ras gene, often mutated or active in tumor cells, and leads to aberrant tumor cell proliferation, programmed cell death, invasion and angiogenesis (<xref rid="b42-ijo-65-01-05660" ref-type="bibr">42</xref>).</p><p>Through the electrophile response element (EpRE), ERK1/2 and p38MAPK signaling pathways actively contribute to upregulation of GGT promoter 5 (GP5) activity in response to 4-hydroxynonenal (HNE) (<xref rid="b43-ijo-65-01-05660" ref-type="bibr">43</xref>). Following activation by redox signaling downstream of the MAPK signal pathway, the EpRE binding protein, also an oxidative stress-associated transcription factor, induces the dissociation of Nrf2 from Keap1 via redox modification and/or phosphorylation of Nrf2. Subsequently, Nrf2 translocates from cytoplasm to the nucleus, forming heterodimers with other proteins to bind to EpRE. This leads to the amplification of GGT transcription. In alveolar type II (L2) cells, EpRE motif in the proximal region of GP5 EpRE induces the expression of the major GGT transcript mRNA V-2 in the lung (<xref rid="b38-ijo-65-01-05660" ref-type="bibr">38</xref>). However, pretreatment with ERK1/2 pathway inhibitor (PD98059) or p38MAPK inhibitor (SB203580) partly decreases the expression of GGT mRNA V-2 induced by HNE in L2 cells (<xref rid="b38-ijo-65-01-05660" ref-type="bibr">38</xref>). Furthermore, activated Ras is also implicated in inducing activation of GP2 and increasing expression of GGT transcriptional products and protein in colon cancer cells treated with naphthoquinone during acute oxidative stress (<xref rid="f3-ijo-65-01-05660" ref-type="fig">Fig. 3</xref>) (<xref rid="b41-ijo-65-01-05660" ref-type="bibr">41</xref>).</p><p>Moreover, inflammatory conditions significantly enhance GGT levels by activating the NF-&#954;B pathway. NF-&#954;B, the core transcription factor in the NF-&#954;B signaling pathway, is a dimer family formed by p50/p105/NF-&#954;B1, p52/p100/NF-&#954;B2, c-Rel, p65/RelA and RelB (<xref rid="b44-ijo-65-01-05660" ref-type="bibr">44</xref>). It regulates the expression of chemokines, cytokines, transcription factors and regulatory proteins, playing a crucial role in inflammation and immunity (<xref rid="b44-ijo-65-01-05660" ref-type="bibr">44</xref>). Upon cell stimulation by an external signal, the NF-&#954;B dimer is released from its inhibitor (I&#954;B) and freely transferred into the nucleus. When the NF-&#954;B pathway is activated, it triggers production of pro-inflammatory proteins downstream, such as tumor necrosis factor-&#945; (TNF-&#945;), which in turn causes inflammatory responses and pain. Furthermore, by serving as NF-&#954;B activators, these inflammatory cytokines intensify inflammation by further triggering the NF-&#954;B pathway (<xref rid="b45-ijo-65-01-05660" ref-type="bibr">45</xref>). In the 536 bp site of the proximal promoter of GGT, a binding site exists between p50, TNF-&#945; and Sp1, regulated by the activation of the NF-&#954;B signaling pathway, thereby promoting expression of GGT and inducing inflammatory response (<xref rid="f3-ijo-65-01-05660" ref-type="fig">Fig. 3</xref>) (<xref rid="b46-ijo-65-01-05660" ref-type="bibr">46</xref>). Moreover, it has been reported (<xref rid="b46-ijo-65-01-05660" ref-type="bibr">46</xref>) that inhibitors of the NF-&#954;B pathway can effectively block the trans-activation of GGT promoters at different levels. For example, remicade, a clinically used anti-TNF-&#945; antibody targeting the p50 and p65 NF-&#954;B subtype of small interfering RNA and curcumin, a well-characterized natural NF-&#954;B inhibitor that is also a dominant negative inhibitor of &#954;B&#945; (I&#954;B&#945;), can inhibit GGT activation through distinct mechanisms. This suggests the involvement of the NF-&#954;B pathway in regulating GGT expression. Therefore, inflammatory conditions may increase GGT synthesis, potentially acting as a cellular protective mechanism under increased oxidative stress or promoting inflammatory progression. Further research is necessary to explore these possibilities.</p></sec><sec><title>ChaC1/ChaC2: Additional perspective</title><p>In addition to the well-established extracellular GSH degradation mechanism, studies have shown an additional intracellular hydrolysis pathway for GSH degradation (<xref rid="b47-ijo-65-01-05660" ref-type="bibr">47</xref>,<xref rid="b48-ijo-65-01-05660" ref-type="bibr">48</xref>). ChaC protein features a BtrG/&#947;-GCT fold and distinctive &#946;-barrels surrounded by &#945;-helices (<xref rid="f4-ijo-65-01-05660" ref-type="fig">Fig. 4</xref>) (<xref rid="b13-ijo-65-01-05660" ref-type="bibr">13</xref>). Mammals exhibit two isoforms of ChaC: Mammalian pro-apoptotic factor ChaC1 (formerly MGC4504) and its homologous counterpart ChaC2. Conversely, only one ChaC member is present in lower eukaryotes, especially in unicellular eukaryotes (<xref rid="b47-ijo-65-01-05660" ref-type="bibr">47</xref>).</p></sec><sec><title>Gene and protein structure of ChaC1/ChaC2</title><p>The human ChaC1 gene is on chromosome 15q15.1 and comprises three exons, encoding a protein with 222 amino acid residues and a molecular weight of ~25 kDa (<xref rid="b49-ijo-65-01-05660" ref-type="bibr">49</xref>). ChaC1, 30% identical to mammalian and prokaryotic genes, serves a crucial role in basic physiology (<xref rid="b12-ijo-65-01-05660" ref-type="bibr">12</xref>).</p><p>ChaC2 is on chromosome 2p16.2 and encodes a protein with 184 amino acid residues and a molecular weight of ~20.9 kDa (<xref rid="b20-ijo-65-01-05660" ref-type="bibr">20</xref>,<xref rid="b47-ijo-65-01-05660" ref-type="bibr">47</xref>,<xref rid="b50-ijo-65-01-05660" ref-type="bibr">50</xref>). A phylogenetic study (<xref rid="b47-ijo-65-01-05660" ref-type="bibr">47</xref>) highlighted that ChaC2 evolved earlier than ChaC1 and shares key structural similarities with ChaC proteins of lower eukaryotes. Human ChaC2 and ChaC1 share 50% of their protein identity (<xref rid="b47-ijo-65-01-05660" ref-type="bibr">47</xref>). ChaC2 typically exists in dimer crystals with a unique flexible loop 2 structure, with an open conformation that can facilitate close contact with crystallographically adjacent ChaC2 molecules. Additionally, ChaC2 E74Q/E83Q active site mutants exhibit a closed conformation, regulating the degradation activity of ChaC2 to GSH (<xref rid="b20-ijo-65-01-05660" ref-type="bibr">20</xref>).</p></sec><sec><title>Catalytic activity of ChaC1/ChaC2</title><p>ChaC1, an inducible enzyme, can be expressed under specific stresses or pathological conditions (<xref rid="b12-ijo-65-01-05660" ref-type="bibr">12</xref>,<xref rid="b47-ijo-65-01-05660" ref-type="bibr">47</xref>). It selectively hydrolyzes GSH, producing Cys-Gly and 5-oxoproline (a cyclized form of glutamate) (<xref rid="b11-ijo-65-01-05660" ref-type="bibr">11</xref>,<xref rid="b51-ijo-65-01-05660" ref-type="bibr">51</xref>), thereby accelerating formation of the cellular oxidative environment. The Michaelis constant of ChaC1 for GSH is ~2.2&#177;0.4 mM (<xref rid="b47-ijo-65-01-05660" ref-type="bibr">47</xref>), comparable with the concentration of intracellular GSH (1-10 mM) under physiological conditions. ChaC1 often forms dimers or tetramers, with dimerization being key for regulating enzyme activity and substrate specificity. Under stress or tumor growth, there is an increased need for enzyme breakdown, which leads to formation of dimers or longer oligomers of ChaC1 (<xref rid="b20-ijo-65-01-05660" ref-type="bibr">20</xref>).</p><p>ChaC2 is constitutively expressed and exhibits catalytic efficiency for GSH 10-20 times weaker than that of ChaC1 (<xref rid="b47-ijo-65-01-05660" ref-type="bibr">47</xref>). The lower activity of ChaC2 may be partly attributed to flexible loop 2, acting as a gating function to achieve specificity for GSH binding and regulate a constant GSH degradation rate. In addition, the Glu74 and Glu83 residues of ChaC2 are key for directing the conformation of the enzyme and regulating enzyme activity (<xref rid="b20-ijo-65-01-05660" ref-type="bibr">20</xref>).</p></sec><sec><title>Expression and regulation of ChaC1/ChaC2</title><p>Various signals, including endoplasmic reticulum (ER) and oxidative stress and viral infection, activate ChaC1 promoters in different cell types, cellular processes and diseases through the unfolded protein response (UPR) (<xref rid="b12-ijo-65-01-05660" ref-type="bibr">12</xref>,<xref rid="b48-ijo-65-01-05660" ref-type="bibr">48</xref>,<xref rid="b52-ijo-65-01-05660" ref-type="bibr">52</xref>). ChaC1 is downstream of the protein kinase R-like ER kinase (PERK)/eukaryotic initiation factor-2&#945; (eIF2&#945;)/activating transcription factor (ATF) 4/ATF3/CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) pathway, serving as a pro-apoptotic and pro-ferroptosis component downstream of UPR. ATF4, ATF3, CHOP and C/EBP-&#946; upregulate ChaC1 transcription (<xref rid="f5-ijo-65-01-05660" ref-type="fig">Fig. 5</xref>). The activation of ChaC1 by UPR primarily relies on ATF4, while the involvement of CHOP, C/EBP-&#946;, and ATF3 is indirect (<xref rid="b12-ijo-65-01-05660" ref-type="bibr">12</xref>). A direct relationship between ATF4 and regulatory elements within the ChaC1 promoter has been identified. A-267 ATF/cAMP response element (CRE) in conjunction with a novel-248 ATF/CRE modifier (ACM), serving as a binding site for ATF4 and ATF3 transcription factors, regulates the activity of the basic ChaC1 promoter. Among these elements, ATF3 predominantly regulates the basal and stress-induced expression of ChaC1 through ATF/CRE, while ATF4 primarily regulates stress-induced ChaC1 expression through ATF/CRE and ACM (<xref rid="b48-ijo-65-01-05660" ref-type="bibr">48</xref>). Additionally, conserved-209 CEBP-ATF response element has a limited impact on regulating human ChaC1 transcription (<xref rid="b48-ijo-65-01-05660" ref-type="bibr">48</xref>,<xref rid="b53-ijo-65-01-05660" ref-type="bibr">53</xref>).</p><p>Amino acid starvation can induce the expression of ChaC1 (<xref rid="f5-ijo-65-01-05660" ref-type="fig">Fig. 5</xref>). The amino acid starvation response activates ATF4 via the general control nonderepressible 2 (GCN2)/eIF2a/ATF4/ATF3 pathway (<xref rid="b54-ijo-65-01-05660" ref-type="bibr">54</xref>). Both ER stress and amino acid starvation induce stress synergistically by activating ATF4 and ChaC1 is one of the downstream targets of ATF4. In regulating ChaC1 expression, C/EBP-&#946; has been observed to recruit ATF4 to the ChaC1 promoter in response to ER stress (<xref rid="b48-ijo-65-01-05660" ref-type="bibr">48</xref>). However, the precise C/EBP-&#946; response element on the ChaC1 promoter remains unclear (<xref rid="b48-ijo-65-01-05660" ref-type="bibr">48</xref>). Further studies are necessary to elucidate the detailed mechanism of C/EBP-&#946;-mediated ATF4 recruitment and its impact on ChaC1 expression. These findings highlight the intricate nature of ChaC1 transcriptional regulation and underscore the importance of maintaining appropriate redox balance in cells (<xref rid="b48-ijo-65-01-05660" ref-type="bibr">48</xref>). The mechanism governing ChaC1 protein expression requires further characterization.</p><p>Understanding of the regulation mechanism of ChaC2 is limited. A previous study (<xref rid="b47-ijo-65-01-05660" ref-type="bibr">47</xref>) suggested that ChaC2 is expressed at higher basal levels under physiological conditions than ChaC1. However, under cellular stress such as ER stress or amino acid starvation, ChaC1 is upregulated, while ChaC2 expression remains unaffected (<xref rid="b47-ijo-65-01-05660" ref-type="bibr">47</xref>). Thus, ChaC2 serves as a constitutively expressed protein for basal hydrolysis of GSH, acting as a steward for slow and continuous GSH turnover (<xref rid="b47-ijo-65-01-05660" ref-type="bibr">47</xref>).</p></sec></sec><sec sec-type="other"><title>3. GSH-degrading enzymes in tumorigenesis and progression</title><p>Tumor cells enhance GGT expression across the entire cell membrane, facilitating the acquisition of additional cysteine and cystine from GSH in blood and interstitial fluid to replenish intracellular GSH levels (<xref rid="b22-ijo-65-01-05660" ref-type="bibr">22</xref>). Consequently, aberrant GGT expression is observed in various types of cancer, including ovarian (<xref rid="b55-ijo-65-01-05660" ref-type="bibr">55</xref>), renal cell (<xref rid="b56-ijo-65-01-05660" ref-type="bibr">56</xref>), lung (<xref rid="b57-ijo-65-01-05660" ref-type="bibr">57</xref>), stomach (<xref rid="b58-ijo-65-01-05660" ref-type="bibr">58</xref>) and pancreatic cancer (<xref rid="b59-ijo-65-01-05660" ref-type="bibr">59</xref>). Elevated GGT expression is generally associated with poor prognosis, as patients with high levels of GGT in tumors exhibit shorter overall and progression-free survival (<xref rid="b60-ijo-65-01-05660" ref-type="bibr">60</xref>). However, some breast tumor tissues exhibit GGT loss (<xref rid="b61-ijo-65-01-05660" ref-type="bibr">61</xref>).</p><p>Studies (<xref rid="b54-ijo-65-01-05660" ref-type="bibr">54</xref>,<xref rid="b62-ijo-65-01-05660" ref-type="bibr">62</xref>,<xref rid="b63-ijo-65-01-05660" ref-type="bibr">63</xref>) of the ChaC family have yielded conflicting findings regarding ChaC expression and its role in tumor tissues, emphasizing the complexity of GSH regulation and function. ChaC1, as a tumor-influencing factor, enhances ER stress, contributing to necroptosis and ferroptosis of multiple cancers, including metastatic melanoma (<xref rid="b64-ijo-65-01-05660" ref-type="bibr">64</xref>), breast (<xref rid="b54-ijo-65-01-05660" ref-type="bibr">54</xref>), prostate (<xref rid="b65-ijo-65-01-05660" ref-type="bibr">65</xref>) and primary liver cancer (<xref rid="b66-ijo-65-01-05660" ref-type="bibr">66</xref>), Burkitt's Lymphoma (<xref rid="b67-ijo-65-01-05660" ref-type="bibr">67</xref>), head and neck squamous cell carcinoma (<xref rid="b68-ijo-65-01-05660" ref-type="bibr">68</xref>), glioblastoma multiforme (GBM) (<xref rid="b69-ijo-65-01-05660" ref-type="bibr">69</xref>), oral squamous cell carcinoma, T lymphoblastic leukemia Molt4 cells and colitis-associated carcinogenesis (<xref rid="b15-ijo-65-01-05660" ref-type="bibr">15</xref>). Decreased ChaC1 expression is an indicator of poor prognosis in kidney renal clear cell carcinoma (KIRC) (<xref rid="b70-ijo-65-01-05660" ref-type="bibr">70</xref>) and certain types of gastric cancer (<xref rid="b71-ijo-65-01-05660" ref-type="bibr">71</xref>,<xref rid="b72-ijo-65-01-05660" ref-type="bibr">72</xref>). Conversely, reports suggest that ChaC1 overexpression may be associated with tumor cell dedifferentiation, proliferation, invasion and migration, leading to lower patient survival rates (<xref rid="b73-ijo-65-01-05660" ref-type="bibr">73</xref>,<xref rid="b74-ijo-65-01-05660" ref-type="bibr">74</xref>). ChaC1 serves as a reliable indicator for poor prognosis of certain types of gastric cancer (<xref rid="b63-ijo-65-01-05660" ref-type="bibr">63</xref>) and melanoma (<xref rid="b75-ijo-65-01-05660" ref-type="bibr">75</xref>,<xref rid="b76-ijo-65-01-05660" ref-type="bibr">76</xref>), as well as an independent indicator for elevated risk for female germ line tumors (including breast and ovarian cancer) (<xref rid="b77-ijo-65-01-05660" ref-type="bibr">77</xref>). Therefore, different effects of ChaC1 may be linked to the specific functions of GSH in different types of tumor tissues.</p><p>ChaC2 may be implicated in numerous vital physiological functions, including DNA replication and repair, cell cycle regulation, RNA and damaged DNA binding, oocyte meiosis and maturation (<xref rid="b50-ijo-65-01-05660" ref-type="bibr">50</xref>). Its important physiological role was initially discerned in undifferentiated human embryonic stem cells (hESCs), where ChaC2 is prominently expressed and maintains cell self-renewal and pluripotency by modulating GSH homeostasis. Conversely, downregulation of ChaC2 decelerates the cell cycle progression of hESCs and triggers cell death (<xref rid="b78-ijo-65-01-05660" ref-type="bibr">78</xref>), underscoring its pivotal role in regulating human growth and development. In pathological functions, ChaC2 exhibits a multifaceted role in tumor tissue. Generally acting as a tumor suppressor, ChaC2 decreases GSH levels in tumor cells, instigates mitochondrial apoptosis and autophagy via UPR and hinders tumor cell proliferation and migration <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> (<xref rid="b79-ijo-65-01-05660" ref-type="bibr">79</xref>). Therefore, ChaC2 expression is commonly downregulated in tumor tissues, such as gastric and colorectal cancer (<xref rid="b79-ijo-65-01-05660" ref-type="bibr">79</xref>). ChaC2 may exert a tissue-specific function, promoting the survival of tumor cells in specific contexts (<xref rid="b50-ijo-65-01-05660" ref-type="bibr">50</xref>,<xref rid="b81-ijo-65-01-05660" ref-type="bibr">81</xref>,<xref rid="b82-ijo-65-01-05660" ref-type="bibr">82</xref>). The expression of ChaC2 increases with progression of lymph node metastasis and the stage of breast cancer, aligning with findings of GGT loss (<xref rid="b61-ijo-65-01-05660" ref-type="bibr">61</xref>) and increased ChaC1 expression (<xref rid="b77-ijo-65-01-05660" ref-type="bibr">77</xref>) in breast cancer cells. The increased expression of ChaC2 is associated with the high expression of p53 (<xref rid="b50-ijo-65-01-05660" ref-type="bibr">50</xref>), and ChaC2 is the upstream regulator of the main antioxidant regulator Nrf2 (<xref rid="b78-ijo-65-01-05660" ref-type="bibr">78</xref>). In addition mutated p53 regulates NRF2-dependent antioxidant responses that are critical for supporting cancer cell survival (<xref rid="b83-ijo-65-01-05660" ref-type="bibr">83</xref>). Therefore, increased ChaC2 expression may be related to regulating the binding of p53 mutants to Nrf2. When transcription and activity of GSH synthase is increased, the GSH level of the tissue is increased (<xref rid="b80-ijo-65-01-05660" ref-type="bibr">80</xref>). The GSH overexpression then foster the survival and proliferation of tumor cells. Additionally, increased ChaC2 expression targets the Cadherin 1 gene (encoding E-cadherin) mutation, resulting in E-cadherin loss, increased epithelial-mesenchymal transformation and lymph node metastasis, ultimately contributing to the low differentiation of breast cancer (<xref rid="b50-ijo-65-01-05660" ref-type="bibr">50</xref>). Consequently, overall ChaC2 expression is associated with lymph node metastasis and stage progression of breast cancer. ChaC2 promotes lung adenocarcinoma growth by elevating ROS levels and activating MAPK signaling pathways (<xref rid="b81-ijo-65-01-05660" ref-type="bibr">81</xref>).</p><p>GGT serves as an extracellular degradation enzyme of GSH, catalyzing enzymatic degradation products to enter cells and providing an additional cysteine source for intracellular GSH synthesis. Intracellular degrading enzymes ChaC1 and ChaC2 play a key role in downregulating intracellular GSH levels, exerting a counteractive effect to regulate intracellular GSH homeostasis. The functions of GGT and ChaC1/ChaC2 include regulation of oxidative and ER stress (<xref rid="b38-ijo-65-01-05660" ref-type="bibr">38</xref>,<xref rid="b84-ijo-65-01-05660" ref-type="bibr">84</xref>), modulation of programmed cell death (<xref rid="b85-ijo-65-01-05660" ref-type="bibr">85</xref>), promotion of inflammation and cell drug resistance (<xref rid="b24-ijo-65-01-05660" ref-type="bibr">24</xref>,<xref rid="b86-ijo-65-01-05660" ref-type="bibr">86</xref>) (<xref rid="f6-ijo-65-01-05660" ref-type="fig">Fig. 6</xref>).</p><p>GSH degradation products such as glutamic acid, glycine and cysteine also play key roles in the metabolic network of the tumor environment. For example, glutamate regulates proliferation, migration and survival of neuroprogenitor cells and immature neurons. While the ability to proliferate and migrate uncontrollably is characteristic of tumor cells, glutamate has been shown to serve as a growth factor and signaling medium in certain types of tumor tissues in both an autocrine and paracrine manner (<xref rid="b17-ijo-65-01-05660" ref-type="bibr">17</xref>). Glycine is involved in cell transformation and tumorigenesis via cleavage into one-carbon metabolism (<xref rid="b18-ijo-65-01-05660" ref-type="bibr">18</xref>). Therefore, exploring the function of GSH-degrading enzymes in tumors may clarify the role of the complex metabolic network of tumors.</p><sec><title>Regulating oxidative and ER stress</title><p>GSH-degrading enzymes key central to coordinating cellular metabolism by regulating amino acid availability under physiological conditions (<xref rid="b11-ijo-65-01-05660" ref-type="bibr">11</xref>). The modulation of the cellular stress environment relies on regulation of GSH metabolism (<xref rid="b4-ijo-65-01-05660" ref-type="bibr">4</xref>). Tumor cells, in their quest for survival and proliferation, generate abnormally high levels of oxidative stress, partly due to increased cellular redox buffer GSH (<xref rid="b87-ijo-65-01-05660" ref-type="bibr">87</xref>). Therefore, the role of GSH-degrading enzymes is key to regulate the cell stress environment.</p><p>The GSH degradation pathway initiated by extracellular GGT effectively controls the intracellular oxidative stress environment (<xref rid="b38-ijo-65-01-05660" ref-type="bibr">38</xref>). GGT deficiency leads to oxidative stress and cellular vulnerability to oxidative damage. Animal studies (<xref rid="b88-ijo-65-01-05660" ref-type="bibr">88</xref>-<xref rid="b90-ijo-65-01-05660" ref-type="bibr">90</xref>) have indicated that GGT knockout mice exhibit 20% of the plasma cysteine concentration in wild-type mice. GGT knockout mice experience increased accumulation of DNA oxidative damage, decreased intracellular GSH levels, elevated oxidative stress and death by 10 weeks of age due to cysteine deficiency (<xref rid="b88-ijo-65-01-05660" ref-type="bibr">88</xref>). Patients with partial GGT homozygous deletions report glutathionuria and neurodevelopmental disorder (<xref rid="b91-ijo-65-01-05660" ref-type="bibr">91</xref>). Hence, maintaining regular GGT expression is essential for cellular GSH homeostasis and protecting cells against oxidative stress.</p><p>Cells overexpressing GGT gain an advantage in environments with physiological and limited cysteine concentrations by efficiently utilizing extracellular GSH as a source of cysteine (<xref rid="b92-ijo-65-01-05660" ref-type="bibr">92</xref>). Tumor cells with elevated intracellular GSH levels often induce overexpression of GGT. It has been reported (<xref rid="b22-ijo-65-01-05660" ref-type="bibr">22</xref>) that both GSH depletion and GGT inhibition significantly enhance cytotoxicity under oxidative stress in tumor cells. Tumor cells with high GGT expression demonstrate notable oxidative stress tolerance without DNA damage, while clones with low GGT expression exhibit increased sensitivity to oxidative stress and apoptosis (<xref rid="b93-ijo-65-01-05660" ref-type="bibr">93</xref>). As a marker of oxidative stress, GGT expression in advanced tumor cells surpasses that in early tumor cells. The increased oxidative stress and impaired immune responses may be key for promoting cancer progression to advanced stages and may be induced by inflammatory mediators within the tumor (<xref rid="b94-ijo-65-01-05660" ref-type="bibr">94</xref>). Therefore, upregulation of GGT in tumor cells provides a potential mechanism to resist oxidative stress and foster tumor progression.</p><p>Simultaneously, changes in the tumor microenvironment generate persistent ER stress signals in various types of tumor (<xref rid="b95-ijo-65-01-05660" ref-type="bibr">95</xref>) such as colorectal (<xref rid="b96-ijo-65-01-05660" ref-type="bibr">96</xref>), pancreatic cancer (<xref rid="b97-ijo-65-01-05660" ref-type="bibr">97</xref>) and so on. This state has a dual effect on tumor cells, on one hand controlling several tumor-promoting features, on the other hand dynamically reprogramming immune cells and inducing tumor cells autophagy, apoptosis and ferroptosis (<xref rid="b95-ijo-65-01-05660" ref-type="bibr">95</xref>). ChaC1, a component of the UPR pathway, is a target of ferroptosis induced by ER stress signals (<xref rid="b12-ijo-65-01-05660" ref-type="bibr">12</xref>). Thus, ChaC1 is as a key regulator of tumor development, metastasis and responses to chemotherapy, targeted therapy and immunotherapy.</p><p>Previous research (<xref rid="b78-ijo-65-01-05660" ref-type="bibr">78</xref>) has also revealed a broader range of functions for ChaC2 than previously understood. ChaC2 inhibits ChaC1-mediated GSH degradation, indicating competition with ChaC1 to maintain GSH homeostasis (<xref rid="b78-ijo-65-01-05660" ref-type="bibr">78</xref>). ChaC2 directly regulates GSH production via a ChaC1-independent pathway (<xref rid="b78-ijo-65-01-05660" ref-type="bibr">78</xref>). ChaC2 enhances GSH production by upregulating Nrf2, a key regulator of antioxidation, and its downstream glutamate-cysteine ligase (<xref rid="b78-ijo-65-01-05660" ref-type="bibr">78</xref>). These diverse actions underscore the importance of ChaC2 in maintaining cellular redox homeostasis and antioxidation mechanisms.</p><p>Extensive crosstalk exists between oxidative and ER stress as oxidative stress can disrupt redox homeostasis in the ER, triggering ER stress (<xref rid="b95-ijo-65-01-05660" ref-type="bibr">95</xref>). GGT and ChaC1 may be key factors in this mechanism. A study (<xref rid="b98-ijo-65-01-05660" ref-type="bibr">98</xref>) demonstrated that GGT1 and GGT7 stimulate induction of ER stress-related protein, CHOP-10 and immunoglobulin heavy chain binding protein BiP, indicating specific roles for these GGT protein subtypes in ER stress response. This suggests possible crosstalk between GGTDelta1, GGTDelta7 and ChaC1 via the ER stress/CHOP pathway. A recent study (<xref rid="b99-ijo-65-01-05660" ref-type="bibr">99</xref>) proposed that the ATF4/CHOP/ChaC1 signaling pathway might be vital for apoptosis induced by crosstalk between oxidative and ER stress. Under extreme heat stress, cells produce a large amount of ROS, leading to oxidative stress and protein misfolding in the ER, resulting in ER stress and triggering ChaC1-associated UPR. Moreover, induction of ChaC1 serves an essential regulatory role in ER stress-mediated apoptosis of cancer cells induced by the anticancer monosaccharide xylitol, leading to secondary induction of oxidative stress in treated cells and apoptosis (<xref rid="b100-ijo-65-01-05660" ref-type="bibr">100</xref>). This evidence collectively demonstrates the key role of GGT and ChaC1 in mediating crosstalk between oxidative and ER stress.</p></sec><sec><title>Modulating programmed cell death</title><p>Programmed cell death, encompassing apoptosis, ferroptosis, necrotic apoptosis and autophagy, is instigated by a series of intracellular processes (<xref rid="b101-ijo-65-01-05660" ref-type="bibr">101</xref>). GGT- and ChaC1/ChaC2-mediated intracellular GSH depletion can concurrently or sequentially initiate multiple forms of programmed cell death. Studies (<xref rid="b101-ijo-65-01-05660" ref-type="bibr">101</xref>,<xref rid="b102-ijo-65-01-05660" ref-type="bibr">102</xref>) have indicated that the GSH/GSSG redox status serves as a vital indicator of tumor programmed cell death, consistently associating programmed cell death with a decrease in the GSH/GSSG ratio. Therefore, targeting GGT and ChaC1/ChaC2 to modulate programmed cell death holds implications for tumor therapy.</p></sec><sec><title>Regulating apoptosis</title><p>Apoptosis, the quintessential programmed cell death process, primarily relies on the caspase family for initiation and is typically characterized by membrane contraction, chromatin concentration and apoptotic body formation (<xref rid="b103-ijo-65-01-05660" ref-type="bibr">103</xref>). In tumor cells, the apoptosis pathway is often impeded by various mechanisms, many of which contribute to intrinsic resistance to chemotherapy, the most prevalent anticancer therapy (<xref rid="b104-ijo-65-01-05660" ref-type="bibr">104</xref>). Reducing GSH impairs cellular antioxidant regulation, increasing ROS production, thereby accelerating mitochondrial damage and apoptosis induction (<xref rid="b101-ijo-65-01-05660" ref-type="bibr">101</xref>). Consequently, inhibiting GGT1 in tumor cells facilitates induction of apoptotic phenotypes (<xref rid="b105-ijo-65-01-05660" ref-type="bibr">105</xref>). Simultaneously, research (<xref rid="b106-ijo-65-01-05660" ref-type="bibr">106</xref>) on another member of the GGT family has shown that low GGT7 expression may elevate cell ROS levels, inhibiting apoptosis and fostering tumor proliferation. This suggests variations in regulation of ROS levels within the GGT family. ChaC1 overexpression can augment apoptosis by activating caspase-3/9, degradation of poly (ADP ribose) polymerase, induction of autophagy, ROS generation, increased intracellular calcium and loss of mitochondrial membrane potential (<xref rid="b69-ijo-65-01-05660" ref-type="bibr">69</xref>).</p></sec><sec><title>Regulating ferroptosis</title><p>Ferroptosis, a distinct iron-dependent form of cell death, arises from lethal accumulation of lipid peroxides (<xref rid="b107-ijo-65-01-05660" ref-type="bibr">107</xref>). In tumor cells, evasion of ferroptosis mediated by oncogenes or carcinogenic signaling contributes to tumor onset, progression, metastasis and resistance to treatment. Simultaneously, some tumor cells, owing to specific mutations, elevated ROS levels and other unique biological features, exhibit ferroptosis susceptibility, with their survival hinging on the ferroptosis defense system (<xref rid="b108-ijo-65-01-05660" ref-type="bibr">108</xref>). For example, ferroptosis resistance is conferred by frequently occurring PI3K activating mutations or loss of phosphatase and tensin homolog deleted on chromosome 10 function in human cancer such as lung adenocarcinoma (<xref rid="b109-ijo-65-01-05660" ref-type="bibr">109</xref>) and breast cancer (<xref rid="b110-ijo-65-01-05660" ref-type="bibr">110</xref>) and so on. Conversely, inhibition of the PI3K/AKT/mTOR signaling axis sensitizes cancer cells to ferroptosis induction (<xref rid="b111-ijo-65-01-05660" ref-type="bibr">111</xref>). Consequently, targeting ferroptosis regulation holds implications for cancer immunotherapy and tumor suppression.</p><p>Regarding ferroptosis regulation, GGT-activated extracellular GSH catabolism produces iron-derived ROS, inducing lipid peroxidation via NF-&#954;B pathway activation (<xref rid="b112-ijo-65-01-05660" ref-type="bibr">112</xref>). GGT-mediated GSH catabolism via lipid peroxidation enhances NF-&#954;B DNA binding capacity in tumor cells (<xref rid="b113-ijo-65-01-05660" ref-type="bibr">113</xref>). GGT increased intracellular GSH levels (<xref rid="b114-ijo-65-01-05660" ref-type="bibr">114</xref>), restores the reduced GSH/GSSG ratio and reactivates GSH peroxidase 4, a core ferroptosis regulator. Therefore, elevated GGT expression increases tumor cell resistance to ferroptosis, safeguarding cells from ROS and lipid peroxidation, thus driving tumor cell proliferation, metastasis and chemotherapy drug resistance (<xref rid="b85-ijo-65-01-05660" ref-type="bibr">85</xref>,<xref rid="b107-ijo-65-01-05660" ref-type="bibr">107</xref>). In addition, GGT activates the mTORC1 pathway and inhibits integrated stress response (ISR) by modulating cystine-GSH crosstalk. This inhibition of ferroptosis promotes cancer development and other cysteine-deficient diseases (<xref rid="b115-ijo-65-01-05660" ref-type="bibr">115</xref>). Inhibiting GGT impairs GSH ability to restore mTORC1 signaling and ISR, inducing ferroptosis. This implies that the role of GGT in inducing capacity of GSH to release cysteine, rather than GSH itself, modulates the mTORC1 pathway, ISR and ferroptosis. By contrast, ChaC1 induces ferroptosis in tumor cells by activating the GCN2/EIF2&#945;/ATF4 pathway to intensify cystine depletion (<xref rid="b116-ijo-65-01-05660" ref-type="bibr">116</xref>). ChaC1 overexpression depletes GSH, initiating and executing ferroptosis. The deletion of ATF4, an upstream factor of ChaC1, in embryonic fibroblasts, results in a ferric oxide-dependent death phenotype, emphasizing the role of ATF4 as a downstream molecule of the eIF2&#945;/ATF4 pathway (<xref rid="b117-ijo-65-01-05660" ref-type="bibr">117</xref>). Hence, ferroptosis control is associated with ChaC1 expression.</p></sec><sec><title>Regulating necroptosis</title><p>Necroptosis, a regulated form of cell death primarily dependent on receptor-interacting protein kinase 3 and mixed lineage kinase domain-like, is characterized by widespread cytoplasm and organelle swelling, plasma membrane rupture and release of cell components into the microenvironment (<xref rid="b118-ijo-65-01-05660" ref-type="bibr">118</xref>). This pro-inflammatory form of cell death holds implication for combating pathogen infection, inflammatory progression (<xref rid="b119-ijo-65-01-05660" ref-type="bibr">119</xref>), and therefore may also contribute to early prevention of inflammatory cancer transformation.</p><p>Understanding of the impact of GGT and ChaC1/ChaC2 on necroptosis is limited. GGT, one of the virulence factors of <italic toggle="yes">Helicobacter pylori</italic>, has been demonstrated to induce necroptosis in gastric epithelial cells (<xref rid="b119-ijo-65-01-05660" ref-type="bibr">119</xref>). In the early stage of infection, necroptosis may serve a protective role in the mucosa by triggering an immune response (<xref rid="b119-ijo-65-01-05660" ref-type="bibr">119</xref>). However, as the disease progresses, uncontrolled necroptosis exacerbates mucosal inflammation and contributes to the transformation of inflammation into cancer (<xref rid="b119-ijo-65-01-05660" ref-type="bibr">119</xref>). Additionally, ChaC1, by stimulating the GCN2/eIF2&#945;/ATF4 pathway, enhances necroptosis induced by cystine deprivation (<xref rid="b54-ijo-65-01-05660" ref-type="bibr">54</xref>).</p></sec><sec><title>Potential regulation of autophagy</title><p>Autophagy, a highly conserved cellular degradation process, involves breaking down cytoplasmic components and damaged organelles via lysosomes, recycling resulting macromolecules to shield cells from diverse stressful conditions. Traditionally viewed as a cytoprotective mechanism, autophagy, when excessive, can also instigate cell death and contribute to tumor suppression (<xref rid="b120-ijo-65-01-05660" ref-type="bibr">120</xref>). GSH is implicated in inducing autophagy, where low GSH levels serve as a signal activating autophagy as an adaptive stress response (<xref rid="b101-ijo-65-01-05660" ref-type="bibr">101</xref>). Inhibition of GGT (<xref rid="b105-ijo-65-01-05660" ref-type="bibr">105</xref>) and elevated expression of ChaC1/ChaC2 (<xref rid="b69-ijo-65-01-05660" ref-type="bibr">69</xref>,<xref rid="b79-ijo-65-01-05660" ref-type="bibr">79</xref>) are associated with autophagy phenotype. Nevertheless, evidence (<xref rid="b79-ijo-65-01-05660" ref-type="bibr">79</xref>,<xref rid="b121-ijo-65-01-05660" ref-type="bibr">121</xref>) elucidating the precise mechanisms and interactions between GGT and ChaC1/ChaC2 and initiation and promotion of autophagy remains limited.</p></sec><sec><title>Promoting inflammation</title><p>Chronic non-specific inflammation is pivotal in tumorigenesis (<xref rid="b122-ijo-65-01-05660" ref-type="bibr">122</xref>) and is a primary environmental factor contributing to the onset and metastasis of specific types of cancer such as non-small cell lung cancer and colorectal cancer (<xref rid="b122-ijo-65-01-05660" ref-type="bibr">122</xref>,<xref rid="b123-ijo-65-01-05660" ref-type="bibr">123</xref>). Various blood tests, either individually or in combination, reflecting local or systemic inflammation, are valuable prognostic indicators for multiple tumor types (<xref rid="b124-ijo-65-01-05660" ref-type="bibr">124</xref>).</p><p>GGT serves as a well-established inflammatory marker associated with inflammatory environments and malignancy (<xref rid="b125-ijo-65-01-05660" ref-type="bibr">125</xref>,<xref rid="b126-ijo-65-01-05660" ref-type="bibr">126</xref>). Combining serum albumin and GGT levels serves as an inflammatory indicator for assessing the prognosis of hepatocellular carcinoma (HCC). Patients with elevated GGT and decreased albumin expression exhibit poorer prognosis, revealing significant differences in tumor characteristics, including larger maximum tumor diameters, more tumor nodules and potential for macroscopic vascular invasion and higher serum tumor marker levels (<xref rid="b124-ijo-65-01-05660" ref-type="bibr">124</xref>).</p><p>Furthermore, although there is limited research on the effect of human GGT on the colonization of <italic toggle="yes">H. pylori</italic>, it is known that <italic toggle="yes">H. pylori</italic> GGT is a bacterial virulence factor that contributes to the colonization of <italic toggle="yes">H. pylori</italic> in human stomach parietal cells, hence inducing inflammation and gastric parietal cell carcinogenesis (<xref rid="b127-ijo-65-01-05660" ref-type="bibr">127</xref>). In <italic toggle="yes">H. pylori</italic> infection, stimulation of <italic toggle="yes">H. pylori</italic> GGT accelerates the decrease of GSH levels in gastric epithelial cells, thereby exacerbating ROS production, leading to DNA damage and playing a key role in the emergence of chronic gastritis and gastric cancer (<xref rid="b127-ijo-65-01-05660" ref-type="bibr">127</xref>). <italic toggle="yes">H. pylori</italic> GGT is also key for the tolerogenic effect of dendritic cells in <italic toggle="yes">H. pylori</italic> infection, ensuring bacterial persistence and cross-protection from chronic inflammation and autoimmune diseases by promoting <italic toggle="yes">H. pylori</italic> to reprogram dendritic cells into tolerogenic phenotypes (<xref rid="b128-ijo-65-01-05660" ref-type="bibr">128</xref>). More research is needed to determine whether human GGT functions similarly in <italic toggle="yes">H. pylori</italic>-infected gastric parietal cells.</p><p>Human ChaC1 has potential ability to promote inflammation (<xref rid="b129-ijo-65-01-05660" ref-type="bibr">129</xref>). ChaC1 is highly expressed in gastric cancer associated with <italic toggle="yes">H. pylori</italic> infection (<xref rid="b129-ijo-65-01-05660" ref-type="bibr">129</xref>). Infection with <italic toggle="yes">H. pylori</italic> triggers ChaC1 overexpression in gastric epithelial cells, leading to GSH degradation and ROS accumulation, suppressing nucleotide alterations in TP53 that induce tumor suppressor gene expression (<xref rid="b130-ijo-65-01-05660" ref-type="bibr">130</xref>). Overexpression of ChaC1 in <italic toggle="yes">H. pylori</italic>-infected parietal cells may also lead to <italic toggle="yes">H. pylori</italic>-induced somatic mutation, thereby promoting the development of gastric cancer (<xref rid="b131-ijo-65-01-05660" ref-type="bibr">131</xref>). In summary, high expression of human ChaC1 is involved in inducing development of gastric cancer.</p><p>ChaC1 expression varies in normal and cystic fibrosis bronchial epithelial cells, with low ChaC1 expression hypothesized to play a significant role in regulating the chronic inflammatory response induced by <italic toggle="yes">Pseudomonas aeruginosa</italic> (Pa) (<xref rid="b132-ijo-65-01-05660" ref-type="bibr">132</xref>). When exposed to Pa and its virulence components, normal bronchial epithelial cells preferentially produce ChaC1. Conversely, low ChaC1 expression is associated with increased secretion of inflammatory markers interleukin-8, interleukin-6 and prostaglandin E2 in the presence of lipopolysaccharide and flagellin stimulation (<xref rid="b132-ijo-65-01-05660" ref-type="bibr">132</xref>). Low ChaC1 expression also promotes increased phosphorylation of NF-&#954;B p65, possibly contributing to the exacerbation of characteristic inflammation in the lungs of patients with cystic fibrosis following Pa infection (<xref rid="b132-ijo-65-01-05660" ref-type="bibr">132</xref>). Cystic fibrosis itself is a risk factor for various cancers, including lung cancer (<xref rid="b133-ijo-65-01-05660" ref-type="bibr">133</xref>).</p></sec><sec><title>Drug resistance</title><p>High GGT and low ChaC1 expression in cancer cells are pivotal factors in developing drug-resistant phenotypes in tumors (<xref rid="b86-ijo-65-01-05660" ref-type="bibr">86</xref>). GGT expression provides cells with an additional supply of cysteine, while low ChaC1 expression hinders degradation of intracellular GSH. Both factors contribute to GSH consumption in tumor cells during anticancer chemotherapy, leading to drug resistance. Maintaining high intracellular GSH expression preserves redox status, allowing cells to respond to proliferative and differentiation signals in tissue after toxin injury (<xref rid="b22-ijo-65-01-05660" ref-type="bibr">22</xref>) and rapidly supplement GSH during pro-oxidant anticancer therapy.</p><p>Chemotherapy-resistant tumors often exhibit high GGT expression, exemplified by cisplatin resistance (<xref rid="b134-ijo-65-01-05660" ref-type="bibr">134</xref>). Platinum (II) class antitumor drugs such as cisplatin and oxaliplatin, widely used in cancer chemotherapy, target DNA damage and overall cytotoxicity in tumor cells, resulting in cell death (<xref rid="b135-ijo-65-01-05660" ref-type="bibr">135</xref>). GGT-related detoxification of Pt(II) medication is a key mechanism of drug resistance (<xref rid="b136-ijo-65-01-05660" ref-type="bibr">136</xref>). Cisplatin can strongly bind to mercaptan metabolites produced by GGT-mediated GSH cleavage, reducing Pt ion entry into cells and inactivating Pt drugs outside the cell (<xref rid="b136-ijo-65-01-05660" ref-type="bibr">136</xref>). GGT-transfected cells show decreased DNA platinization, resulting in decreased sensitivity to cisplatin and lower susceptibility to DNA damage (<xref rid="b114-ijo-65-01-05660" ref-type="bibr">114</xref>). GGT-transfected HeLa cells exposed to cisplatin exhibit a 10-fold increase in cisplatin resistance (<xref rid="b134-ijo-65-01-05660" ref-type="bibr">134</xref>). Systematic inhibition of GGT expression is conducive to suppressing nephrotoxic side effects of cisplatin without diminishing its intracellular toxicity to tumor cells (<xref rid="b137-ijo-65-01-05660" ref-type="bibr">137</xref>). These findings underscore the key role of high GGT expression in promoting drug-resistant phenotypes in tumor cells.</p><p>By contrast with GGT, high ChaC1 expression, combined with drugs such as bortezomib and docetaxel, inhibits tumor cell viability by blocking cell cycle progression from the G1 phase to the mitotic S phase. Additionally, high ChaC1 expression increases tumor cell sensitivity to anti-tumor drugs by inducing ER stress and ferroptosis (<xref rid="b65-ijo-65-01-05660" ref-type="bibr">65</xref>,<xref rid="b69-ijo-65-01-05660" ref-type="bibr">69</xref>,<xref rid="b138-ijo-65-01-05660" ref-type="bibr">138</xref>). GSH depletion triggered by the Nrf2/ATF3/4/ChaC1 pathway appears to be the primary factor inducing death in drug-resistant tumor cells (<xref rid="b138-ijo-65-01-05660" ref-type="bibr">138</xref>), positioning ChaC1 as a key target for certain potential anti-tumor drugs such as busatol (<xref rid="b139-ijo-65-01-05660" ref-type="bibr">139</xref>) and glaucocalyxin A (<xref rid="b140-ijo-65-01-05660" ref-type="bibr">140</xref>). Low expression of ChaC1 appears in the drug-resistant phenotype of tumor cells (<xref rid="b141-ijo-65-01-05660" ref-type="bibr">141</xref>), which may be related to enhanced intracellular GSH levels.</p></sec></sec><sec sec-type="other"><title>4. Role of GSH-degrading enzymes in medicine</title><sec><title>Promising tumor biomarkers</title><p>Early tumor screening and diagnosis are key for effective treatment and favorable prognosis. Reliable and specific tumor biomarkers are key for accurate screening and diagnosis. The aberrant expression of GSH-degrading enzymes is associated with the prognosis of certain cancers such as gastric adenocarcinoma (<xref rid="b72-ijo-65-01-05660" ref-type="bibr">72</xref>), breast cancer (<xref rid="b74-ijo-65-01-05660" ref-type="bibr">74</xref>) and so on, making them promising tumor biomarkers.</p></sec><sec><title>GGT as a biomarker</title><p>GGT has been extensively studied and is widely used as a biomarker in clinical practice (<xref rid="b142-ijo-65-01-05660" ref-type="bibr">142</xref>-<xref rid="b144-ijo-65-01-05660" ref-type="bibr">144</xref>). Serum GGT activity is a rapid, reliable and cost-effective method to assess liver function (<xref rid="b145-ijo-65-01-05660" ref-type="bibr">145</xref>). Therefore, GGT has the potential to serve as a tumor biomarker. Elevated GGT expression can indicate the early-stage risk of tumor development, as suggested by an epidemiological study linking high GGT expression with increased risk of prostate cancer development (<xref rid="b145-ijo-65-01-05660" ref-type="bibr">145</xref>). Moreover, high GGT expression indicates poor prognosis in various types of tumors, including renal cell carcinoma and prostate and urothelial cancer (<xref rid="b145-ijo-65-01-05660" ref-type="bibr">145</xref>). The Cancer antigen 19-9/GGT ratio serves as an independent prognostic predictor following radical resection in ampulla carcinoma (<xref rid="b146-ijo-65-01-05660" ref-type="bibr">146</xref>). GGT6 and GGT2 are novel synergistic prognostic biomarkers for low-grade glioma and GBM, potentially aiding early detection (<xref rid="b30-ijo-65-01-05660" ref-type="bibr">30</xref>).</p><p>GGT probes have been developed to detect GGT activity accurately for tumor imaging. However, the imaging process often requires organic solvents, posing risks of damage to the enzyme and body. A water-soluble fluorescent probe, TCF-GGT (<xref rid="b147-ijo-65-01-05660" ref-type="bibr">147</xref>), has shown promise by producing red fluorescence during GGT catalytic hydrolysis without interference from the background. This water-soluble compound holds clinical value due to its practical imaging, quick metabolic cycle and excellent water solubility. Due to shallow tissue penetration of many GGT-targeted fluorescent probes, their clinical application is limited. A novel positron emission tomography imaging probe, ([<sup>18</sup>F]GCPA)<sub>2</sub>, has been designed to sensitively and precisely monitor GGT levels in living subjects because of the high sensitivity and intense tissue penetration of positron emission tomography (<xref rid="b148-ijo-65-01-05660" ref-type="bibr">148</xref>). In addition, Cy-GSH, a zero-crosstalk ratio near-infrared GGT fluorescent probe, has also been designed to visualize deep cancer <italic toggle="yes">in vivo</italic>. The probe accurately visualizes tumors and metastases in mice, suggesting that it could be a convenient tool for fluorescence-guided cancer surgery (<xref rid="b149-ijo-65-01-05660" ref-type="bibr">149</xref>). More clinically applicable GGT-targeted probes for visualizing deep cancer need further studies, which may contribute to the early diagnosis of clinical tumors.</p></sec><sec><title>ChaC1/ChaC2 as biomarkers</title><p>ChaC1, a GSH-degrading enzyme, is biomarker for certain types of tumors. <italic toggle="yes">In vitro</italic>, ChaC1 induces cell death in KIRC cell lines, signifying its potential as an effective marker for poor prognosis in KIRC (<xref rid="b70-ijo-65-01-05660" ref-type="bibr">70</xref>). High ChaC1 expression also serves as a biomarker for adverse outcomes in gastric adenocarcinoma (<xref rid="b72-ijo-65-01-05660" ref-type="bibr">72</xref>), corpus endometrial (<xref rid="b73-ijo-65-01-05660" ref-type="bibr">73</xref>) and breast cancer (<xref rid="b74-ijo-65-01-05660" ref-type="bibr">74</xref>) and uveal melanoma (<xref rid="b75-ijo-65-01-05660" ref-type="bibr">75</xref>). Notably, a positive correlation exists between ChaC1 expression and immune infiltrating cells in corpus endometrial carcinoma (<xref rid="b73-ijo-65-01-05660" ref-type="bibr">73</xref>). In uveal melanoma (<xref rid="b75-ijo-65-01-05660" ref-type="bibr">75</xref>,<xref rid="b150-ijo-65-01-05660" ref-type="bibr">150</xref>), ChaC1 is associated with poor overall, progression-free and disease-specific survival and progression-free interval, making it a promising indicator of unfavorable tumor prognosis. In aggressive breast tumor subtypes such as triple-negative breast cancer, ChaC1 exhibits significant upregulation (<xref rid="b151-ijo-65-01-05660" ref-type="bibr">151</xref>). In addition, malignant breast cancer tissue with active lymph node metastases and high proliferation rates demonstrates elevated levels of ChaC1, supporting its potential for defining tumor progression and metastasis (<xref rid="tII-ijo-65-01-05660" ref-type="table">Table II</xref>).</p><p>The abnormal expression of ChaC2 as a tumor biomarker has garnered recent attention (<xref rid="b50-ijo-65-01-05660" ref-type="bibr">50</xref>,<xref rid="b81-ijo-65-01-05660" ref-type="bibr">81</xref>). As an independent marker of poor prognosis for certain types of tumors such as breast cancer (<xref rid="b50-ijo-65-01-05660" ref-type="bibr">50</xref>) and hepatocellular carcinoma (<xref rid="b82-ijo-65-01-05660" ref-type="bibr">82</xref>), ChaC2 can monitor early tumor occurrence and treatment effects. Low expression of ChaC2 independently indicates poor prognosis in gastrointestinal tumors. ChaC2 induces mitochondrial apoptosis and autophagy via UPR, serving a pivotal role as a tumor suppressor gene in the onset, proliferation and metastasis of gastric and colorectal cancer (<xref rid="b79-ijo-65-01-05660" ref-type="bibr">79</xref>). Immunohistochemistry and western blot analysis reveal ChaC2 downregulation in most tumor tissue, with ChaC2 expression positively correlating with 3-year survival rate (<xref rid="b79-ijo-65-01-05660" ref-type="bibr">79</xref>). However, recent findings indicate that high ChaC2 expression is inversely correlated with overall survival in patients with breast cancer (<xref rid="b50-ijo-65-01-05660" ref-type="bibr">50</xref>). Elevated ChaC2 expression is also associated with poor prognosis in HCC (<xref rid="b82-ijo-65-01-05660" ref-type="bibr">82</xref>). This underscores the tissue-specific effect of ChaC2 on tumors, necessitating further study (<xref rid="tII-ijo-65-01-05660" ref-type="table">Table II</xref>).</p><p>Further, the previous study (<xref rid="b152-ijo-65-01-05660" ref-type="bibr">152</xref>) integrates traditional predictors and ChaC1, a novel biomarker, to develop a prognostic score for patients with tumors. The score can be used as a reference for clinical chemotherapy decision-making (<xref rid="b152-ijo-65-01-05660" ref-type="bibr">152</xref>). In evaluating patients with primary breast cancer, including ChaC1 mRNA expression levels in the scoring model led to changes in chemotherapy decisions in 16% of patients (<xref rid="b152-ijo-65-01-05660" ref-type="bibr">152</xref>). In addition, ChaC1 has been included in prognostic models of renal cell carcinoma (<xref rid="b153-ijo-65-01-05660" ref-type="bibr">153</xref>) and glioblastoma (<xref rid="b154-ijo-65-01-05660" ref-type="bibr">154</xref>). Including ChaC1 in tumor prognosis predictions may guide personalized treatment options. ChaC1/ChaC2 may be promising targets for precision medicine.</p><p>While studies (<xref rid="b50-ijo-65-01-05660" ref-type="bibr">50</xref>,<xref rid="b73-ijo-65-01-05660" ref-type="bibr">73</xref>,<xref rid="b74-ijo-65-01-05660" ref-type="bibr">74</xref>,<xref rid="b151-ijo-65-01-05660" ref-type="bibr">151</xref>,<xref rid="b82-ijo-65-01-05660" ref-type="bibr">82</xref>) have reported ChaC1/ChaC2 as tumor biomarkers, the development of ChaC1/ChaC2 tracer fluorescent probes remains unexplored. Fluorescent probes are the foundation for tumor-specific imaging in clinical applications. Therefore, developing optical probes to track ChaC1/ChaC2 <italic toggle="yes">in vivo</italic> or <italic toggle="yes">in vitro</italic> is key for fully realizing the clinical potential of ChaC1/ChaC2 as tumor markers.</p></sec><sec><title>Therapeutic targets for tumors</title><p>Drug selection and emerging drug development. Exploration of GSH-degrading enzyme modulators presents a promising avenue for impeding cancer progression, overcoming tumor resistance to pro-oxidative therapy and preserving tumor sensitivity to chemotherapy (<xref rid="tIII-ijo-65-01-05660" ref-type="table">Table III</xref>).</p><p>Diminishing GGT expression is beneficial for tumor treatment. Classical GGT inhibitors, including glutamate analogs such as acivicin, 6-diazo-5-oxo-L-norleucine, and azaserine (<xref rid="b155-ijo-65-01-05660" ref-type="bibr">155</xref>), have shown clinical toxicity against embryonic cells (<xref rid="b156-ijo-65-01-05660" ref-type="bibr">156</xref>). &#947; phosphonoglutamate analogs such as GGsTop and derivatives of the lead compound N-[5-(4-methoxybenzyl)-1,3,4-thiadiazol-2-yl]benzenesulfonamide, OU749, represent another class of GGT inhibitors (<xref rid="b22-ijo-65-01-05660" ref-type="bibr">22</xref>). GGsTop targets GGT, can reduce the immunosuppressive function of anti-tumor drugs when used in combination with anti-tumor drugs (<xref rid="b157-ijo-65-01-05660" ref-type="bibr">157</xref>). OU749, a species-specific uncompetitive GGT inhibitor, exhibits low toxicity and a broad therapeutic window for humans.</p><p>The development of ChaC1 modulators introduces innovative approaches to cancer treatment. Various potential ChaC1 modulators have been reported, targeting tumor cell cycle arrest and apoptosis (<xref rid="b68-ijo-65-01-05660" ref-type="bibr">68</xref>,<xref rid="b158-ijo-65-01-05660" ref-type="bibr">158</xref>). Metformin, by regulating the Loc100506691-miR-26a-5p-miR-330-5p-CHAC1 axis, induces cell cycle arrest in the G2/M phase, inhibiting cancer cell proliferation (<xref rid="b71-ijo-65-01-05660" ref-type="bibr">71</xref>). Nisin, an apoptotic bacteriocin, induces ChaC1 activation, calcium influx and cell cycle arrest in the G2 phase, leading to increased apoptosis and decreased cell proliferation <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> (<xref rid="b68-ijo-65-01-05660" ref-type="bibr">68</xref>). Atovaquone, an anti-parasitic agent, induces eIF2a phosphorylation at serine 51, amplifying the eIF2&#945;/ATF/CHOP/ChaC1 signaling pathway under ER stress (<xref rid="b158-ijo-65-01-05660" ref-type="bibr">158</xref>).</p><p>Natural extracts and their bioactive compounds have recently gained recognition as potential lead molecules in drug discovery for cancer treatment (<xref rid="b159-ijo-65-01-05660" ref-type="bibr">159</xref>,<xref rid="b160-ijo-65-01-05660" ref-type="bibr">160</xref>). They offer an alternative to chemical synthetic drugs, potentially minimizing toxic side effects and holding promise for enhancing clinical anti-tumor therapy. GGT and ChaC1 modulators derived from natural extracts have been explored. Ovothiol, a marine-derived 5(N)-methyl-thiohistidine, is a more effective non-competitive-like GGT inhibitor than traditional counterparts such as acivicin, 6-diazo-5-oxo-norleucine and azaserine (<xref rid="b105-ijo-65-01-05660" ref-type="bibr">105</xref>,<xref rid="b161-ijo-65-01-05660" ref-type="bibr">161</xref>). Ovothiol (<xref rid="b105-ijo-65-01-05660" ref-type="bibr">105</xref>) induces apoptosis and autophagy in GGT-overexpressing cells. The anticancer monosaccharide xylitol (<xref rid="b100-ijo-65-01-05660" ref-type="bibr">100</xref>) and natural Chinese herbal extracts, including dihydroartemisinin (<xref rid="b66-ijo-65-01-05660" ref-type="bibr">66</xref>), artesunate (<xref rid="b67-ijo-65-01-05660" ref-type="bibr">67</xref>), glaucocalyxin A (<xref rid="b140-ijo-65-01-05660" ref-type="bibr">140</xref>), and tanshinone IIA (<xref rid="b162-ijo-65-01-05660" ref-type="bibr">162</xref>), upregulate Prostaglandin-Endoperoxide Synthase 2, p53 and ChaC1 expression. This amplifies the ATF4/CHOP/ChaC1 cascade under ER stress, resulting in decreased intracellular GSH and cysteine, increased intracellular ROS, redox homeostasis disruption, secondary oxidative stress in cancer cells and selective ferroptosis of cancer cells (<xref rid="b66-ijo-65-01-05660" ref-type="bibr">66</xref>,<xref rid="b100-ijo-65-01-05660" ref-type="bibr">100</xref>).</p><p>In clinical treatment of tumors, a key goal is to decrease toxicity and resistance of anti-tumor drugs by regulating low expression of GGT (<xref rid="b22-ijo-65-01-05660" ref-type="bibr">22</xref>) and high expression of ChaC1 (<xref rid="b65-ijo-65-01-05660" ref-type="bibr">65</xref>). Blocking nephrotoxicity induced by the anti-tumor drug cisplatin is achieved by inhibiting GGT (<xref rid="b137-ijo-65-01-05660" ref-type="bibr">137</xref>). The unique renal sulfhydryl acid metabolic pathway, involving degradation of GSH by GGT, contributes to cisplatin nephrotoxicity (<xref rid="b163-ijo-65-01-05660" ref-type="bibr">163</xref>). Supramolecular Pt prodrug nano-assemblies inhibiting c-glutamyl transferase prove beneficial for overcoming tumor resistance (<xref rid="b136-ijo-65-01-05660" ref-type="bibr">136</xref>). GGT inhibitor amlodipine, through its anti-inflammatory effect, suppresses p38 MAPK-triggered pro-inflammatory signaling, decreasing expression of TNF-&#945; and other downstream targets while upregulating expression of the transcription factor Nrf2 and the antioxidant protein heme oxygenase-1 (<xref rid="b164-ijo-65-01-05660" ref-type="bibr">164</xref>). Amlodipine diminishes the pro-apoptotic effector/anti-apoptotic protein expression ratio induced by cisplatin, preventing inflammation, oxidative stress and apoptotic damage (<xref rid="b165-ijo-65-01-05660" ref-type="bibr">165</xref>).</p><p>Combining ChaC1 overexpression with chemotherapy is advantageous in decreasing cell drug resistance. Temozolomide, for example, induces binding of ChaC1 to the Notch3 protein, inhibiting activation of Notch3. This weakens the Notch3-mediated downstream signaling pathway, inducing glioma cell death and indicating that ChaC1 can influence the cytotoxicity of tumor cells induced by temozolomide (<xref rid="b69-ijo-65-01-05660" ref-type="bibr">69</xref>). The omega-3 fatty acids docosahexaenoic acid and eicosapentaenoic acid serve a role in reducing the resistance of tumor cells to bortezomib by activating the serine synthesis pathway, mitochondrial folate cycle, methionine cycle-associated GSH synthesis and ChaC1-mediated GSH degradation in tumor cells, ultimately promoting GSH degradation (<xref rid="b138-ijo-65-01-05660" ref-type="bibr">138</xref>).</p></sec></sec><sec sec-type="conclusions"><title>5. Conclusion</title><p>Recent years have seen notable advancements in understanding the role of the intracellular degrading enzyme ChaC family in regulating cellular GSH levels (<xref rid="b165-ijo-65-01-05660" ref-type="bibr">165</xref>,<xref rid="b166-ijo-65-01-05660" ref-type="bibr">166</xref>). Notably, coordinated actions of GGT and ChaC1/ChaC2 have been identified in modulating GSH levels both within and outside the cell (<xref rid="b11-ijo-65-01-05660" ref-type="bibr">11</xref>). These changes in intracellular GSH levels affect key biological processes, including signal transduction, cell survival, proliferation (<xref rid="b167-ijo-65-01-05660" ref-type="bibr">167</xref>) and various forms of cell death (<xref rid="b168-ijo-65-01-05660" ref-type="bibr">168</xref>,<xref rid="b169-ijo-65-01-05660" ref-type="bibr">169</xref>).</p><p>The present review underscores the pivotal role of GSH-degrading enzymes, specifically GGT and ChaC1, in cancer development. GGT, via degradation of extracellular GSH, provides cysteine for intracellular GSH synthesis and regeneration, elevating intracellular GSH levels (<xref rid="b170-ijo-65-01-05660" ref-type="bibr">170</xref>). Consequently, GGT can modulate the oxidative stress state of cancer cells, inhibiting programmed cell death (<xref rid="b170-ijo-65-01-05660" ref-type="bibr">170</xref>). GSH regeneration also counteracts the depletion induced by cancer chemotherapeutic agents, potentially leading to development of cancer drug resistance (<xref rid="b171-ijo-65-01-05660" ref-type="bibr">171</xref>). By contrast, intracellular degradation enzyme ChaC1, differentially expressed in tumor cells, serves as a pro-apoptotic molecule by downregulating intracellular GSH levels under amino acid linkage and ER stress (<xref rid="b99-ijo-65-01-05660" ref-type="bibr">99</xref>). ChaC1 induces various forms of cell death, enhancing ER stress and influencing the tumor microenvironment (<xref rid="b70-ijo-65-01-05660" ref-type="bibr">70</xref>,<xref rid="b151-ijo-65-01-05660" ref-type="bibr">151</xref>). Moreover, ChaC1 has a mitigating effect on cell resistance to cancer drugs (<xref rid="b69-ijo-65-01-05660" ref-type="bibr">69</xref>). Together, GGT and ChaC1 regulate both intracellular and extracellular GSH degradation, emerging as promising prognostic markers and therapeutic targets for specific types of tumor such as liver cancer (<xref rid="b172-ijo-65-01-05660" ref-type="bibr">172</xref>,<xref rid="b173-ijo-65-01-05660" ref-type="bibr">173</xref>), breast cancer (<xref rid="b74-ijo-65-01-05660" ref-type="bibr">74</xref>) and so on. Leveraging these enzymes for targeted anti-tumor therapy holds the advantage of precision targeting, minimal damage to healthy cells and reduced toxic side effects, thereby enhancing and reversing tumor drug resistance.</p><p>Despite advancements, unanswered questions persist regarding GSH-degrading enzymes. The determinants of functional and regulatory changes in GGT and ChaC1/ChaC2 across different malignancies or settings remain elusive. Although external stimuli induce ChaC1/ChaC2 gene and GGT expression (<xref rid="b15-ijo-65-01-05660" ref-type="bibr">15</xref>,<xref rid="b174-ijo-65-01-05660" ref-type="bibr">174</xref>,<xref rid="b175-ijo-65-01-05660" ref-type="bibr">175</xref>), the specific regulatory mechanisms governing these inductions remain unclear. Additionally, crosstalk effect of different pathways in GGT and ChaC1/ChaC2 regulation requires further investigation. Furthermore, while the roles of GGT and ChaC1/ChaC2 in tumor tissue are known, these enzymes represent only the initial steps in GSH degradation. The interaction between GGT, ChaC1/ChaC2 and downstream enzymes in the complete degradation of GSH, Cys-Gly degrading enzymes and 5-oxo-proline (<xref rid="b176-ijo-65-01-05660" ref-type="bibr">176</xref>-<xref rid="b179-ijo-65-01-05660" ref-type="bibr">179</xref>) remains unclear. The development of tumor treatment strategies targeting GSH-degrading enzymes faces challenges, including different roles of these enzymes in different types of tumor and their impact on the immune response or tumor microenvironment.</p><p>In conclusion, GGT and the ChaC family of GSH degrading enzymes, both intracellularly and extracellularly, are key for maintaining GSH homeostasis and serve key roles in normal cellular processes and tumor-related stress conditions. A more comprehensive understanding of these mechanisms may clarify the potential of GSH-degrading enzymes as targets for tumor diagnosis and therapeutic interventions.</p></sec></body><back><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><sec sec-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></sec><sec sec-type="other"><title>Authors' contributions</title><p>TZ and CY wrote and revised the manuscript. CY, DH and WS conceived and designed the review. XZ, SL, LQ, SZ and CZ performed the literature review. DH and WS revised the manuscript. Data authentication is not applicable. All authors have read and approved the final manuscript.</p></sec><sec sec-type="other"><title>Ethics approval and consent to participate</title><p>Not applicable.</p></sec><sec sec-type="other"><title>Patient consent for publication</title><p>Not applicable.</p></sec><sec sec-type="COI-statement"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><glossary><title>Abbreviations</title><def-list><def-item><term>ACM</term><def><p>a novel-248 ATF/CRE modifier</p></def></def-item><def-item><term>AP-1</term><def><p>activator protein 1</p></def></def-item><def-item><term>AP-2</term><def><p>activating protein 2</p></def></def-item><def-item><term>ATF</term><def><p>activating transcription factor</p></def></def-item><def-item><term>C/EBP-&#946;</term><def><p>CCAAT/enhancer binding protein &#946;</p></def></def-item><def-item><term>ChaC1</term><def><p>cation transport regulator homolog glutathione specific &#947;-glutamylcyclotransferase 1</p></def></def-item><def-item><term>CHOP</term><def><p>C/EBP homologous protein</p></def></def-item><def-item><term>eIF2&#945;</term><def><p>eukaryotic initiation factor-2&#945;</p></def></def-item><def-item><term>EpRE</term><def><p>electrophile response element</p></def></def-item><def-item><term>ER</term><def><p>endoplasmic reticulum</p></def></def-item><def-item><term>GBM</term><def><p>glioblastoma multiforme</p></def></def-item><def-item><term>GCN2</term><def><p>general control nonderepressible 2</p></def></def-item><def-item><term>GGT</term><def><p>&#947;-glutamyl transpeptidase</p></def></def-item><def-item><term>GP5</term><def><p>GGT promoter 5</p></def></def-item><def-item><term>HCC</term><def><p>hepatocellular carcinoma</p></def></def-item><def-item><term>hESC</term><def><p>human embryonic stem cell</p></def></def-item><def-item><term>HNE</term><def><p>4-hydroxynonenal</p></def></def-item><def-item><term>ISR</term><def><p>integrated stress response</p></def></def-item><def-item><term>I&#954;B</term><def><p>inhibitor of &#954;B</p></def></def-item><def-item><term>KIRC</term><def><p>kidney renal clear cell carcinoma</p></def></def-item><def-item><term>L2</term><def><p>alveolar type II</p></def></def-item><def-item><term>Pa</term><def><p>Pseudomonas aeruginosa</p></def></def-item><def-item><term>ROS</term><def><p>reactive oxygen species</p></def></def-item><def-item><term>Sp1</term><def><p>specific protein 1</p></def></def-item><def-item><term>UPR</term><def><p>unfolded protein response</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="b1-ijo-65-01-05660"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lushchak</surname><given-names>VI</given-names></name></person-group><article-title>Glutathione homeostasis and functions: potential targets for medical interventions</article-title><source>J Amino Acids</source><volume>2012</volume><fpage>736837</fpage><year>2012</year><pub-id pub-id-type="doi">10.1155/2012/736837</pub-id><pub-id pub-id-type="pmid">22500213</pub-id><pub-id pub-id-type="pmcid">PMC3303626</pub-id></element-citation></ref><ref id="b2-ijo-65-01-05660"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>SC</given-names></name></person-group><article-title>Regulation of glutathione synthesis</article-title><source>Mol Aspects Med</source><volume>30</volume><fpage>42</fpage><lpage>59</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.mam.2008.05.005</pub-id><pub-id pub-id-type="pmid">18601945</pub-id><pub-id pub-id-type="pmcid">PMC2704241</pub-id></element-citation></ref><ref id="b3-ijo-65-01-05660"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kennedy</surname><given-names>L</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>JK</given-names></name><name name-style="western"><surname>Harper</surname><given-names>ME</given-names></name><name name-style="western"><surname>Cuperlovic-Culf</surname><given-names>M</given-names></name></person-group><article-title>Role of glutathione in cancer: From mechanisms to therapies</article-title><source>Biomolecules</source><volume>10</volume><fpage>1429</fpage><year>2020</year><pub-id pub-id-type="doi">10.3390/biom10101429</pub-id><pub-id pub-id-type="pmid">33050144</pub-id><pub-id pub-id-type="pmcid">PMC7600400</pub-id></element-citation></ref><ref id="b4-ijo-65-01-05660"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansal</surname><given-names>A</given-names></name><name name-style="western"><surname>Simon</surname><given-names>MC</given-names></name></person-group><article-title>Glutathione metabolism in cancer progression and treatment resistance</article-title><source>J Cell Biol</source><volume>217</volume><fpage>2291</fpage><lpage>2298</lpage><year>2018</year><pub-id pub-id-type="doi">10.1083/jcb.201804161</pub-id><pub-id pub-id-type="pmid">29915025</pub-id><pub-id pub-id-type="pmcid">PMC6028537</pub-id></element-citation></ref><ref id="b5-ijo-65-01-05660"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Checa</surname><given-names>J</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsukamoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Kaplowitz</surname><given-names>N</given-names></name></person-group><article-title>Mitochondrial glutathione depletion in alcoholic liver disease</article-title><source>Alcohol</source><volume>10</volume><fpage>469</fpage><lpage>475</lpage><year>1993</year><pub-id pub-id-type="doi">10.1016/0741-8329(93)90067-X</pub-id><pub-id pub-id-type="pmid">8123202</pub-id></element-citation></ref><ref id="b6-ijo-65-01-05660"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guarino</surname><given-names>MP</given-names></name><name name-style="western"><surname>Afonso</surname><given-names>RA</given-names></name><name name-style="western"><surname>Raimundo</surname><given-names>N</given-names></name><name name-style="western"><surname>Raposo</surname><given-names>JF</given-names></name><name name-style="western"><surname>Macedo</surname><given-names>MP</given-names></name></person-group><article-title>Hepatic glutathione and nitric oxide are critical for hepatic insulin-sensitizing substance action</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><volume>284</volume><fpage>G588</fpage><lpage>G594</lpage><year>2003</year><pub-id pub-id-type="doi">10.1152/ajpgi.00423.2002</pub-id><pub-id pub-id-type="pmid">12466146</pub-id></element-citation></ref><ref id="b7-ijo-65-01-05660"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandal</surname><given-names>PK</given-names></name><name name-style="western"><surname>Roy</surname><given-names>RG</given-names></name><name name-style="western"><surname>Samkaria</surname><given-names>A</given-names></name></person-group><article-title>Oxidative stress: Glutathione and its potential to protect methionine-35 of abeta peptide from oxidation</article-title><source>ACS Omega</source><volume>7</volume><fpage>27052</fpage><lpage>27061</lpage><year>2022</year><pub-id pub-id-type="doi">10.1021/acsomega.2c02760</pub-id><pub-id pub-id-type="pmid">35967059</pub-id><pub-id pub-id-type="pmcid">PMC9366984</pub-id></element-citation></ref><ref id="b8-ijo-65-01-05660"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charisis</surname><given-names>S</given-names></name><name name-style="western"><surname>Ntanasi</surname><given-names>E</given-names></name><name name-style="western"><surname>Stamelou</surname><given-names>M</given-names></name><name name-style="western"><surname>Xiromerisiou</surname><given-names>G</given-names></name><name name-style="western"><surname>Maraki</surname><given-names>M</given-names></name><name name-style="western"><surname>Veskoukis</surname><given-names>AS</given-names></name><name name-style="western"><surname>Yannakoulia</surname><given-names>M</given-names></name><name name-style="western"><surname>Kosmidis</surname><given-names>MH</given-names></name><name name-style="western"><surname>Anastasiou</surname><given-names>CA</given-names></name><name name-style="western"><surname>Giagkou</surname><given-names>N</given-names></name><etal/></person-group><article-title>Plasma glutathione and prodromal parkinson's disease probability</article-title><source>Mov Disord</source><volume>37</volume><fpage>200</fpage><lpage>205</lpage><year>2022</year><pub-id pub-id-type="doi">10.1002/mds.28826</pub-id><pub-id pub-id-type="pmid">34695238</pub-id></element-citation></ref><ref id="b9-ijo-65-01-05660"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>B</given-names></name><name name-style="western"><surname>Liao</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wen</surname><given-names>T</given-names></name><name name-style="western"><surname>Quan</surname><given-names>G</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name></person-group><article-title>Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy</article-title><source>Biomaterials</source><volume>277</volume><fpage>121110</fpage><year>2021</year><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121110</pub-id><pub-id pub-id-type="pmid">34482088</pub-id></element-citation></ref><ref id="b10-ijo-65-01-05660"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachhawat</surname><given-names>AK</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>S</given-names></name></person-group><article-title>The glutathione cycle: Glutathione metabolism beyond the &#947;-glutamyl cycle</article-title><source>IUBMB Life</source><volume>70</volume><fpage>585</fpage><lpage>592</lpage><year>2018</year><pub-id pub-id-type="doi">10.1002/iub.1756</pub-id><pub-id pub-id-type="pmid">29667297</pub-id></element-citation></ref><ref id="b11-ijo-65-01-05660"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachhawat</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>A</given-names></name></person-group><article-title>Glutathione degradation</article-title><source>Antioxid Redox Signal</source><volume>27</volume><fpage>1200</fpage><lpage>1216</lpage><year>2017</year><pub-id pub-id-type="doi">10.1089/ars.2017.7136</pub-id><pub-id pub-id-type="pmid">28537416</pub-id></element-citation></ref><ref id="b12-ijo-65-01-05660"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mungrue</surname><given-names>I</given-names></name><name name-style="western"><surname>Pagnon</surname><given-names>J</given-names></name><name name-style="western"><surname>Kohannim</surname><given-names>O</given-names></name><name name-style="western"><surname>Gargalovic</surname><given-names>P</given-names></name><name name-style="western"><surname>Lusis</surname><given-names>A</given-names></name></person-group><article-title>CHAC1/MGC4504 is a novel proapoptotic component of the unfolded protein response, downstream of the ATF4-ATF3-CHOP cascade</article-title><source>J Immunol</source><volume>182</volume><fpage>466</fpage><lpage>476</lpage><year>2009</year><pub-id pub-id-type="doi">10.4049/jimmunol.182.1.466</pub-id><pub-id pub-id-type="pmid">19109178</pub-id><pub-id pub-id-type="pmcid">PMC2846782</pub-id></element-citation></ref><ref id="b13-ijo-65-01-05660"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Tikoo</surname><given-names>S</given-names></name><name name-style="western"><surname>Maity</surname><given-names>S</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>A</given-names></name><name name-style="western"><surname>Bachhawat</surname><given-names>AK</given-names></name></person-group><article-title>Mammalian proapoptotic factor ChaC1 and its homologues function as &#947;-glutamyl cyclotransferases acting specifically on glutathione</article-title><source>EMBO Rep</source><volume>13</volume><fpage>1095</fpage><lpage>1101</lpage><year>2012</year><pub-id pub-id-type="doi">10.1038/embor.2012.156</pub-id><pub-id pub-id-type="pmid">23070364</pub-id><pub-id pub-id-type="pmcid">PMC3512401</pub-id></element-citation></ref><ref id="b14-ijo-65-01-05660"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lou</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Miao</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name></person-group><article-title>MicroRNA-142-3p promotes renal cell carcinoma progression by targeting RhoBTB3 to regulate HIF-1 signaling and GGT/GSH pathways</article-title><source>Sci Rep</source><volume>13</volume><fpage>5935</fpage><year>2023</year><pub-id pub-id-type="doi">10.1038/s41598-022-21447-2</pub-id><pub-id pub-id-type="pmid">37045834</pub-id><pub-id pub-id-type="pmcid">PMC10097650</pub-id></element-citation></ref><ref id="b15-ijo-65-01-05660"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>High-fat diet aggravates colitis-associated carcinogenesis by evading ferroptosis in the ER stress-mediated pathway</article-title><source>Free Radic Biol Med</source><volume>177</volume><fpage>156</fpage><lpage>166</lpage><year>2021</year><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.10.022</pub-id><pub-id pub-id-type="pmid">34688836</pub-id></element-citation></ref><ref id="b16-ijo-65-01-05660"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alborzinia</surname><given-names>H</given-names></name><name name-style="western"><surname>Fl&#243;rez</surname><given-names>AF</given-names></name><name name-style="western"><surname>Kreth</surname><given-names>S</given-names></name><name name-style="western"><surname>Br&#252;ckner</surname><given-names>LM</given-names></name><name name-style="western"><surname>Yildiz</surname><given-names>U</given-names></name><name name-style="western"><surname>Gartlgruber</surname><given-names>M</given-names></name><name name-style="western"><surname>Odoni</surname><given-names>DI</given-names></name><name name-style="western"><surname>Poschet</surname><given-names>G</given-names></name><name name-style="western"><surname>Garbowicz</surname><given-names>K</given-names></name><name name-style="western"><surname>Shao</surname><given-names>C</given-names></name><etal/></person-group><article-title>MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis</article-title><source>Nat Cancer</source><volume>3</volume><fpage>471</fpage><lpage>485</lpage><year>2022</year><pub-id pub-id-type="doi">10.1038/s43018-022-00355-4</pub-id><pub-id pub-id-type="pmid">35484422</pub-id><pub-id pub-id-type="pmcid">PMC9050595</pub-id></element-citation></ref><ref id="b17-ijo-65-01-05660"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stepulak</surname><given-names>A</given-names></name><name name-style="western"><surname>Rola</surname><given-names>R</given-names></name><name name-style="western"><surname>Polberg</surname><given-names>K</given-names></name><name name-style="western"><surname>Ikonomidou</surname><given-names>C</given-names></name></person-group><article-title>Glutamate and its receptors in cancer</article-title><source>J Neural Transm (Vienna)</source><volume>121</volume><fpage>933</fpage><lpage>944</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s00702-014-1182-6</pub-id><pub-id pub-id-type="pmid">24610491</pub-id><pub-id pub-id-type="pmcid">PMC4133641</pub-id></element-citation></ref><ref id="b18-ijo-65-01-05660"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Locasale</surname><given-names>JW</given-names></name></person-group><article-title>Serine, glycine and one-carbon units: Cancer metabolism in full circle</article-title><source>Nat Rev Cancer</source><volume>13</volume><fpage>572</fpage><lpage>583</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/nrc3557</pub-id><pub-id pub-id-type="pmid">23822983</pub-id><pub-id pub-id-type="pmcid">PMC3806315</pub-id></element-citation></ref><ref id="b19-ijo-65-01-05660"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cole</surname><given-names>SP</given-names></name><name name-style="western"><surname>Deeley</surname><given-names>RG</given-names></name></person-group><article-title>Transport of glutathione and glutathione conjugates by MRP1</article-title><source>Trends Pharmacol Sci</source><volume>27</volume><fpage>438</fpage><lpage>446</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.tips.2006.06.008</pub-id><pub-id pub-id-type="pmid">16820223</pub-id></element-citation></ref><ref id="b20-ijo-65-01-05660"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>YTK</given-names></name><name name-style="western"><surname>Park</surname><given-names>JS</given-names></name><name name-style="western"><surname>Jang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KR</given-names></name><name name-style="western"><surname>Vo</surname><given-names>TTL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KW</given-names></name><name name-style="western"><surname>Han</surname><given-names>BW</given-names></name></person-group><article-title>Structural and functional analyses of human ChaC2 in glutathione metabolism</article-title><source>Biomolecules</source><volume>10</volume><fpage>31</fpage><year>2019</year><pub-id pub-id-type="doi">10.3390/biom10010031</pub-id><pub-id pub-id-type="pmid">31878259</pub-id><pub-id pub-id-type="pmcid">PMC7022552</pub-id></element-citation></ref><ref id="b21-ijo-65-01-05660"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orlowski</surname><given-names>M</given-names></name><name name-style="western"><surname>Meister</surname><given-names>A</given-names></name></person-group><article-title>The gamma-glutamyl cycle: A possible transport system for amino acids</article-title><source>Proc Natl Acad Sci USA</source><volume>67</volume><fpage>1248</fpage><lpage>1255</lpage><year>1970</year><pub-id pub-id-type="doi">10.1073/pnas.67.3.1248</pub-id><pub-id pub-id-type="pmid">5274454</pub-id><pub-id pub-id-type="pmcid">PMC283344</pub-id></element-citation></ref><ref id="b22-ijo-65-01-05660"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanigan</surname><given-names>MH</given-names></name></person-group><article-title>Gamma-glutamyl transpeptidase: Redox regulation and drug resistance</article-title><source>Adv Cancer Res</source><volume>122</volume><fpage>103</fpage><lpage>141</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/B978-0-12-420117-0.00003-7</pub-id><pub-id pub-id-type="pmid">24974180</pub-id><pub-id pub-id-type="pmcid">PMC4388159</pub-id></element-citation></ref><ref id="b23-ijo-65-01-05660"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>VV</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R</given-names></name><name name-style="western"><surname>Goel</surname><given-names>M</given-names></name></person-group><article-title>Phylogenetic and evolutionary analysis of functional divergence among gamma glutamyl transpeptidase (GGT) subfamilies</article-title><source>Biol Direct</source><volume>10</volume><fpage>49</fpage><year>2015</year><pub-id pub-id-type="doi">10.1186/s13062-015-0080-7</pub-id><pub-id pub-id-type="pmid">26370226</pub-id><pub-id pub-id-type="pmcid">PMC4568574</pub-id></element-citation></ref><ref id="b24-ijo-65-01-05660"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mistry</surname><given-names>D</given-names></name><name name-style="western"><surname>Stockley</surname><given-names>RA</given-names></name></person-group><article-title>Gamma-glutamyl transferase: The silent partner?</article-title><source>COPD</source><volume>7</volume><fpage>285</fpage><lpage>290</lpage><year>2010</year><pub-id pub-id-type="doi">10.3109/15412555.2010.496819</pub-id><pub-id pub-id-type="pmid">20673038</pub-id></element-citation></ref><ref id="b25-ijo-65-01-05660"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanigan</surname><given-names>MH</given-names></name><name name-style="western"><surname>Frierson</surname><given-names>HF</given-names><suffix>Jr</suffix></name></person-group><article-title>Immunohistochemical detection of gamma-glutamyl transpeptidase in normal human tissue</article-title><source>J Histochem Cytochem</source><volume>44</volume><fpage>1101</fpage><lpage>1108</lpage><year>1996</year><pub-id pub-id-type="doi">10.1177/44.10.8813074</pub-id><pub-id pub-id-type="pmid">8813074</pub-id></element-citation></ref><ref id="b26-ijo-65-01-05660"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Figlewicz</surname><given-names>DA</given-names></name><name name-style="western"><surname>Delattre</surname><given-names>O</given-names></name><name name-style="western"><surname>Guellaen</surname><given-names>G</given-names></name><name name-style="western"><surname>Krizus</surname><given-names>A</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>G</given-names></name><name name-style="western"><surname>Zucman</surname><given-names>J</given-names></name><name name-style="western"><surname>Rouleau</surname><given-names>GA</given-names></name></person-group><article-title>Mapping of human gamma-glutamyl transpeptidase genes on chromosome 22 and other human autosomes</article-title><source>Genomics</source><volume>17</volume><fpage>299</fpage><lpage>305</lpage><year>1993</year><pub-id pub-id-type="doi">10.1006/geno.1993.1325</pub-id><pub-id pub-id-type="pmid">8104871</pub-id></element-citation></ref><ref id="b27-ijo-65-01-05660"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>C</given-names></name><name name-style="western"><surname>Courtay</surname><given-names>C</given-names></name><name name-style="western"><surname>van Kessel</surname><given-names>AG</given-names></name><name name-style="western"><surname>ten Hoeve</surname><given-names>J</given-names></name><name name-style="western"><surname>Heisterkamp</surname><given-names>N</given-names></name><name name-style="western"><surname>Groffen</surname><given-names>J</given-names></name></person-group><article-title>Localization of a gamma-glutamyl-transferase-related gene family on chromosome 22</article-title><source>Hum Genet</source><volume>91</volume><fpage>31</fpage><lpage>36</lpage><year>1993</year><pub-id pub-id-type="doi">10.1007/BF00230218</pub-id><pub-id pub-id-type="pmid">8095916</pub-id></element-citation></ref><ref id="b28-ijo-65-01-05660"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heisterkamp</surname><given-names>N</given-names></name><name name-style="western"><surname>Groffen</surname><given-names>J</given-names></name><name name-style="western"><surname>Warburton</surname><given-names>D</given-names></name><name name-style="western"><surname>Sneddon</surname><given-names>TP</given-names></name></person-group><article-title>The human gamma-glutamyltransferase gene family</article-title><source>Hum Genet</source><volume>123</volume><fpage>321</fpage><lpage>232</lpage><year>2008</year><pub-id pub-id-type="doi">10.1007/s00439-008-0487-7</pub-id><pub-id pub-id-type="pmid">18357469</pub-id></element-citation></ref><ref id="b29-ijo-65-01-05660"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wickham</surname><given-names>S</given-names></name><name name-style="western"><surname>West</surname><given-names>MB</given-names></name><name name-style="western"><surname>Cook</surname><given-names>PF</given-names></name><name name-style="western"><surname>Hanigan</surname><given-names>MH</given-names></name></person-group><article-title>Gamma-glutamyl compounds: Substrate specificity of gamma-glutamyl transpeptidase enzymes</article-title><source>Anal Biochem</source><volume>414</volume><fpage>208</fpage><lpage>214</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.ab.2011.03.026</pub-id><pub-id pub-id-type="pmid">21447318</pub-id><pub-id pub-id-type="pmcid">PMC3099546</pub-id></element-citation></ref><ref id="b30-ijo-65-01-05660"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mottaghitalab</surname><given-names>F</given-names></name><name name-style="western"><surname>Lanjanian</surname><given-names>H</given-names></name><name name-style="western"><surname>Masoudi-Nejad</surname><given-names>A</given-names></name></person-group><article-title>Revealing transcriptional and post-transcriptional regulatory mechanisms of &#947;-glutamyl transferase and keratin isoforms as novel cooperative biomarkers in low-grade glioma and glioblastoma multiforme</article-title><source>Genomics</source><volume>113</volume><fpage>2623</fpage><lpage>2633</lpage><year>2021</year><pub-id pub-id-type="doi">10.1016/j.ygeno.2021.06.014</pub-id><pub-id pub-id-type="pmid">34118380</pub-id></element-citation></ref><ref id="b31-ijo-65-01-05660"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chan</surname><given-names>FKL</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>JQ</given-names></name></person-group><article-title>Gamma-glutamyltransferase 7 suppresses gastric cancer by cooperating with RAB7 to induce mitophagy</article-title><source>Oncogene</source><volume>41</volume><fpage>3485</fpage><lpage>3497</lpage><year>2022</year><pub-id pub-id-type="doi">10.1038/s41388-022-02339-1</pub-id><pub-id pub-id-type="pmid">35662282</pub-id></element-citation></ref><ref id="b32-ijo-65-01-05660"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>W</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name></person-group><article-title>Expression status and prognostic significance of gamma-glutamyl transpeptidase family genes in hepatocellular carcinoma</article-title><source>Front Oncol</source><volume>11</volume><fpage>731144</fpage><year>2021</year><pub-id pub-id-type="doi">10.3389/fonc.2021.731144</pub-id><pub-id pub-id-type="pmid">34513707</pub-id><pub-id pub-id-type="pmcid">PMC8426663</pub-id></element-citation></ref><ref id="b33-ijo-65-01-05660"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samgina</surname><given-names>TA</given-names></name><name name-style="western"><surname>Lazarenko</surname><given-names>VA</given-names></name></person-group><article-title>The role of polymorphic variants rs11546155 and rs6119534 of the GGT7 gene and risk factors in the development of acute pancreatitis</article-title><source>Vopr Pitan</source><volume>91</volume><fpage>43</fpage><lpage>50</lpage><year>2022</year><comment>In Russian</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.33029/0042-8833-2022-91-2-43-50</pub-id><pub-id pub-id-type="pmid">35596634</pub-id></element-citation></ref><ref id="b34-ijo-65-01-05660"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>MB</given-names></name><name name-style="western"><surname>Wickham</surname><given-names>S</given-names></name><name name-style="western"><surname>Parks</surname><given-names>EE</given-names></name><name name-style="western"><surname>Sherry</surname><given-names>DM</given-names></name><name name-style="western"><surname>Hanigan</surname><given-names>MH</given-names></name></person-group><article-title>Human GGT2 does not autocleave into a functional enzyme: A cautionary tale for interpretation of microarray data on redox signaling</article-title><source>Antioxid Redox Signal</source><volume>19</volume><fpage>1877</fpage><lpage>1888</lpage><year>2013</year><pub-id pub-id-type="doi">10.1089/ars.2012.4997</pub-id><pub-id pub-id-type="pmid">23682772</pub-id><pub-id pub-id-type="pmcid">PMC3852618</pub-id></element-citation></ref><ref id="b35-ijo-65-01-05660"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>DO</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BY</given-names></name><name name-style="western"><surname>Jang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MO</given-names></name><name name-style="western"><surname>Jayasooriya</surname><given-names>RG</given-names></name><name name-style="western"><surname>Kang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>YH</given-names></name><name name-style="western"><surname>Moon</surname><given-names>SK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>GY</given-names></name></person-group><article-title>K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2</article-title><source>Toxicol In Vitro</source><volume>26</volume><fpage>429</fpage><lpage>434</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.tiv.2012.01.013</pub-id><pub-id pub-id-type="pmid">22269385</pub-id></element-citation></ref><ref id="b36-ijo-65-01-05660"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courtay</surname><given-names>C</given-names></name><name name-style="western"><surname>Heisterkamp</surname><given-names>N</given-names></name><name name-style="western"><surname>Siest</surname><given-names>G</given-names></name><name name-style="western"><surname>Groffen</surname><given-names>J</given-names></name></person-group><article-title>Expression of multiple gamma-glutamyltransferase genes in man</article-title><source>Biochem J</source><volume>297</volume><fpage>503</fpage><lpage>508</lpage><year>1994</year><pub-id pub-id-type="doi">10.1042/bj2970503</pub-id><pub-id pub-id-type="pmid">7906515</pub-id><pub-id pub-id-type="pmcid">PMC1137862</pub-id></element-citation></ref><ref id="b37-ijo-65-01-05660"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taniguchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>Y</given-names></name></person-group><article-title>Gamma-glutamyl transpeptidase: Catalytic mechanism and gene expression</article-title><source>Adv Enzymol Relat Areas Mol Biol</source><volume>72</volume><fpage>239</fpage><lpage>278</lpage><year>1998</year><pub-id pub-id-type="pmid">9559055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/9780470123188.ch7</pub-id></element-citation></ref><ref id="b38-ijo-65-01-05660"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Forman</surname><given-names>HJ</given-names></name></person-group><article-title>Redox regulation of gamma-glutamyl transpeptidase</article-title><source>Am J Respir Cell Mol Biol</source><volume>41</volume><fpage>509</fpage><lpage>515</lpage><year>2009</year><pub-id pub-id-type="doi">10.1165/rcmb.2009-0169TR</pub-id><pub-id pub-id-type="pmid">19684307</pub-id><pub-id pub-id-type="pmcid">PMC2778158</pub-id></element-citation></ref><ref id="b39-ijo-65-01-05660"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daubeuf</surname><given-names>S</given-names></name><name name-style="western"><surname>Duvoix</surname><given-names>A</given-names></name><name name-style="western"><surname>Wellman-Rousseau</surname><given-names>M</given-names></name><name name-style="western"><surname>Diederich</surname><given-names>M</given-names></name><name name-style="western"><surname>Visvikis</surname><given-names>A</given-names></name></person-group><article-title>Phorbol ester regulation of the human gamma-glutamyltransferase gene promoter</article-title><source>Biochem Biophys Res Commun</source><volume>313</volume><fpage>300</fpage><lpage>307</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2003.11.121</pub-id><pub-id pub-id-type="pmid">14684160</pub-id></element-citation></ref><ref id="b40-ijo-65-01-05660"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pawlak</surname><given-names>A</given-names></name><name name-style="western"><surname>Lahuna</surname><given-names>O</given-names></name><name name-style="western"><surname>Bulle</surname><given-names>F</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>A</given-names></name><name name-style="western"><surname>Ferry</surname><given-names>N</given-names></name><name name-style="western"><surname>Siegrist</surname><given-names>S</given-names></name><name name-style="western"><surname>Chikhi</surname><given-names>N</given-names></name><name name-style="western"><surname>Chobert</surname><given-names>MN</given-names></name><name name-style="western"><surname>Guellaen</surname><given-names>G</given-names></name><name name-style="western"><surname>Laperche</surname><given-names>Y</given-names></name></person-group><article-title>Gamma-glutamyl transpeptidase: A single copy gene in the rat and a multigene family in the human genome</article-title><source>J Biol Chem</source><volume>263</volume><fpage>9913</fpage><lpage>9916</lpage><year>1988</year><pub-id pub-id-type="doi">10.1016/S0021-9258(19)81604-6</pub-id><pub-id pub-id-type="pmid">2898474</pub-id></element-citation></ref><ref id="b41-ijo-65-01-05660"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandur</surname><given-names>S</given-names></name><name name-style="western"><surname>Pankiv</surname><given-names>S</given-names></name><name name-style="western"><surname>Johannessen</surname><given-names>M</given-names></name><name name-style="western"><surname>Moens</surname><given-names>U</given-names></name><name name-style="western"><surname>Huseby</surname><given-names>NE</given-names></name></person-group><article-title>Gamma-glutamyltransferase is upregulated after oxidative stress through the Ras signal transduction pathway in rat colon carcinoma cells</article-title><source>Free Radic Res</source><volume>41</volume><fpage>1376</fpage><lpage>1384</lpage><year>2007</year><pub-id pub-id-type="doi">10.1080/10715760701739488</pub-id><pub-id pub-id-type="pmid">18075840</pub-id></element-citation></ref><ref id="b42-ijo-65-01-05660"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Downward</surname><given-names>J</given-names></name></person-group><article-title>Targeting RAS signalling pathways in cancer therapy</article-title><source>Nat Rev Cancer</source><volume>3</volume><fpage>11</fpage><lpage>22</lpage><year>2003</year><pub-id pub-id-type="doi">10.1038/nrc969</pub-id><pub-id pub-id-type="pmid">12509763</pub-id></element-citation></ref><ref id="b43-ijo-65-01-05660"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Iles</surname><given-names>KE</given-names></name><name name-style="western"><surname>Liu</surname><given-names>RM</given-names></name><name name-style="western"><surname>Postlethwait</surname><given-names>EM</given-names></name><name name-style="western"><surname>Laperche</surname><given-names>Y</given-names></name><name name-style="western"><surname>Forman</surname><given-names>HJ</given-names></name></person-group><article-title>4-Hydroxynonenal induces rat gamma-glutamyl transpeptidase through mitogen-activated protein kinase-mediated electrophile response element/nuclear factor erythroid 2-related factor 2 signaling</article-title><source>Am J Respir Cell Mol Biol</source><volume>34</volume><fpage>174</fpage><lpage>181</lpage><year>2006</year><pub-id pub-id-type="doi">10.1165/rcmb.2005-0280OC</pub-id><pub-id pub-id-type="pmid">16195535</pub-id><pub-id pub-id-type="pmcid">PMC2696200</pub-id></element-citation></ref><ref id="b44-ijo-65-01-05660"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mussbacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Derler</surname><given-names>M</given-names></name><name name-style="western"><surname>Basilio</surname><given-names>J</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>JA</given-names></name></person-group><article-title>NF-&#954;B in monocytes and macrophages-an inflammatory master regulator in multitalented immune cells</article-title><source>Front Immunol</source><volume>14</volume><fpage>1134661</fpage><year>2023</year><pub-id pub-id-type="doi">10.3389/fimmu.2023.1134661</pub-id><pub-id pub-id-type="pmid">36911661</pub-id><pub-id pub-id-type="pmcid">PMC9995663</pub-id></element-citation></ref><ref id="b45-ijo-65-01-05660"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>C</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S</given-names></name><name name-style="western"><surname>Tao</surname><given-names>J</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Transcriptome profiling of microRNAs reveals potential mechanisms of manual therapy alleviating neuropathic pain through microRNA-547-3p-mediated Map4k4/NF-&#954;b signaling pathway</article-title><source>J Neuroinflammation</source><volume>19</volume><fpage>211</fpage><year>2022</year><pub-id pub-id-type="doi">10.1186/s12974-022-02568-x</pub-id><pub-id pub-id-type="pmid">36045396</pub-id><pub-id pub-id-type="pmcid">PMC9434879</pub-id></element-citation></ref><ref id="b46-ijo-65-01-05660"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reuter</surname><given-names>S</given-names></name><name name-style="western"><surname>Schnekenburger</surname><given-names>M</given-names></name><name name-style="western"><surname>Cristofanon</surname><given-names>S</given-names></name><name name-style="western"><surname>Buck</surname><given-names>I</given-names></name><name name-style="western"><surname>Teiten</surname><given-names>MH</given-names></name><name name-style="western"><surname>Daubeuf</surname><given-names>S</given-names></name><name name-style="western"><surname>Eifes</surname><given-names>S</given-names></name><name name-style="western"><surname>Dicato</surname><given-names>M</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>BB</given-names></name><name name-style="western"><surname>Visvikis</surname><given-names>A</given-names></name><name name-style="western"><surname>Diederich</surname><given-names>M</given-names></name></person-group><article-title>Tumor necrosis factor alpha induces gamma-glutamyltransferase expression via nuclear factor-kappaB in cooperation with Sp1</article-title><source>Biochem Pharmacol</source><volume>77</volume><fpage>397</fpage><lpage>411</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.bcp.2008.09.041</pub-id><pub-id pub-id-type="pmid">18996094</pub-id></element-citation></ref><ref id="b47-ijo-65-01-05660"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>A</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>R</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>R</given-names></name><name name-style="western"><surname>Chandel</surname><given-names>A</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Karthikeyan</surname><given-names>S</given-names></name><name name-style="western"><surname>Bachhawat</surname><given-names>AK</given-names></name></person-group><article-title>ChaC2, an enzyme for slow turnover of cytosolic glutathione</article-title><source>J Biol Chem</source><volume>292</volume><fpage>638</fpage><lpage>651</lpage><year>2017</year><pub-id pub-id-type="doi">10.1074/jbc.M116.727479</pub-id><pub-id pub-id-type="pmid">27913623</pub-id><pub-id pub-id-type="pmcid">PMC5241738</pub-id></element-citation></ref><ref id="b48-ijo-65-01-05660"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crawford</surname><given-names>RR</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>ET</given-names></name><name name-style="western"><surname>Sylvester</surname><given-names>CF</given-names></name><name name-style="western"><surname>Higdon</surname><given-names>AN</given-names></name><name name-style="western"><surname>Shan</surname><given-names>J</given-names></name><name name-style="western"><surname>Kilberg</surname><given-names>MS</given-names></name><name name-style="western"><surname>Mungrue</surname><given-names>IN</given-names></name></person-group><article-title>Human CHAC1 protein degrades glutathione, and mRNA induction is regulated by the transcription factors ATF4 and ATF3 and a bipartite ATF/CRE regulatory element</article-title><source>J Biol Chem</source><volume>290</volume><fpage>15878</fpage><lpage>15891</lpage><year>2015</year><pub-id pub-id-type="doi">10.1074/jbc.M114.635144</pub-id><pub-id pub-id-type="pmid">25931127</pub-id><pub-id pub-id-type="pmcid">PMC4505494</pub-id></element-citation></ref><ref id="b49-ijo-65-01-05660"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M</given-names></name></person-group><article-title>Biological characteristics and functions of ChaC1-catalyzed clutathione degradation in the cytoplasm</article-title><source>Chin J Biochem Mol Biol</source><volume>38</volume><fpage>284</fpage><lpage>289</lpage><year>2022</year></element-citation></ref><ref id="b50-ijo-65-01-05660"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chand</surname><given-names>S</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>V</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>RK</given-names></name><name name-style="western"><surname>Anvikar</surname><given-names>AR</given-names></name><name name-style="western"><surname>Chander</surname><given-names>H</given-names></name></person-group><article-title>Cancer informatics analysis indicates high CHAC2 associated with unfavorable prognosis in breast cancer</article-title><source>Front Oncol</source><volume>12</volume><fpage>1058931</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fonc.2022.1058931</pub-id><pub-id pub-id-type="pmid">36568153</pub-id><pub-id pub-id-type="pmcid">PMC9780439</pub-id></element-citation></ref><ref id="b51-ijo-65-01-05660"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsunoda</surname><given-names>S</given-names></name><name name-style="western"><surname>Avezov</surname><given-names>E</given-names></name><name name-style="western"><surname>Zyryanova</surname><given-names>A</given-names></name><name name-style="western"><surname>Konno</surname><given-names>T</given-names></name><name name-style="western"><surname>Mendes-Silva</surname><given-names>L</given-names></name><name name-style="western"><surname>Pinho Melo</surname><given-names>E</given-names></name><name name-style="western"><surname>Harding</surname><given-names>HP</given-names></name><name name-style="western"><surname>Ron</surname><given-names>D</given-names></name></person-group><article-title>Intact protein folding in the glutathione-depleted endoplasmic reticulum implicates alternative protein thiol reductants</article-title><source>Elife</source><volume>3</volume><fpage>e03421</fpage><year>2014</year><pub-id pub-id-type="doi">10.7554/eLife.03421</pub-id><pub-id pub-id-type="pmid">25073928</pub-id><pub-id pub-id-type="pmcid">PMC4109312</pub-id></element-citation></ref><ref id="b52-ijo-65-01-05660"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suyal</surname><given-names>S</given-names></name><name name-style="western"><surname>Choudhury</surname><given-names>C</given-names></name><name name-style="western"><surname>Bachhawat</surname><given-names>AK</given-names></name></person-group><article-title>The ChaC1 active site: Defining the residues and determining the role of ChaC1-exclusive residues in the structural and functional stability</article-title><source>Proteins</source><volume>91</volume><fpage>567</fpage><lpage>580</lpage><year>2023</year><pub-id pub-id-type="doi">10.1002/prot.26450</pub-id><pub-id pub-id-type="pmid">36456186</pub-id></element-citation></ref><ref id="b53-ijo-65-01-05660"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh-Hashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>K</given-names></name><name name-style="western"><surname>Koga</surname><given-names>H</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kiuchi</surname><given-names>K</given-names></name></person-group><article-title>Transcriptional and post-translational regulation of mouse cation transport regulator homolog 1</article-title><source>Mol Cell Biochem</source><volume>380</volume><fpage>97</fpage><lpage>106</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s11010-013-1663-1</pub-id><pub-id pub-id-type="pmid">23615711</pub-id></element-citation></ref><ref id="b54-ijo-65-01-05660"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>MS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SF</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>CY</given-names></name><name name-style="western"><surname>Yin</surname><given-names>PH</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>TS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HC</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>LM</given-names></name></person-group><article-title>CHAC1 degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-eIF2&#945;-ATF4 pathway</article-title><source>Oncotarget</source><volume>8</volume><fpage>114588</fpage><lpage>114602</lpage><year>2017</year><pub-id pub-id-type="doi">10.18632/oncotarget.23055</pub-id><pub-id pub-id-type="pmid">29383104</pub-id><pub-id pub-id-type="pmcid">PMC5777716</pub-id></element-citation></ref><ref id="b55-ijo-65-01-05660"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grimm</surname><given-names>C</given-names></name><name name-style="western"><surname>Hofstetter</surname><given-names>G</given-names></name><name name-style="western"><surname>Aust</surname><given-names>S</given-names></name><name name-style="western"><surname>Mutz-Dehbalaie</surname><given-names>I</given-names></name><name name-style="western"><surname>Bruch</surname><given-names>M</given-names></name><name name-style="western"><surname>Heinze</surname><given-names>G</given-names></name><name name-style="western"><surname>Rahhal-Schupp</surname><given-names>J</given-names></name><name name-style="western"><surname>Reinthaller</surname><given-names>A</given-names></name><name name-style="western"><surname>Concin</surname><given-names>N</given-names></name><name name-style="western"><surname>Polterauer</surname><given-names>S</given-names></name></person-group><article-title>Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer</article-title><source>Br J Cancer</source><volume>109</volume><fpage>610</fpage><lpage>614</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/bjc.2013.323</pub-id><pub-id pub-id-type="pmid">23921280</pub-id><pub-id pub-id-type="pmcid">PMC3738124</pub-id></element-citation></ref><ref id="b56-ijo-65-01-05660"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofbauer</surname><given-names>SL</given-names></name><name name-style="western"><surname>Stangl</surname><given-names>KI</given-names></name><name name-style="western"><surname>de Martino</surname><given-names>M</given-names></name><name name-style="western"><surname>Lucca</surname><given-names>I</given-names></name><name name-style="western"><surname>Haitel</surname><given-names>A</given-names></name><name name-style="western"><surname>Shariat</surname><given-names>SF</given-names></name><name name-style="western"><surname>Klatte</surname><given-names>T</given-names></name></person-group><article-title>Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma</article-title><source>Br J Cancer</source><volume>111</volume><fpage>1526</fpage><lpage>1531</lpage><year>2014</year><pub-id pub-id-type="doi">10.1038/bjc.2014.450</pub-id><pub-id pub-id-type="pmid">25117808</pub-id><pub-id pub-id-type="pmcid">PMC4200090</pub-id></element-citation></ref><ref id="b57-ijo-65-01-05660"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>JR</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Cancer-associated fibroblasts-derived gamma-glutamyltransferase 5 promotes tumor growth and drug resistance in lung adenocarcinoma</article-title><source>Aging (Albany NY)</source><volume>12</volume><fpage>13220</fpage><lpage>13233</lpage><year>2020</year><pub-id pub-id-type="doi">10.18632/aging.103429</pub-id><pub-id pub-id-type="pmid">32640421</pub-id><pub-id pub-id-type="pmcid">PMC7377883</pub-id></element-citation></ref><ref id="b58-ijo-65-01-05660"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name></person-group><article-title>GGT5 is an independent prognostic biomarker in stomach adenocarcinoma</article-title><source>Can J Gastroenterol Hepatol</source><volume>2022</volume><fpage>9983351</fpage><year>2022</year><pub-id pub-id-type="doi">10.1155/2022/9983351</pub-id><pub-id pub-id-type="pmid">35257007</pub-id><pub-id pub-id-type="pmcid">PMC8898138</pub-id></element-citation></ref><ref id="b59-ijo-65-01-05660"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Risch</surname><given-names>HA</given-names></name></person-group><article-title>Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer</article-title><source>BMC Cancer</source><volume>19</volume><fpage>1020</fpage><year>2019</year><pub-id pub-id-type="doi">10.1186/s12885-019-6250-8</pub-id><pub-id pub-id-type="pmid">31664937</pub-id><pub-id pub-id-type="pmcid">PMC6819453</pub-id></element-citation></ref><ref id="b60-ijo-65-01-05660"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shu</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Teng</surname><given-names>R</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Tumor and serum gamma-glutamyl transpeptidase, new prognostic and molecular interpretation of an old biomarker in gastric cancer</article-title><source>Oncotarget</source><volume>8</volume><fpage>36171</fpage><year>2017</year><pub-id pub-id-type="doi">10.18632/oncotarget.15609</pub-id><pub-id pub-id-type="pmid">28404903</pub-id><pub-id pub-id-type="pmcid">PMC5482647</pub-id></element-citation></ref><ref id="b61-ijo-65-01-05660"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durham</surname><given-names>JR</given-names></name><name name-style="western"><surname>Frierson</surname><given-names>HF</given-names></name><name name-style="western"><surname>Hanigan</surname><given-names>MH</given-names></name></person-group><article-title>Gamma-glutamyl transpeptidase immunoreactivity in benign and malignant breast tissue</article-title><source>Breast Cancer Res Treat</source><volume>45</volume><fpage>55</fpage><lpage>62</lpage><year>1997</year><pub-id pub-id-type="doi">10.1023/A:1005889006557</pub-id><pub-id pub-id-type="pmid">9285117</pub-id></element-citation></ref><ref id="b62-ijo-65-01-05660"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name></person-group><article-title>Identification of novel antioxidant gene signature to predict the prognosis of patients with gastric cancer</article-title><source>World J Surg Oncol</source><volume>19</volume><fpage>219</fpage><year>2021</year><pub-id pub-id-type="doi">10.1186/s12957-021-02328-w</pub-id><pub-id pub-id-type="pmid">34284774</pub-id><pub-id pub-id-type="pmcid">PMC8293592</pub-id></element-citation></ref><ref id="b63-ijo-65-01-05660"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Ophiopogonin B induces gastric cancer cell death by blocking the GPX4/xCT-dependent ferroptosis pathway</article-title><source>Oncol Lett</source><volume>23</volume><fpage>104</fpage><year>2022</year><pub-id pub-id-type="doi">10.3892/ol.2022.13224</pub-id><pub-id pub-id-type="pmid">35154435</pub-id><pub-id pub-id-type="pmcid">PMC8822489</pub-id></element-citation></ref><ref id="b64-ijo-65-01-05660"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gagliardi</surname><given-names>M</given-names></name><name name-style="western"><surname>Cotella</surname><given-names>D</given-names></name><name name-style="western"><surname>Santoro</surname><given-names>C</given-names></name><name name-style="western"><surname>Cora</surname><given-names>D</given-names></name><name name-style="western"><surname>Barlev</surname><given-names>NA</given-names></name><name name-style="western"><surname>Piacentini</surname><given-names>M</given-names></name><name name-style="western"><surname>Corazzari</surname><given-names>M</given-names></name></person-group><article-title>Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis</article-title><source>Cell Death Dis</source><volume>10</volume><fpage>902</fpage><year>2019</year><pub-id pub-id-type="doi">10.1038/s41419-019-2143-7</pub-id><pub-id pub-id-type="pmid">31780644</pub-id><pub-id pub-id-type="pmcid">PMC6883066</pub-id></element-citation></ref><ref id="b65-ijo-65-01-05660"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xia</surname><given-names>W</given-names></name></person-group><article-title>ChaC glutathione specific &#947;-glutamylcyclotransferase 1 inhibits cell viability and increases the sensitivity of prostate cancer cells to docetaxel by inducing endoplasmic reticulum stress and ferroptosis</article-title><source>Exp Ther Med</source><volume>22</volume><fpage>997</fpage><year>2021</year><pub-id pub-id-type="doi">10.3892/etm.2021.10429</pub-id><pub-id pub-id-type="pmid">34345279</pub-id><pub-id pub-id-type="pmcid">PMC8311285</pub-id></element-citation></ref><ref id="b66-ijo-65-01-05660"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bai</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name></person-group><article-title>Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response-induced upregulation of CHAC1 expression</article-title><source>Oncol Rep</source><volume>46</volume><fpage>240</fpage><year>2021</year><pub-id pub-id-type="doi">10.3892/or.2021.8191</pub-id><pub-id pub-id-type="pmid">34558645</pub-id><pub-id pub-id-type="pmcid">PMC8485000</pub-id></element-citation></ref><ref id="b67-ijo-65-01-05660"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>GZ</given-names></name><name name-style="western"><surname>Yin</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bian</surname><given-names>ZX</given-names></name></person-group><article-title>Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt's Lymphoma</article-title><source>Biochem Biophys Res Commun</source><volume>519</volume><fpage>533</fpage><lpage>539</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.09.023</pub-id><pub-id pub-id-type="pmid">31537387</pub-id></element-citation></ref><ref id="b68-ijo-65-01-05660"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joo</surname><given-names>NE</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K</given-names></name><name name-style="western"><surname>Kamarajan</surname><given-names>P</given-names></name><name name-style="western"><surname>Miao</surname><given-names>D</given-names></name><name name-style="western"><surname>Kapila</surname><given-names>YL</given-names></name></person-group><article-title>Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1</article-title><source>Cancer Med</source><volume>1</volume><fpage>295</fpage><lpage>305</lpage><year>2012</year><pub-id pub-id-type="doi">10.1002/cam4.35</pub-id><pub-id pub-id-type="pmid">23342279</pub-id><pub-id pub-id-type="pmcid">PMC3544465</pub-id></element-citation></ref><ref id="b69-ijo-65-01-05660"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>PH</given-names></name><name name-style="western"><surname>Shen</surname><given-names>WL</given-names></name><name name-style="western"><surname>Shih</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ho</surname><given-names>KH</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>KC</given-names></name></person-group><article-title>The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity</article-title><source>Neuropharmacology</source><volume>116</volume><fpage>300</fpage><lpage>314</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.12.011</pub-id><pub-id pub-id-type="pmid">27986595</pub-id></element-citation></ref><ref id="b70-ijo-65-01-05660"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Ferroptosis-related gene CHAC1 is a valid indicator for the poor prognosis of kidney renal clear cell carcinoma</article-title><source>J Cell Mol Med</source><volume>25</volume><fpage>3610</fpage><lpage>3621</lpage><year>2021</year><pub-id pub-id-type="doi">10.1111/jcmm.16458</pub-id><pub-id pub-id-type="pmid">33728749</pub-id><pub-id pub-id-type="pmcid">PMC8034464</pub-id></element-citation></ref><ref id="b71-ijo-65-01-05660"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>HH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Chou</surname><given-names>NH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>LF</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YF</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>CY</given-names></name><name name-style="western"><surname>Kung</surname><given-names>ML</given-names></name><name name-style="western"><surname>Tu</surname><given-names>YT</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>KW</given-names></name></person-group><article-title>Metformin inhibits gastric cancer cell proliferation by regulation of a novel Loc100506691-CHAC1 axis</article-title><source>Mol Ther Oncolytics</source><volume>22</volume><fpage>180</fpage><lpage>194</lpage><year>2021</year><pub-id pub-id-type="doi">10.1016/j.omto.2021.08.006</pub-id><pub-id pub-id-type="pmid">34514098</pub-id><pub-id pub-id-type="pmcid">PMC8416970</pub-id></element-citation></ref><ref id="b72-ijo-65-01-05660"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Ding</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bian</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>W</given-names></name></person-group><article-title>Ferroptosis-related gene NOX4, CHAC1 and HIF1A are valid biomarkers for stomach adenocarcinoma</article-title><source>J Cell Mol Med</source><volume>26</volume><fpage>1183</fpage><lpage>1193</lpage><year>2022</year><pub-id pub-id-type="doi">10.1111/jcmm.17171</pub-id><pub-id pub-id-type="pmid">35023280</pub-id><pub-id pub-id-type="pmcid">PMC8831942</pub-id></element-citation></ref><ref id="b73-ijo-65-01-05660"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name></person-group><article-title>Construction of oxidative stress-related genes risk model predicts the prognosis of uterine corpus endometrial cancer patients</article-title><source>Cancers (Basel)</source><volume>14</volume><fpage>5572</fpage><year>2022</year><pub-id pub-id-type="doi">10.3390/cancers14225572</pub-id><pub-id pub-id-type="pmid">36428665</pub-id><pub-id pub-id-type="pmcid">PMC9688652</pub-id></element-citation></ref><ref id="b74-ijo-65-01-05660"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>V</given-names></name><name name-style="western"><surname>Suman</surname><given-names>P</given-names></name><name name-style="western"><surname>Chander</surname><given-names>H</given-names></name></person-group><article-title>High levels of unfolded protein response component CHAC1 associates with cancer progression signatures in malignant breast cancer tissues</article-title><source>Clin Transl Oncol</source><volume>24</volume><fpage>2351</fpage><lpage>2365</lpage><year>2022</year><pub-id pub-id-type="doi">10.1007/s12094-022-02889-6</pub-id><pub-id pub-id-type="pmid">35930144</pub-id></element-citation></ref><ref id="b75-ijo-65-01-05660"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Shi</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name></person-group><article-title>Higher expression of cation transport regulator-like protein 1 (CHAC1) predicts of poor outcomes in uveal melanoma (UM) patients</article-title><source>Int Ophthalmol</source><volume>39</volume><fpage>2825</fpage><lpage>2832</lpage><year>2019</year><pub-id pub-id-type="doi">10.1007/s10792-019-01129-1</pub-id><pub-id pub-id-type="pmid">31161335</pub-id></element-citation></ref><ref id="b76-ijo-65-01-05660"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>A</given-names></name></person-group><article-title>Comprehensive analysis of ferroptosis-related genes and prognosis of cutaneous melanoma</article-title><source>BMC Med Genomics</source><volume>15</volume><fpage>39</fpage><year>2022</year><pub-id pub-id-type="doi">10.1186/s12920-022-01194-z</pub-id><pub-id pub-id-type="pmid">35232428</pub-id><pub-id pub-id-type="pmcid">PMC8886785</pub-id></element-citation></ref><ref id="b77-ijo-65-01-05660"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goebel</surname><given-names>G</given-names></name><name name-style="western"><surname>Berger</surname><given-names>R</given-names></name><name name-style="western"><surname>Strasak</surname><given-names>AM</given-names></name><name name-style="western"><surname>Egle</surname><given-names>D</given-names></name><name name-style="western"><surname>M&#252;ller-Holzner</surname><given-names>E</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>S</given-names></name><name name-style="western"><surname>Rainer</surname><given-names>J</given-names></name><name name-style="western"><surname>Presul</surname><given-names>E</given-names></name><name name-style="western"><surname>Parson</surname><given-names>W</given-names></name><name name-style="western"><surname>Lang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients</article-title><source>Br J Cancer</source><volume>106</volume><fpage>189</fpage><lpage>198</lpage><year>2012</year><pub-id pub-id-type="doi">10.1038/bjc.2011.510</pub-id><pub-id pub-id-type="pmid">22108517</pub-id><pub-id pub-id-type="pmcid">PMC3251857</pub-id></element-citation></ref><ref id="b78-ijo-65-01-05660"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>CK</given-names></name><name name-style="western"><surname>Yang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>FP</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SF</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>CL</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>FL</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name></person-group><article-title>CHAC2 is essential for self-renewal and glutathione maintenance in human embryonic stem cells</article-title><source>Free Radic Biol Med</source><volume>113</volume><fpage>439</fpage><lpage>451</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2017.10.345</pub-id><pub-id pub-id-type="pmid">29054545</pub-id></element-citation></ref><ref id="b79-ijo-65-01-05660"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Fei</surname><given-names>W</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>He</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name></person-group><article-title>CHAC2, downregulated in gastric and colorectal cancers, acted as a tumor suppressor inducing apoptosis and autophagy through unfolded protein response</article-title><source>Cell Death Dis</source><volume>8</volume><fpage>e3009</fpage><year>2017</year><pub-id pub-id-type="doi">10.1038/cddis.2017.405</pub-id><pub-id pub-id-type="pmid">28837156</pub-id><pub-id pub-id-type="pmcid">PMC5596586</pub-id></element-citation></ref><ref id="b80-ijo-65-01-05660"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tchantchou</surname><given-names>F</given-names></name><name name-style="western"><surname>Graves</surname><given-names>M</given-names></name><name name-style="western"><surname>Ashline</surname><given-names>D</given-names></name><name name-style="western"><surname>Morin</surname><given-names>A</given-names></name><name name-style="western"><surname>Pimenta</surname><given-names>A</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>D</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>E</given-names></name><name name-style="western"><surname>Shea</surname><given-names>TB</given-names></name></person-group><article-title>Increased transcription and activity of glutathione synthase in response to deficiencies in folate, vitamin E, and apolipoprotein E</article-title><source>J Neurosci Res</source><volume>75</volume><fpage>508</fpage><lpage>515</lpage><year>2004</year><pub-id pub-id-type="doi">10.1002/jnr.10867</pub-id><pub-id pub-id-type="pmid">14743434</pub-id></element-citation></ref><ref id="b81-ijo-65-01-05660"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>W</given-names></name><name name-style="western"><surname>Wen</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>R</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name></person-group><article-title>CHAC2 promotes lung adenocarcinoma by regulating ROS-mediated MAPK pathway activation</article-title><source>J Cancer</source><volume>14</volume><fpage>1309</fpage><lpage>1320</lpage><year>2023</year><pub-id pub-id-type="doi">10.7150/jca.84036</pub-id><pub-id pub-id-type="pmid">37283797</pub-id><pub-id pub-id-type="pmcid">PMC10240664</pub-id></element-citation></ref><ref id="b82-ijo-65-01-05660"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></name></person-group><article-title>A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma</article-title><source>Front Mol Biosci</source><volume>9</volume><fpage>988323</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fmolb.2022.988323</pub-id><pub-id pub-id-type="pmid">36250026</pub-id><pub-id pub-id-type="pmcid">PMC9561844</pub-id></element-citation></ref><ref id="b83-ijo-65-01-05660"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lisek</surname><given-names>K</given-names></name><name name-style="western"><surname>Campaner</surname><given-names>E</given-names></name><name name-style="western"><surname>Ciani</surname><given-names>Y</given-names></name><name name-style="western"><surname>Walerych</surname><given-names>D</given-names></name><name name-style="western"><surname>Del Sal</surname><given-names>G</given-names></name></person-group><article-title>Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells</article-title><source>Oncotarget</source><volume>9</volume><fpage>20508</fpage><lpage>20523</lpage><year>2018</year><pub-id pub-id-type="doi">10.18632/oncotarget.24974</pub-id><pub-id pub-id-type="pmid">29755668</pub-id><pub-id pub-id-type="pmcid">PMC5945496</pub-id></element-citation></ref><ref id="b84-ijo-65-01-05660"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyce-Brady</surname><given-names>M</given-names></name><name name-style="western"><surname>Jean</surname><given-names>JC</given-names></name><name name-style="western"><surname>Hughey</surname><given-names>RP</given-names></name></person-group><article-title>Gamma-glutamyltransferase and its isoform mediate an endoplasmic reticulum stress response</article-title><source>J Biol Chem</source><volume>276</volume><fpage>9468</fpage><lpage>9477</lpage><year>2001</year><pub-id pub-id-type="doi">10.1074/jbc.M004352200</pub-id><pub-id pub-id-type="pmid">11116135</pub-id></element-citation></ref><ref id="b85-ijo-65-01-05660"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayashima</surname><given-names>K</given-names></name><name name-style="western"><surname>Katoh</surname><given-names>H</given-names></name></person-group><article-title>Expression of gamma-glutamyltransferase 1 in glioblastoma cells confers resistance to cystine deprivation-induced ferroptosis</article-title><source>J Biol Chem</source><volume>298</volume><fpage>101703</fpage><year>2022</year><pub-id pub-id-type="doi">10.1016/j.jbc.2022.101703</pub-id><pub-id pub-id-type="pmid">35148992</pub-id><pub-id pub-id-type="pmcid">PMC8897698</pub-id></element-citation></ref><ref id="b86-ijo-65-01-05660"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramsay</surname><given-names>EE</given-names></name><name name-style="western"><surname>Dilda</surname><given-names>PJ</given-names></name></person-group><article-title>Glutathione S-conjugates as prodrugs to target drug-resistant tumors</article-title><source>Front Pharmacol</source><volume>5</volume><fpage>181</fpage><year>2014</year><pub-id pub-id-type="doi">10.3389/fphar.2014.00181</pub-id><pub-id pub-id-type="pmid">25157234</pub-id><pub-id pub-id-type="pmcid">PMC4127970</pub-id></element-citation></ref><ref id="b87-ijo-65-01-05660"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hyde</surname><given-names>AS</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Barycki</surname><given-names>JJ</given-names></name></person-group><article-title>Emerging regulatory paradigms in glutathione metabolism</article-title><source>Adv Cancer Res</source><volume>122</volume><fpage>69</fpage><lpage>101</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/B978-0-12-420117-0.00002-5</pub-id><pub-id pub-id-type="pmid">24974179</pub-id><pub-id pub-id-type="pmcid">PMC4515967</pub-id></element-citation></ref><ref id="b88-ijo-65-01-05660"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lieberman</surname><given-names>MW</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Shi</surname><given-names>ZZ</given-names></name><name name-style="western"><surname>Carter</surname><given-names>BZ</given-names></name><name name-style="western"><surname>Barrios</surname><given-names>R</given-names></name><name name-style="western"><surname>Ou</surname><given-names>CN</given-names></name><name name-style="western"><surname>Ch&#233;vez-Barrios</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Habib</surname><given-names>GM</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Growth retardation and cysteine deficiency in gamma-glutamyl transpeptidase-deficient mice</article-title><source>Proc Natl Acad Sci USA</source><volume>93</volume><fpage>7923</fpage><lpage>7926</lpage><year>1996</year><pub-id pub-id-type="doi">10.1073/pnas.93.15.7923</pub-id><pub-id pub-id-type="pmid">8755578</pub-id><pub-id pub-id-type="pmcid">PMC38850</pub-id></element-citation></ref><ref id="b89-ijo-65-01-05660"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrios</surname><given-names>R</given-names></name><name name-style="western"><surname>Shi</surname><given-names>ZZ</given-names></name><name name-style="western"><surname>Kala</surname><given-names>SV</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Welty</surname><given-names>SE</given-names></name><name name-style="western"><surname>Kala</surname><given-names>G</given-names></name><name name-style="western"><surname>Bahler</surname><given-names>AA</given-names></name><name name-style="western"><surname>Ou</surname><given-names>CN</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>MW</given-names></name></person-group><article-title>Oxygen-induced pulmonary injury in gamma-glutamyl transpeptidase-deficient mice</article-title><source>Lung</source><volume>179</volume><fpage>319</fpage><lpage>330</lpage><year>2001</year><pub-id pub-id-type="doi">10.1007/s004080000071</pub-id><pub-id pub-id-type="pmid">11976899</pub-id></element-citation></ref><ref id="b90-ijo-65-01-05660"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojas</surname><given-names>E</given-names></name><name name-style="western"><surname>Valverde</surname><given-names>M</given-names></name><name name-style="western"><surname>Kala</surname><given-names>SV</given-names></name><name name-style="western"><surname>Kala</surname><given-names>G</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>MW</given-names></name></person-group><article-title>Accumulation of DNA damage in the organs of mice deficient in gamma-glutamyltranspeptidase</article-title><source>Mutat Res</source><volume>447</volume><fpage>305</fpage><lpage>316</lpage><year>2000</year><pub-id pub-id-type="doi">10.1016/S0027-5107(99)00191-8</pub-id><pub-id pub-id-type="pmid">10751614</pub-id></element-citation></ref><ref id="b91-ijo-65-01-05660"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darin</surname><given-names>N</given-names></name><name name-style="western"><surname>Leckstr&#246;m</surname><given-names>K</given-names></name><name name-style="western"><surname>Sikora</surname><given-names>P</given-names></name><name name-style="western"><surname>Lindgren</surname><given-names>J</given-names></name><name name-style="western"><surname>Alm&#233;n</surname><given-names>G</given-names></name><name name-style="western"><surname>Asin-Cayuela</surname><given-names>J</given-names></name></person-group><article-title>&#947;-glutamyl transpeptidase deficiency caused by a large homozygous intragenic deletion in GGT1</article-title><source>Eur J Hum Genet</source><volume>26</volume><fpage>808</fpage><lpage>817</lpage><year>2018</year><pub-id pub-id-type="doi">10.1038/s41431-018-0122-6</pub-id><pub-id pub-id-type="pmid">29483667</pub-id><pub-id pub-id-type="pmcid">PMC5974402</pub-id></element-citation></ref><ref id="b92-ijo-65-01-05660"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alessandro</surname><given-names>C</given-names></name><name name-style="western"><surname>Maria</surname><given-names>F</given-names></name><name name-style="western"><surname>Aldo</surname><given-names>P</given-names></name><name name-style="western"><surname>Alfonso</surname><given-names>P</given-names></name></person-group><article-title>Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting</article-title><source>Anticancer Res</source><volume>30</volume><fpage>1169</fpage><lpage>1181</lpage><year>2010</year><pub-id pub-id-type="pmid">20530424</pub-id></element-citation></ref><ref id="b93-ijo-65-01-05660"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giommarelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Corti</surname><given-names>A</given-names></name><name name-style="western"><surname>Supino</surname><given-names>R</given-names></name><name name-style="western"><surname>Favini</surname><given-names>E</given-names></name><name name-style="western"><surname>Paolicchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Pompella</surname><given-names>A</given-names></name><name name-style="western"><surname>Zunino</surname><given-names>F</given-names></name></person-group><article-title>Cellular response to oxidative stress and ascorbic acid in melanoma cells overexpressing gamma-glutamyltransferase</article-title><source>Eur J Cancer</source><volume>44</volume><fpage>750</fpage><lpage>759</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/j.ejca.2008.02.010</pub-id><pub-id pub-id-type="pmid">18314325</pub-id></element-citation></ref><ref id="b94-ijo-65-01-05660"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panis</surname><given-names>C</given-names></name><name name-style="western"><surname>Victorino</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>AC</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>LF</given-names></name><name name-style="western"><surname>De Rossi</surname><given-names>T</given-names></name><name name-style="western"><surname>Campos</surname><given-names>FC</given-names></name><name name-style="western"><surname>Sim&#227;o</surname><given-names>AN</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>DS</given-names></name><name name-style="western"><surname>Pinge-Filho</surname><given-names>P</given-names></name><name name-style="western"><surname>Cecchini</surname><given-names>R</given-names></name><name name-style="western"><surname>Cecchini</surname><given-names>AL</given-names></name></person-group><article-title>Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer</article-title><source>Breast Cancer Res Treat</source><volume>133</volume><fpage>881</fpage><lpage>888</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s10549-011-1851-1</pub-id><pub-id pub-id-type="pmid">22048816</pub-id></element-citation></ref><ref id="b95-ijo-65-01-05660"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Cubillos-Ruiz</surname><given-names>JR</given-names></name></person-group><article-title>Endoplasmic reticulum stress signals in the tumour and its microenvironment</article-title><source>Nat Rev Cancer</source><volume>21</volume><fpage>71</fpage><lpage>88</lpage><year>2021</year><pub-id pub-id-type="doi">10.1038/s41568-020-00312-2</pub-id><pub-id pub-id-type="pmid">33214692</pub-id><pub-id pub-id-type="pmcid">PMC7927882</pub-id></element-citation></ref><ref id="b96-ijo-65-01-05660"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name></person-group><article-title>Induction mechanisms of autophagy and endoplasmic reticulum stress in intestinal ischemia-reperfusion injury, inflammatory bowel disease, and colorectal cancer</article-title><source>Biomed Pharmacother</source><volume>170</volume><fpage>115984</fpage><year>2024</year><pub-id pub-id-type="doi">10.1016/j.biopha.2023.115984</pub-id><pub-id pub-id-type="pmid">38070244</pub-id></element-citation></ref><ref id="b97-ijo-65-01-05660"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>N</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name></person-group><article-title>A risk signature based on endoplasmic reticulum stress-associated genes predicts prognosis and immunity in pancreatic cancer</article-title><source>Front Mol Biosci</source><volume>10</volume><fpage>1298077</fpage><year>2023</year><pub-id pub-id-type="doi">10.3389/fmolb.2023.1298077</pub-id><pub-id pub-id-type="pmid">38106991</pub-id><pub-id pub-id-type="pmcid">PMC10721979</pub-id></element-citation></ref><ref id="b98-ijo-65-01-05660"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyce-Brady</surname><given-names>M</given-names></name><name name-style="western"><surname>Jean</surname><given-names>JC</given-names></name><name name-style="western"><surname>Hughey</surname><given-names>RP</given-names></name></person-group><article-title>Gamma-glutamyltransferase and its isoform mediate an endoplasmic reticulum stress response</article-title><source>J Biol Chem</source><volume>276</volume><fpage>9468</fpage><lpage>9477</lpage><year>2001</year><pub-id pub-id-type="doi">10.1074/jbc.M004352200</pub-id><pub-id pub-id-type="pmid">11116135</pub-id></element-citation></ref><ref id="b99-ijo-65-01-05660"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Mo</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>XC</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Crosstalk between endoplasmic reticulum stress and oxidative stress in heat exposure-induced apoptosis is dependent on the ATF4-CHOP-CHAC1 signal pathway in IPEC-J2 cells</article-title><source>J Agric Food Chem</source><volume>69</volume><fpage>15495</fpage><lpage>15511</lpage><year>2021</year><pub-id pub-id-type="doi">10.1021/acs.jafc.1c03361</pub-id><pub-id pub-id-type="pmid">34919378</pub-id></element-citation></ref><ref id="b100-ijo-65-01-05660"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomonobu</surname><given-names>N</given-names></name><name name-style="western"><surname>Komalasari</surname><given-names>NLGY</given-names></name><name name-style="western"><surname>Sumardika</surname><given-names>IW</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>KI</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>R</given-names></name><name name-style="western"><surname>Murata</surname><given-names>H</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>M</given-names></name></person-group><article-title>Xylitol acts as an anticancer monosaccharide to induce selective cancer death via regulation of the glutathione level</article-title><source>Chem Biol Interact</source><volume>324</volume><fpage>109085</fpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cbi.2020.109085</pub-id><pub-id pub-id-type="pmid">32275922</pub-id></element-citation></ref><ref id="b101-ijo-65-01-05660"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhen</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Shang</surname><given-names>P</given-names></name></person-group><article-title>Unraveling the potential role of glutathione in multiple forms of cell death in cancer therapy</article-title><source>Oxid Med Cell Longev</source><volume>2019</volume><fpage>3150145</fpage><year>2019</year><pub-id pub-id-type="doi">10.1155/2019/3150145</pub-id><pub-id pub-id-type="pmid">31281572</pub-id><pub-id pub-id-type="pmcid">PMC6590529</pub-id></element-citation></ref><ref id="b102-ijo-65-01-05660"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>HW</given-names></name><name name-style="western"><surname>Pang</surname><given-names>FX</given-names></name><name name-style="western"><surname>Ding</surname><given-names>SC</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Mai</surname><given-names>YX</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>ST</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>JF</given-names></name></person-group><article-title>Baicalin induces ferroptosis in osteosarcomas through a novel Nrf2/xCT/GPX4 regulatory axis</article-title><source>Phytomedicine</source><volume>116</volume><fpage>154881</fpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.phymed.2023.154881</pub-id><pub-id pub-id-type="pmid">37209607</pub-id></element-citation></ref><ref id="b103-ijo-65-01-05660"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmore</surname><given-names>S</given-names></name></person-group><article-title>Apoptosis: A review of programmed cell death</article-title><source>Toxicol Pathol</source><volume>35</volume><fpage>495</fpage><lpage>516</lpage><year>2007</year><pub-id pub-id-type="doi">10.1080/01926230701320337</pub-id><pub-id pub-id-type="pmid">17562483</pub-id><pub-id pub-id-type="pmcid">PMC2117903</pub-id></element-citation></ref><ref id="b104-ijo-65-01-05660"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfeffer</surname><given-names>CM</given-names></name><name name-style="western"><surname>Singh</surname><given-names>ATK</given-names></name></person-group><article-title>Apoptosis: A target for anticancer therapy</article-title><source>Int J Mol Sci</source><volume>19</volume><fpage>448</fpage><year>2018</year><pub-id pub-id-type="doi">10.3390/ijms19020448</pub-id><pub-id pub-id-type="pmid">29393886</pub-id><pub-id pub-id-type="pmcid">PMC5855670</pub-id></element-citation></ref><ref id="b105-ijo-65-01-05660"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brancaccio</surname><given-names>M</given-names></name><name name-style="western"><surname>Russo</surname><given-names>M</given-names></name><name name-style="western"><surname>Masullo</surname><given-names>M</given-names></name><name name-style="western"><surname>Palumbo</surname><given-names>A</given-names></name><name name-style="western"><surname>Russo</surname><given-names>GL</given-names></name><name name-style="western"><surname>Castellano</surname><given-names>I</given-names></name></person-group><article-title>Sulfur-containing histidine compounds inhibit &#947;-glutamyl transpeptidase activity in human cancer cells</article-title><source>J Biol Chem</source><volume>294</volume><fpage>14603</fpage><lpage>14614</lpage><year>2019</year><pub-id pub-id-type="doi">10.1074/jbc.RA119.009304</pub-id><pub-id pub-id-type="pmid">31375562</pub-id><pub-id pub-id-type="pmcid">PMC6779435</pub-id></element-citation></ref><ref id="b106-ijo-65-01-05660"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bui</surname><given-names>TT</given-names></name><name name-style="western"><surname>Nitta</surname><given-names>RT</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>SA</given-names></name><name name-style="western"><surname>Razavi</surname><given-names>SM</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>M</given-names></name><name name-style="western"><surname>Aujla</surname><given-names>P</given-names></name><name name-style="western"><surname>Gholamin</surname><given-names>S</given-names></name><name name-style="western"><surname>Recht</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name></person-group><article-title>&#947;-Glutamyl transferase 7 is a novel regulator of glioblastoma growth</article-title><source>BMC Cancer</source><volume>15</volume><fpage>225</fpage><year>2015</year><pub-id pub-id-type="doi">10.1186/s12885-015-1232-y</pub-id><pub-id pub-id-type="pmid">25884624</pub-id><pub-id pub-id-type="pmcid">PMC4393868</pub-id></element-citation></ref><ref id="b107-ijo-65-01-05660"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirschhorn</surname><given-names>T</given-names></name><name name-style="western"><surname>Stockwell</surname><given-names>BR</given-names></name></person-group><article-title>The development of the concept of ferroptosis</article-title><source>Free Radic Biol Med</source><volume>133</volume><fpage>130</fpage><lpage>143</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2018.09.043</pub-id><pub-id pub-id-type="pmid">30268886</pub-id><pub-id pub-id-type="pmcid">PMC6368883</pub-id></element-citation></ref><ref id="b108-ijo-65-01-05660"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>L</given-names></name><name name-style="western"><surname>Gan</surname><given-names>B</given-names></name></person-group><article-title>Targeting ferroptosis as a vulnerability in cancer</article-title><source>Nat Rev Cancer</source><volume>22</volume><fpage>381</fpage><lpage>396</lpage><year>2022</year><pub-id pub-id-type="doi">10.1038/s41568-022-00459-0</pub-id><pub-id pub-id-type="pmid">35338310</pub-id><pub-id pub-id-type="pmcid">PMC10243716</pub-id></element-citation></ref><ref id="b109-ijo-65-01-05660"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wen</surname><given-names>T</given-names></name><name name-style="western"><surname>Marzio</surname><given-names>A</given-names></name><name name-style="western"><surname>Song</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Ferri</surname><given-names>A</given-names></name><etal/></person-group><article-title>FBXO32-mediated degradation of PTEN promotes lung adenocarcinoma progression</article-title><source>Cell Death Dis</source><volume>15</volume><fpage>282</fpage><year>2024</year><pub-id pub-id-type="doi">10.1038/s41419-024-06635-4</pub-id><pub-id pub-id-type="pmid">38643215</pub-id><pub-id pub-id-type="pmcid">PMC11032391</pub-id></element-citation></ref><ref id="b110-ijo-65-01-05660"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>CH</given-names></name><name name-style="western"><surname>Ding</surname><given-names>DS</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HL</given-names></name><name name-style="western"><surname>Mao</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>GJ</given-names></name></person-group><article-title>The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the PTEN/PI3K/AKT/mTOR signaling</article-title><source>Bioengineered</source><volume>13</volume><fpage>8478</fpage><lpage>8489</lpage><year>2022</year><pub-id pub-id-type="doi">10.1080/21655979.2022.2051687</pub-id><pub-id pub-id-type="pmid">35322748</pub-id><pub-id pub-id-type="pmcid">PMC9161980</pub-id></element-citation></ref><ref id="b111-ijo-65-01-05660"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>CB</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name></person-group><article-title>Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis</article-title><source>Proc Natl Acad Sci USA</source><volume>117</volume><fpage>31189</fpage><lpage>31197</lpage><year>2020</year><pub-id pub-id-type="doi">10.1073/pnas.2017152117</pub-id><pub-id pub-id-type="pmid">33229547</pub-id><pub-id pub-id-type="pmcid">PMC7733797</pub-id></element-citation></ref><ref id="b112-ijo-65-01-05660"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Accaoui</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Enoiu</surname><given-names>M</given-names></name><name name-style="western"><surname>Mergny</surname><given-names>M</given-names></name><name name-style="western"><surname>Masson</surname><given-names>C</given-names></name><name name-style="western"><surname>Dominici</surname><given-names>S</given-names></name><name name-style="western"><surname>Wellman</surname><given-names>M</given-names></name><name name-style="western"><surname>Visvikis</surname><given-names>A</given-names></name></person-group><article-title>Gamma-glutamyltranspeptidase-dependent glutathione catabolism results in activation of NF-kB</article-title><source>Biochem Biophys Res Commun</source><volume>276</volume><fpage>1062</fpage><lpage>1067</lpage><year>2000</year><pub-id pub-id-type="doi">10.1006/bbrc.2000.3585</pub-id><pub-id pub-id-type="pmid">11027590</pub-id></element-citation></ref><ref id="b113-ijo-65-01-05660"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djavaheri-Mergny</surname><given-names>M</given-names></name><name name-style="western"><surname>Accaoui</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Rouillard</surname><given-names>D</given-names></name><name name-style="western"><surname>Wietzerbin</surname><given-names>J</given-names></name></person-group><article-title>Gamma-glutamyl transpeptidase activity mediates NF-kappaB activation through lipid peroxidation in human leukemia U937 cells</article-title><source>Mol Cell Biochem</source><volume>232</volume><fpage>103</fpage><lpage>111</lpage><year>2002</year><pub-id pub-id-type="doi">10.1023/A:1014834315936</pub-id><pub-id pub-id-type="pmid">12030366</pub-id></element-citation></ref><ref id="b114-ijo-65-01-05660"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franzini</surname><given-names>M</given-names></name><name name-style="western"><surname>Corti</surname><given-names>A</given-names></name><name name-style="western"><surname>Lorenzini</surname><given-names>E</given-names></name><name name-style="western"><surname>Paolicchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Pompella</surname><given-names>A</given-names></name><name name-style="western"><surname>De Cesare</surname><given-names>M</given-names></name><name name-style="western"><surname>Perego</surname><given-names>P</given-names></name><name name-style="western"><surname>Gatti</surname><given-names>L</given-names></name><name name-style="western"><surname>Leone</surname><given-names>R</given-names></name><name name-style="western"><surname>Apostoli</surname><given-names>P</given-names></name><name name-style="western"><surname>Zunino</surname><given-names>F</given-names></name></person-group><article-title>Modulation of cell growth and cisplatin sensitivity by membrane gamma-glutamyltransferase in melanoma cells</article-title><source>Eur J Cancer</source><volume>42</volume><fpage>2623</fpage><lpage>2630</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.ejca.2006.04.016</pub-id><pub-id pub-id-type="pmid">16928443</pub-id></element-citation></ref><ref id="b115-ijo-65-01-05660"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Long</surname><given-names>YC</given-names></name></person-group><article-title>Crosstalk between cystine and glutathione is critical for the regulation of amino acid signaling pathways and ferroptosis</article-title><source>Sci Rep</source><volume>6</volume><fpage>30033</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/srep30033</pub-id><pub-id pub-id-type="pmid">27425006</pub-id><pub-id pub-id-type="pmcid">PMC4948025</pub-id></element-citation></ref><ref id="b116-ijo-65-01-05660"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ding</surname><given-names>CK</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Sjol</surname><given-names>J</given-names></name><name name-style="western"><surname>Wardell</surname><given-names>S</given-names></name><name name-style="western"><surname>Spasojevic</surname><given-names>I</given-names></name><name name-style="western"><surname>George</surname><given-names>D</given-names></name><name name-style="western"><surname>McDonnell</surname><given-names>DP</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>DS</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JT</given-names></name><name name-style="western"><surname>Chi</surname><given-names>JT</given-names></name></person-group><article-title>Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling</article-title><source>Oncogene</source><volume>36</volume><fpage>4235</fpage><lpage>4242</lpage><year>2017</year><pub-id pub-id-type="doi">10.1038/onc.2016.394</pub-id><pub-id pub-id-type="pmid">27869167</pub-id><pub-id pub-id-type="pmcid">PMC5438912</pub-id></element-citation></ref><ref id="b117-ijo-65-01-05660"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dixon</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Patel</surname><given-names>DN</given-names></name><name name-style="western"><surname>Welsch</surname><given-names>M</given-names></name><name name-style="western"><surname>Skouta</surname><given-names>R</given-names></name><name name-style="western"><surname>Lee</surname><given-names>ED</given-names></name><name name-style="western"><surname>Hayano</surname><given-names>M</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>AG</given-names></name><name name-style="western"><surname>Gleason</surname><given-names>CE</given-names></name><name name-style="western"><surname>Tatonetti</surname><given-names>NP</given-names></name><name name-style="western"><surname>Slusher</surname><given-names>BS</given-names></name><name name-style="western"><surname>Stockwell</surname><given-names>BR</given-names></name></person-group><article-title>Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis</article-title><source>Elife</source><volume>3</volume><fpage>e02523</fpage><year>2014</year><pub-id pub-id-type="doi">10.7554/eLife.02523</pub-id><pub-id pub-id-type="pmid">24844246</pub-id><pub-id pub-id-type="pmcid">PMC4054777</pub-id></element-citation></ref><ref id="b118-ijo-65-01-05660"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galluzzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>O</given-names></name><name name-style="western"><surname>Chan</surname><given-names>FKM</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Necroptosis: Mechanisms and relevance to disease</article-title><source>Annu Rev Pathol</source><volume>12</volume><fpage>103</fpage><lpage>130</lpage><year>2017</year><pub-id pub-id-type="doi">10.1146/annurev-pathol-052016-100247</pub-id><pub-id pub-id-type="pmid">27959630</pub-id><pub-id pub-id-type="pmcid">PMC5786374</pub-id></element-citation></ref><ref id="b119-ijo-65-01-05660"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xin</surname><given-names>T</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Raheem</surname><given-names>A</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CR</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J</given-names></name></person-group><article-title>Regulated necrosis, a proinflammatory cell death, potentially counteracts pathogenic infections</article-title><source>Cell Death Dis</source><volume>13</volume><fpage>637</fpage><year>2022</year><pub-id pub-id-type="doi">10.1038/s41419-022-05066-3</pub-id><pub-id pub-id-type="pmid">35869043</pub-id><pub-id pub-id-type="pmcid">PMC9307826</pub-id></element-citation></ref><ref id="b120-ijo-65-01-05660"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Klionsky</surname><given-names>DJ</given-names></name></person-group><article-title>An overview of the molecular mechanism of autophagy</article-title><source>Curr Top Microbiol Immunol</source><volume>335</volume><fpage>1</fpage><lpage>32</lpage><year>2009</year><pub-id pub-id-type="pmid">19802558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-642-00302-8_1</pub-id><pub-id pub-id-type="pmcid">PMC2832191</pub-id></element-citation></ref><ref id="b121-ijo-65-01-05660"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Deng</surname><given-names>R</given-names></name></person-group><article-title>GGT1 suppresses the development of ferroptosis and autophagy in mouse retinal ganglion cell through targeting GCLC</article-title><source>Eye Brain</source><volume>15</volume><fpage>139</fpage><lpage>151</lpage><year>2023</year><pub-id pub-id-type="doi">10.2147/EB.S434280</pub-id><pub-id pub-id-type="pmid">38020723</pub-id><pub-id pub-id-type="pmcid">PMC10676118</pub-id></element-citation></ref><ref id="b122-ijo-65-01-05660"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohrab</surname><given-names>SS</given-names></name><name name-style="western"><surname>Raj</surname><given-names>R</given-names></name><name name-style="western"><surname>Nagar</surname><given-names>A</given-names></name><name name-style="western"><surname>Hawthorne</surname><given-names>S</given-names></name><name name-style="western"><surname>Paiva-Santos</surname><given-names>AC</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>MA</given-names></name><name name-style="western"><surname>El-Daly</surname><given-names>MM</given-names></name><name name-style="western"><surname>Azhar</surname><given-names>EI</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name></person-group><article-title>Chronic inflammation's transformation to cancer: A nanotherapeutic paradigm</article-title><source>Molecules</source><volume>28</volume><fpage>4413</fpage><year>2023</year><pub-id pub-id-type="doi">10.3390/molecules28114413</pub-id><pub-id pub-id-type="pmid">37298889</pub-id><pub-id pub-id-type="pmcid">PMC10254455</pub-id></element-citation></ref><ref id="b123-ijo-65-01-05660"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ying</surname><given-names>HQ</given-names></name><name name-style="western"><surname>Liao</surname><given-names>YC</given-names></name><name name-style="western"><surname>Luo</surname><given-names>YR</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>G</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nie</surname><given-names>RW</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>CF</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>XX</given-names></name></person-group><article-title>Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC</article-title><source>Pharmacol Res</source><volume>170</volume><fpage>105734</fpage><year>2021</year><pub-id pub-id-type="doi">10.1016/j.phrs.2021.105734</pub-id><pub-id pub-id-type="pmid">34157424</pub-id></element-citation></ref><ref id="b124-ijo-65-01-05660"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carr</surname><given-names>B</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>V</given-names></name></person-group><article-title>Serum inflammation parameters and survival in hepatocellular carcinoma patients: Importance of albumin and gamma-glutamyltranspeptidase</article-title><source>Oncology</source><volume>101</volume><fpage>313</fpage><lpage>320</lpage><year>2023</year><pub-id pub-id-type="doi">10.1159/000527650</pub-id><pub-id pub-id-type="pmid">36878197</pub-id><pub-id pub-id-type="pmcid">PMC10238618</pub-id></element-citation></ref><ref id="b125-ijo-65-01-05660"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozcelik</surname><given-names>F</given-names></name></person-group><article-title>Prognostic value of gamma-glutamyl transpeptidase in liver cirrhosis and hepatocellular cancer regardless of other parameters</article-title><source>Clin Res Hepatol Gastroenterol</source><volume>45</volume><fpage>101708</fpage><year>2021</year><pub-id pub-id-type="doi">10.1016/j.clinre.2021.101708</pub-id><pub-id pub-id-type="pmid">33930592</pub-id></element-citation></ref><ref id="b126-ijo-65-01-05660"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>J</given-names></name><name name-style="western"><surname>Chander</surname><given-names>J</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>G</given-names></name><name name-style="western"><surname>Atal</surname><given-names>CK</given-names></name></person-group><article-title>Gamma-glutamyl transpeptidase: A novel biochemical marker in inflammation</article-title><source>Biochem Pharmacol</source><volume>35</volume><fpage>3753</fpage><lpage>3760</lpage><year>1986</year><pub-id pub-id-type="doi">10.1016/0006-2952(86)90661-1</pub-id><pub-id pub-id-type="pmid">2877669</pub-id></element-citation></ref><ref id="b127-ijo-65-01-05660"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ricci</surname><given-names>V</given-names></name><name name-style="western"><surname>Giannouli</surname><given-names>M</given-names></name><name name-style="western"><surname>Romano</surname><given-names>M</given-names></name><name name-style="western"><surname>Zarrilli</surname><given-names>R</given-names></name></person-group><article-title>Helicobacter pylori gamma-glutamyl transpeptidase and its pathogenic role</article-title><source>World J Gastroenterol</source><volume>20</volume><fpage>630</fpage><lpage>638</lpage><year>2014</year><pub-id pub-id-type="doi">10.3748/wjg.v20.i3.630</pub-id><pub-id pub-id-type="pmid">24574736</pub-id><pub-id pub-id-type="pmcid">PMC3921472</pub-id></element-citation></ref><ref id="b128-ijo-65-01-05660"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oertli</surname><given-names>M</given-names></name><name name-style="western"><surname>Noben</surname><given-names>M</given-names></name><name name-style="western"><surname>Engler</surname><given-names>DB</given-names></name><name name-style="western"><surname>Semper</surname><given-names>RP</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>S</given-names></name><name name-style="western"><surname>Maxeiner</surname><given-names>J</given-names></name><name name-style="western"><surname>Gerhard</surname><given-names>M</given-names></name><name name-style="western"><surname>Taube</surname><given-names>C</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>A</given-names></name></person-group><article-title>Helicobacter pylori &#947;-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance</article-title><source>Proc Natl Acad Sci USA</source><volume>110</volume><fpage>3047</fpage><lpage>3052</lpage><year>2013</year><pub-id pub-id-type="doi">10.1073/pnas.1211248110</pub-id><pub-id pub-id-type="pmid">23382221</pub-id><pub-id pub-id-type="pmcid">PMC3581963</pub-id></element-citation></ref><ref id="b129-ijo-65-01-05660"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C</given-names></name><name name-style="western"><surname>He</surname><given-names>C</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>NH</given-names></name></person-group><article-title>Integrative analysis of differential lncRNA/mRNA expression profiling in Helicobacter pylori infection-associated gastric carcinogenesis</article-title><source>Front Microbiol</source><volume>11</volume><fpage>880</fpage><year>2020</year><pub-id pub-id-type="doi">10.3389/fmicb.2020.00880</pub-id><pub-id pub-id-type="pmid">32457731</pub-id><pub-id pub-id-type="pmcid">PMC7225608</pub-id></element-citation></ref><ref id="b130-ijo-65-01-05660"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takemura</surname><given-names>K</given-names></name><name name-style="western"><surname>Tummala</surname><given-names>P</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>K</given-names></name><name name-style="western"><surname>Kitagaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Ishige</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ito</surname><given-names>T</given-names></name><name name-style="western"><surname>Hara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Helicobacter pylori induces somatic mutations in TP53 via overexpression of CHAC1 in infected gastric epithelial cells</article-title><source>FEBS Open Bio</source><volume>8</volume><fpage>671</fpage><lpage>679</lpage><year>2018</year><pub-id pub-id-type="doi">10.1002/2211-5463.12402</pub-id><pub-id pub-id-type="pmid">29632819</pub-id><pub-id pub-id-type="pmcid">PMC5881537</pub-id></element-citation></ref><ref id="b131-ijo-65-01-05660"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Wada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takemura</surname><given-names>K</given-names></name><name name-style="western"><surname>Board</surname><given-names>PG</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>K</given-names></name><name name-style="western"><surname>Kitagaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Tokairin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Eishi</surname><given-names>Y</given-names></name></person-group><article-title>CHAC1 overexpression in human gastric parietal cells with Helicobacter pylori infection in the secretory canaliculi</article-title><source>Helicobacter</source><volume>24</volume><fpage>e12598</fpage><year>2019</year><pub-id pub-id-type="doi">10.1111/hel.12598</pub-id><pub-id pub-id-type="pmid">31111570</pub-id><pub-id pub-id-type="pmcid">PMC6618068</pub-id></element-citation></ref><ref id="b132-ijo-65-01-05660"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perra</surname><given-names>L</given-names></name><name name-style="western"><surname>Balloy</surname><given-names>V</given-names></name><name name-style="western"><surname>Foussigni&#232;re</surname><given-names>T</given-names></name><name name-style="western"><surname>Moissenet</surname><given-names>D</given-names></name><name name-style="western"><surname>Petat</surname><given-names>H</given-names></name><name name-style="western"><surname>Mungrue</surname><given-names>IN</given-names></name><name name-style="western"><surname>Touqui</surname><given-names>L</given-names></name><name name-style="western"><surname>Corvol</surname><given-names>H</given-names></name><name name-style="western"><surname>Chignard</surname><given-names>M</given-names></name><name name-style="western"><surname>Guillot</surname><given-names>L</given-names></name></person-group><article-title>CHAC1 is differentially expressed in normal and cystic fibrosis bronchial epithelial cells and regulates the inflammatory response induced by Pseudomonas aeruginosa</article-title><source>Front Immunol</source><volume>9</volume><fpage>2823</fpage><year>2018</year><pub-id pub-id-type="doi">10.3389/fimmu.2018.02823</pub-id><pub-id pub-id-type="pmid">30555487</pub-id><pub-id pub-id-type="pmcid">PMC6282009</pub-id></element-citation></ref><ref id="b133-ijo-65-01-05660"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rousset-Jablonski</surname><given-names>C</given-names></name><name name-style="western"><surname>Dalon</surname><given-names>F</given-names></name><name name-style="western"><surname>Reynaud</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lemonnier</surname><given-names>L</given-names></name><name name-style="western"><surname>Dehillotte</surname><given-names>C</given-names></name><name name-style="western"><surname>Jacoud</surname><given-names>F</given-names></name><name name-style="western"><surname>Berard</surname><given-names>M</given-names></name><name name-style="western"><surname>Viprey</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Ganse</surname><given-names>E</given-names></name><name name-style="western"><surname>Durieu</surname><given-names>I</given-names></name><name name-style="western"><surname>Belhassen</surname><given-names>M</given-names></name></person-group><article-title>Cancer incidence and prevalence in cystic fibrosis patients with and without a lung transplant in France</article-title><source>Front Public Health</source><volume>10</volume><fpage>1043691</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fpubh.2022.1043691</pub-id><pub-id pub-id-type="pmid">36483264</pub-id><pub-id pub-id-type="pmcid">PMC9723348</pub-id></element-citation></ref><ref id="b134-ijo-65-01-05660"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daubeuf</surname><given-names>S</given-names></name><name name-style="western"><surname>Leroy</surname><given-names>P</given-names></name><name name-style="western"><surname>Paolicchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Pompella</surname><given-names>A</given-names></name><name name-style="western"><surname>Wellman</surname><given-names>M</given-names></name><name name-style="western"><surname>Galteau</surname><given-names>MM</given-names></name><name name-style="western"><surname>Visvikis</surname><given-names>A</given-names></name></person-group><article-title>Enhanced resistance of HeLa cells to cisplatin by overexpression of gamma-glutamyltransferase</article-title><source>Biochem Pharmacol</source><volume>64</volume><fpage>207</fpage><lpage>216</lpage><year>2002</year><pub-id pub-id-type="doi">10.1016/S0006-2952(02)01118-8</pub-id><pub-id pub-id-type="pmid">12123741</pub-id></element-citation></ref><ref id="b135-ijo-65-01-05660"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Q</given-names></name></person-group><article-title>Platinum-based drugs for cancer therapy and anti-tumor strategies</article-title><source>Theranostics</source><volume>12</volume><fpage>2115</fpage><lpage>2132</lpage><year>2022</year><pub-id pub-id-type="doi">10.7150/thno.69424</pub-id><pub-id pub-id-type="pmid">35265202</pub-id><pub-id pub-id-type="pmcid">PMC8899578</pub-id></element-citation></ref><ref id="b136-ijo-65-01-05660"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>He</surname><given-names>S</given-names></name><name name-style="western"><surname>He</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Fighting against drug-resistant tumors by the inhibition of &#947;-glutamyl transferase with supramolecular platinum prodrug nano-assemblies</article-title><source>J Mater Chem B</source><volume>9</volume><fpage>4587</fpage><lpage>4595</lpage><year>2021</year><pub-id pub-id-type="doi">10.1039/D1TB00149C</pub-id><pub-id pub-id-type="pmid">34059856</pub-id></element-citation></ref><ref id="b137-ijo-65-01-05660"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanigan</surname><given-names>MH</given-names></name><name name-style="western"><surname>Frierson</surname><given-names>HF</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Abeler</surname><given-names>VM</given-names></name><name name-style="western"><surname>Kaern</surname><given-names>J</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>PT</given-names><suffix>Jr</suffix></name></person-group><article-title>Human germ cell tumours: Expression of gamma-glutamyl transpeptidase and sensitivity to cisplatin</article-title><source>Br J Cancer</source><volume>81</volume><fpage>75</fpage><lpage>79</lpage><year>1999</year><pub-id pub-id-type="doi">10.1038/sj.bjc.6690653</pub-id><pub-id pub-id-type="pmid">10487615</pub-id><pub-id pub-id-type="pmcid">PMC2374348</pub-id></element-citation></ref><ref id="b138-ijo-65-01-05660"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Zaal</surname><given-names>EA</given-names></name><name name-style="western"><surname>Berkers</surname><given-names>CR</given-names></name><name name-style="western"><surname>Ruijtenbeek</surname><given-names>R</given-names></name><name name-style="western"><surname>Garssen</surname><given-names>J</given-names></name><name name-style="western"><surname>Redegeld</surname><given-names>FA</given-names></name></person-group><article-title>Omega-3 fatty acids DHA and EPA reduce bortezomib resistance in multiple myeloma cells by promoting glutathione degradation</article-title><source>Cells</source><volume>10</volume><fpage>2287</fpage><year>2021</year><pub-id pub-id-type="doi">10.3390/cells10092287</pub-id><pub-id pub-id-type="pmid">34571936</pub-id><pub-id pub-id-type="pmcid">PMC8465636</pub-id></element-citation></ref><ref id="b139-ijo-65-01-05660"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ke</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name></person-group><article-title>Brusatol hinders the progression of bladder cancer by Chac1/Nrf2/SLC7A11 pathway</article-title><source>Exp Cell Res</source><volume>438</volume><fpage>114053</fpage><year>2024</year><pub-id pub-id-type="doi">10.1016/j.yexcr.2024.114053</pub-id><pub-id pub-id-type="pmid">38663476</pub-id></element-citation></ref><ref id="b140-ijo-65-01-05660"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Bai</surname><given-names>YT</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G</given-names></name></person-group><article-title>Glaucocalyxin A impairs tumor growth via amplification of the ATF4/CHOP/CHAC1 cascade in human oral squamous cell carcinoma</article-title><source>J Ethnopharmacol</source><volume>290</volume><fpage>115100</fpage><year>2022</year><pub-id pub-id-type="doi">10.1016/j.jep.2022.115100</pub-id><pub-id pub-id-type="pmid">35151835</pub-id></element-citation></ref><ref id="b141-ijo-65-01-05660"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Analysis of lncRNA UCA1-related downstream pathways and molecules of cisplatin resistance in lung adenocarcinoma</article-title><source>J Clin Lab Anal</source><volume>34</volume><fpage>e23312</fpage><year>2020</year><pub-id pub-id-type="doi">10.1002/jcla.23312</pub-id><pub-id pub-id-type="pmid">32249461</pub-id><pub-id pub-id-type="pmcid">PMC7439354</pub-id></element-citation></ref><ref id="b142-ijo-65-01-05660"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chon</surname><given-names>YE</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MN</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>SG</given-names></name></person-group><article-title>Gamma-glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non-alcoholic fatty liver disease</article-title><source>J Gastroenterol Hepatol</source><volume>37</volume><fpage>1624</fpage><lpage>1632</lpage><year>2022</year><pub-id pub-id-type="doi">10.1111/jgh.15871</pub-id><pub-id pub-id-type="pmid">35467042</pub-id></element-citation></ref><ref id="b143-ijo-65-01-05660"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name></person-group><article-title>Gamma-glutamyl transpeptidase to albumin ratio holds a prognostic significance after hepatectomy in patients with hepatocellular carcinoma and liver cirrhosis</article-title><source>Asian J Surg</source><volume>46</volume><fpage>1327</fpage><lpage>1328</lpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.asjsur.2022.08.098</pub-id><pub-id pub-id-type="pmid">36114069</pub-id></element-citation></ref><ref id="b144-ijo-65-01-05660"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishizaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Kido</surname><given-names>T</given-names></name><name name-style="western"><surname>Honda</surname><given-names>R</given-names></name><name name-style="western"><surname>Tsuritani</surname><given-names>I</given-names></name><name name-style="western"><surname>Ikai</surname><given-names>E</given-names></name><name name-style="western"><surname>Yamaya</surname><given-names>H</given-names></name></person-group><article-title>Alcohol, high blood pressure, and serum gamma-glutamyl transpeptidase level</article-title><source>Hypertension</source><volume>18</volume><fpage>819</fpage><lpage>826</lpage><year>1991</year><pub-id pub-id-type="doi">10.1161/01.HYP.18.6.819</pub-id><pub-id pub-id-type="pmid">1683858</pub-id></element-citation></ref><ref id="b145-ijo-65-01-05660"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takemura</surname><given-names>K</given-names></name><name name-style="western"><surname>Board</surname><given-names>PG</given-names></name><name name-style="western"><surname>Koga</surname><given-names>F</given-names></name></person-group><article-title>A systematic review of serum &#947;-glutamyltransferase as a prognostic biomarker in patients with genitourinary cancer</article-title><source>Antioxidants (Basel)</source><volume>10</volume><fpage>549</fpage><year>2021</year><pub-id pub-id-type="doi">10.3390/antiox10040549</pub-id><pub-id pub-id-type="pmid">33916150</pub-id><pub-id pub-id-type="pmcid">PMC8066142</pub-id></element-citation></ref><ref id="b146-ijo-65-01-05660"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>RQ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Jia</surname><given-names>YM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>RX</given-names></name><name name-style="western"><surname>Peng</surname><given-names>L</given-names></name></person-group><article-title>Preoperative CA19-9 and GGT ratio as a prognostic indicator in ampullary carcinoma</article-title><source>BMC Gastroenterol</source><volume>23</volume><fpage>72</fpage><year>2023</year><pub-id pub-id-type="doi">10.1186/s12876-022-02623-0</pub-id><pub-id pub-id-type="pmid">36915042</pub-id><pub-id pub-id-type="pmcid">PMC10012447</pub-id></element-citation></ref><ref id="b147-ijo-65-01-05660"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name></person-group><article-title>A water-soluble fluorescent probe for the determination of &#947;-glutamyltransferase activity and its application in tumor imaging</article-title><source>Talanta</source><volume>253</volume><fpage>123943</fpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.talanta.2022.123943</pub-id><pub-id pub-id-type="pmid">36150339</pub-id></element-citation></ref><ref id="b148-ijo-65-01-05660"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>D</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lv</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L</given-names></name></person-group><article-title>A fluorine-18 labeled radiotracer for PET imaging of &#947;-glutamyltranspeptidase in living subjects</article-title><source>RSC Adv</source><volume>11</volume><fpage>18738</fpage><lpage>18747</lpage><year>2021</year><pub-id pub-id-type="doi">10.1039/D1RA01324F</pub-id><pub-id pub-id-type="pmid">35478654</pub-id><pub-id pub-id-type="pmcid">PMC9033604</pub-id></element-citation></ref><ref id="b149-ijo-65-01-05660"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou-Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>WL</given-names></name><name name-style="western"><surname>He</surname><given-names>SY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>HW</given-names></name><name name-style="western"><surname>Li</surname><given-names>CY</given-names></name></person-group><article-title>Fluorescence-guided cancer diagnosis and surgery by a zero cross-talk ratiometric near-infrared &#947;-glutamyltranspeptidase fluorescent probe</article-title><source>Anal Chem</source><volume>91</volume><fpage>1056</fpage><lpage>1063</lpage><year>2019</year><pub-id pub-id-type="doi">10.1021/acs.analchem.8b04416</pub-id><pub-id pub-id-type="pmid">30539637</pub-id></element-citation></ref><ref id="b150-ijo-65-01-05660"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>He</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gong</surname><given-names>L</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>K</given-names></name></person-group><article-title>Analysis of ferroptosis-mediated modification patterns and tumor immune microenvironment characterization in uveal melanoma</article-title><source>Front Cell Dev Biol</source><volume>9</volume><fpage>685120</fpage><year>2021</year><pub-id pub-id-type="doi">10.3389/fcell.2021.685120</pub-id><pub-id pub-id-type="pmid">34386492</pub-id><pub-id pub-id-type="pmcid">PMC8353259</pub-id></element-citation></ref><ref id="b151-ijo-65-01-05660"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>V</given-names></name><name name-style="western"><surname>Meena</surname><given-names>J</given-names></name><name name-style="western"><surname>Kasana</surname><given-names>H</given-names></name><name name-style="western"><surname>Munshi</surname><given-names>A</given-names></name><name name-style="western"><surname>Chander</surname><given-names>H</given-names></name></person-group><article-title>Prognostic significance of CHAC1 expression in breast cancer</article-title><source>Mol Biol Rep</source><volume>49</volume><fpage>8517</fpage><lpage>8526</lpage><year>2022</year><pub-id pub-id-type="doi">10.1007/s11033-022-07673-x</pub-id><pub-id pub-id-type="pmid">35729480</pub-id></element-citation></ref><ref id="b152-ijo-65-01-05660"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jahn</surname><given-names>B</given-names></name><name name-style="western"><surname>Arvandi</surname><given-names>M</given-names></name><name name-style="western"><surname>Rochau</surname><given-names>U</given-names></name><name name-style="western"><surname>Fiegl</surname><given-names>H</given-names></name><name name-style="western"><surname>Goebel</surname><given-names>G</given-names></name><name name-style="western"><surname>Marth</surname><given-names>C</given-names></name><name name-style="western"><surname>Siebert</surname><given-names>U</given-names></name></person-group><article-title>Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1</article-title><source>J Comp Eff Res</source><volume>6</volume><fpage>563</fpage><lpage>574</lpage><year>2017</year><pub-id pub-id-type="doi">10.2217/cer-2017-0015</pub-id><pub-id pub-id-type="pmid">29091014</pub-id></element-citation></ref><ref id="b153-ijo-65-01-05660"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>D</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Exploring a ferroptosis and oxidative stress-based prognostic model for clear cell renal cell carcinoma</article-title><source>Front Oncol</source><volume>13</volume><fpage>1131473</fpage><year>2023</year><pub-id pub-id-type="doi">10.3389/fonc.2023.1131473</pub-id><pub-id pub-id-type="pmid">37064095</pub-id><pub-id pub-id-type="pmcid">PMC10098013</pub-id></element-citation></ref><ref id="b154-ijo-65-01-05660"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Lei</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W</given-names></name></person-group><article-title>Prognostic prediction model for glioblastoma: A ferroptosis-related gene prediction model and independent external validation</article-title><source>J Clin Med</source><volume>12</volume><fpage>1341</fpage><year>2023</year><pub-id pub-id-type="doi">10.3390/jcm12041341</pub-id><pub-id pub-id-type="pmid">36835877</pub-id><pub-id pub-id-type="pmcid">PMC9960289</pub-id></element-citation></ref><ref id="b155-ijo-65-01-05660"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahluwalia</surname><given-names>GS</given-names></name><name name-style="western"><surname>Grem</surname><given-names>JL</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cooney</surname><given-names>DA</given-names></name></person-group><article-title>Metabolism and action of amino acid analog anti-cancer agents</article-title><source>Pharmacol Ther</source><volume>46</volume><fpage>243</fpage><lpage>271</lpage><year>1990</year><pub-id pub-id-type="doi">10.1016/0163-7258(90)90094-I</pub-id><pub-id pub-id-type="pmid">2108451</pub-id></element-citation></ref><ref id="b156-ijo-65-01-05660"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vi&#241;a</surname><given-names>JR</given-names></name><name name-style="western"><surname>Palacin</surname><given-names>M</given-names></name><name name-style="western"><surname>Puertes</surname><given-names>IR</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>R</given-names></name><name name-style="western"><surname>Vi&#241;a</surname><given-names>J</given-names></name></person-group><article-title>Role of the gamma-glutamyl cycle in the regulation of amino acid translocation</article-title><source>Am J Physiol</source><volume>257</volume><fpage>E916</fpage><lpage>E922</lpage><year>1989</year><pub-id pub-id-type="pmid">2575355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpendo.1989.257.6.E916</pub-id></element-citation></ref><ref id="b157-ijo-65-01-05660"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Okuzaki</surname><given-names>D</given-names></name><name name-style="western"><surname>Okada</surname><given-names>N</given-names></name><name name-style="western"><surname>Tachibana</surname><given-names>M</given-names></name></person-group><article-title>Targeting GGT1 eliminates the tumor-promoting effect and enhanced immunosuppressive function of myeloid-derived suppressor cells caused by G-CSF</article-title><source>Front Pharmacol</source><volume>13</volume><fpage>873792</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fphar.2022.873792</pub-id><pub-id pub-id-type="pmid">35548341</pub-id><pub-id pub-id-type="pmcid">PMC9081766</pub-id></element-citation></ref><ref id="b158-ijo-65-01-05660"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>AM</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>M</given-names></name><name name-style="western"><surname>Heppler</surname><given-names>LN</given-names></name><name name-style="western"><surname>To&#353;i&#263;</surname><given-names>I</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>K</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>JO</given-names></name><name name-style="western"><surname>Gaikwad</surname><given-names>AS</given-names></name><name name-style="western"><surname>Horton</surname><given-names>TM</given-names></name><name name-style="western"><surname>Long</surname><given-names>X</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation</article-title><source>Blood Adv</source><volume>3</volume><fpage>4215</fpage><lpage>4227</lpage><year>2019</year><pub-id pub-id-type="doi">10.1182/bloodadvances.2019000499</pub-id><pub-id pub-id-type="pmid">31856268</pub-id><pub-id pub-id-type="pmcid">PMC6929386</pub-id></element-citation></ref><ref id="b159-ijo-65-01-05660"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>U Ferreira</surname><given-names>MJ</given-names></name></person-group><article-title>Natural product-derived compounds for targeting multidrug resistance in cancer and microorganisms</article-title><source>Int J Mol Sci</source><volume>24</volume><fpage>14321</fpage><year>2023</year><pub-id pub-id-type="doi">10.3390/ijms241814321</pub-id><pub-id pub-id-type="pmid">37762623</pub-id><pub-id pub-id-type="pmcid">PMC10531746</pub-id></element-citation></ref><ref id="b160-ijo-65-01-05660"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashrafizadeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Aref</surname><given-names>AR</given-names></name><name name-style="western"><surname>Sethi</surname><given-names>G</given-names></name><name name-style="western"><surname>Ertas</surname><given-names>YN</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Natural product/diet-based regulation of macrophage polarization: Implications in treatment of inflammatory-related diseases and cancer</article-title><source>J Nutr Biochem</source><fpage>109647</fpage><year>2024</year><pub-id pub-id-type="doi">10.1016/j.jnutbio.2024.109647</pub-id><pub-id pub-id-type="pmid">38604457</pub-id></element-citation></ref><ref id="b161-ijo-65-01-05660"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyons</surname><given-names>SD</given-names></name><name name-style="western"><surname>Sant</surname><given-names>ME</given-names></name><name name-style="western"><surname>Christopherson</surname><given-names>RI</given-names></name></person-group><article-title>Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia</article-title><source>J Biol Chem</source><volume>265</volume><fpage>11377</fpage><lpage>11381</lpage><year>1990</year><pub-id pub-id-type="doi">10.1016/S0021-9258(19)38603-X</pub-id><pub-id pub-id-type="pmid">2358467</pub-id></element-citation></ref><ref id="b162-ijo-65-01-05660"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>N</given-names></name></person-group><article-title>Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation</article-title><source>Biosci Rep</source><volume>40</volume><fpage>BSR20201807</fpage><year>2020</year><pub-id pub-id-type="doi">10.1042/BSR20201807</pub-id><pub-id pub-id-type="pmid">32776119</pub-id><pub-id pub-id-type="pmcid">PMC7953492</pub-id></element-citation></ref><ref id="b163-ijo-65-01-05660"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Townsend</surname><given-names>DM</given-names></name><name name-style="western"><surname>Deng</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lapus</surname><given-names>MG</given-names></name><name name-style="western"><surname>Hanigan</surname><given-names>MH</given-names></name></person-group><article-title>Metabolism of cisplatin to a nephrotoxin in proximal tubule cells</article-title><source>J Am Soc Nephrol</source><volume>14</volume><fpage>1</fpage><lpage>10</lpage><year>2003</year><pub-id pub-id-type="doi">10.1097/01.ASN.0000042803.28024.92</pub-id><pub-id pub-id-type="pmid">12506132</pub-id><pub-id pub-id-type="pmcid">PMC6361148</pub-id></element-citation></ref><ref id="b164-ijo-65-01-05660"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azouz</surname><given-names>AA</given-names></name><name name-style="western"><surname>Abdel-Nassir Abdel-Razek</surname><given-names>E</given-names></name><name name-style="western"><surname>Abo-Youssef</surname><given-names>AM</given-names></name></person-group><article-title>Amlodipine alleviates cisplatin-induced nephrotoxicity in rats through gamma-glutamyl transpeptidase (GGT) enzyme inhibition, associated with regulation of Nrf2/HO-1, MAPK/NF-&#954;B, and Bax/Bcl-2 signaling</article-title><source>Saudi Pharm J</source><volume>28</volume><fpage>1317</fpage><lpage>1325</lpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jsps.2020.08.022</pub-id><pub-id pub-id-type="pmid">33250641</pub-id><pub-id pub-id-type="pmcid">PMC7679434</pub-id></element-citation></ref><ref id="b165-ijo-65-01-05660"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>F</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade</article-title><source>Nat Commun</source><volume>14</volume><fpage>4758</fpage><year>2023</year><pub-id pub-id-type="doi">10.1038/s41467-023-40518-0</pub-id><pub-id pub-id-type="pmid">37553341</pub-id><pub-id pub-id-type="pmcid">PMC10409767</pub-id></element-citation></ref><ref id="b166-ijo-65-01-05660"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumi</surname><given-names>D</given-names></name><name name-style="western"><surname>Taguchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Fujishiro</surname><given-names>H</given-names></name></person-group><article-title>CHAC1 exacerbates arsenite cytotoxicity by lowering intracellular glutathione levels</article-title><source>J Toxicol Sci</source><volume>48</volume><fpage>487</fpage><lpage>494</lpage><year>2023</year><pub-id pub-id-type="doi">10.2131/jts.48.487</pub-id><pub-id pub-id-type="pmid">37661365</pub-id></element-citation></ref><ref id="b167-ijo-65-01-05660"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>P</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>M</given-names></name><name name-style="western"><surname>Billingham</surname><given-names>LK</given-names></name><name name-style="western"><surname>Miska</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JD</given-names></name><name name-style="western"><surname>Wainwright</surname><given-names>DA</given-names></name><name name-style="western"><surname>Fang</surname><given-names>D</given-names></name><etal/></person-group><article-title>CD8+ T cells sustain antitumor response by mediating crosstalk between adenosine A2A receptor and glutathione/GPX4</article-title><source>J Clin Invest</source><volume>134</volume><fpage>e170071</fpage><year>2024</year><pub-id pub-id-type="doi">10.1172/JCI170071</pub-id><pub-id pub-id-type="pmid">38441967</pub-id><pub-id pub-id-type="pmcid">PMC11014673</pub-id></element-citation></ref><ref id="b168-ijo-65-01-05660"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Anisomycin has the potential to induce human ovarian cancer stem cell ferroptosis by influencing glutathione metabolism and autophagy signal transduction pathways</article-title><source>J Cancer</source><volume>14</volume><fpage>1202</fpage><lpage>1215</lpage><year>2023</year><pub-id pub-id-type="doi">10.7150/jca.83355</pub-id><pub-id pub-id-type="pmid">37215446</pub-id><pub-id pub-id-type="pmcid">PMC10197939</pub-id></element-citation></ref><ref id="b169-ijo-65-01-05660"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>CX</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>XF</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ding</surname><given-names>HX</given-names></name><name name-style="western"><surname>Li</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Du</surname><given-names>FK</given-names></name><name name-style="western"><surname>Li</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Bile acids inhibit ferroptosis sensitivity through activating farnesoid X receptor in gastric cancer cells</article-title><source>World J Gastroenterol</source><volume>30</volume><fpage>485</fpage><lpage>498</lpage><year>2024</year><pub-id pub-id-type="doi">10.3748/wjg.v30.i5.485</pub-id><pub-id pub-id-type="pmid">38414591</pub-id><pub-id pub-id-type="pmcid">PMC10895598</pub-id></element-citation></ref><ref id="b170-ijo-65-01-05660"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitri&#263;</surname><given-names>A</given-names></name><name name-style="western"><surname>Castellano</surname><given-names>I</given-names></name></person-group><article-title>Targeting gamma-glutamyl transpeptidase: A pleiotropic enzyme involved in glutathione metabolism and in the control of redox homeostasis</article-title><source>Free Radic Biol Med</source><volume>208</volume><fpage>672</fpage><lpage>683</lpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2023.09.020</pub-id><pub-id pub-id-type="pmid">37739139</pub-id></element-citation></ref><ref id="b171-ijo-65-01-05660"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pompella</surname><given-names>A</given-names></name><name name-style="western"><surname>Corti</surname><given-names>A</given-names></name><name name-style="western"><surname>Paolicchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Giommarelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Zunino</surname><given-names>F</given-names></name></person-group><article-title>Gamma-glutamyltransferase, redox regulation and cancer drug resistance</article-title><source>Curr Opin Pharmacol</source><volume>7</volume><fpage>360</fpage><lpage>366</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/j.coph.2007.04.004</pub-id><pub-id pub-id-type="pmid">17613273</pub-id></element-citation></ref><ref id="b172-ijo-65-01-05660"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dou</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Gamma-glutamyltransferase activity (GGT) is a long-sought biomarker of redox status in blood circulation: A retrospective clinical study of 44 types of human diseases</article-title><source>Oxid Med Cell Longev</source><volume>2022</volume><fpage>8494076</fpage><year>2022</year><pub-id pub-id-type="doi">10.1155/2022/8494076</pub-id><pub-id pub-id-type="pmid">35707277</pub-id><pub-id pub-id-type="pmcid">PMC9192220</pub-id></element-citation></ref><ref id="b173-ijo-65-01-05660"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamano</surname><given-names>M</given-names></name><name name-style="western"><surname>Tomonaga</surname><given-names>S</given-names></name><name name-style="western"><surname>Osaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oda</surname><given-names>H</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H</given-names></name><name name-style="western"><surname>Furuya</surname><given-names>S</given-names></name></person-group><article-title>Transcriptional activation of Chac1 and other Atf4-target genes induced by extracellular l-serine depletion is negated with glycine consumption in Hepa1-6 hepatocarcinoma cells</article-title><source>Nutrients</source><volume>12</volume><fpage>3018</fpage><year>2020</year><pub-id pub-id-type="doi">10.3390/nu12103018</pub-id><pub-id pub-id-type="pmid">33023086</pub-id><pub-id pub-id-type="pmcid">PMC7600170</pub-id></element-citation></ref><ref id="b174-ijo-65-01-05660"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>X</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Ying</surname><given-names>P</given-names></name><name name-style="western"><surname>Ke</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>Treatment with paraquat affects the expression of ferroptosis-related genes</article-title><source>Hum Exp Toxicol</source><volume>42</volume><fpage>9603271231167585</fpage><year>2023</year><pub-id pub-id-type="doi">10.1177/09603271231167585</pub-id><pub-id pub-id-type="pmid">36960817</pub-id></element-citation></ref><ref id="b175-ijo-65-01-05660"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dosumu</surname><given-names>OA</given-names></name><name name-style="western"><surname>Rotimi</surname><given-names>SO</given-names></name><name name-style="western"><surname>Adeleye</surname><given-names>OO</given-names></name><name name-style="western"><surname>Akamo</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Osinuga</surname><given-names>KT</given-names></name><name name-style="western"><surname>Taiwo</surname><given-names>OA</given-names></name><name name-style="western"><surname>Omotosho</surname><given-names>OO</given-names></name><name name-style="western"><surname>Sani</surname><given-names>LO</given-names></name></person-group><article-title>Vitamin K protects against 7,12-dimethylbenz(A)anthracene induced hepatotoxicity in Wistar rats</article-title><source>Environ Toxicol</source><volume>36</volume><fpage>362</fpage><lpage>373</lpage><year>2021</year><pub-id pub-id-type="doi">10.1002/tox.23042</pub-id><pub-id pub-id-type="pmid">33063951</pub-id></element-citation></ref><ref id="b176-ijo-65-01-05660"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schreiber</surname><given-names>CL</given-names></name><name name-style="western"><surname>Smith</surname><given-names>BD</given-names></name></person-group><article-title>Molecular imaging of aminopeptidase N in cancer and angiogenesis</article-title><source>Contrast Media Mol Imaging</source><volume>2018</volume><fpage>5315172</fpage><year>2018</year><pub-id pub-id-type="doi">10.1155/2018/5315172</pub-id><pub-id pub-id-type="pmid">30046296</pub-id><pub-id pub-id-type="pmcid">PMC6036854</pub-id></element-citation></ref><ref id="b177-ijo-65-01-05660"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amin</surname><given-names>SA</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>N</given-names></name><name name-style="western"><surname>Jha</surname><given-names>T</given-names></name></person-group><article-title>Design of aminopeptidase N inhibitors as anti-cancer agents</article-title><source>J Med Chem</source><volume>61</volume><fpage>6468</fpage><lpage>6490</lpage><year>2018</year><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00782</pub-id><pub-id pub-id-type="pmid">29630364</pub-id></element-citation></ref><ref id="b178-ijo-65-01-05660"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzman-Rojas</surname><given-names>L</given-names></name><name name-style="western"><surname>Rangel</surname><given-names>R</given-names></name><name name-style="western"><surname>Salameh</surname><given-names>A</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>JK</given-names></name><name name-style="western"><surname>Dondossola</surname><given-names>E</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YG</given-names></name><name name-style="western"><surname>Saghatelian</surname><given-names>A</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Kolonin</surname><given-names>MG</given-names></name><name name-style="western"><surname>Staquicini</surname><given-names>FI</given-names></name><etal/></person-group><article-title>Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment</article-title><source>Proc Natl Acad Sci USA</source><volume>109</volume><fpage>1637</fpage><lpage>1642</lpage><year>2012</year><pub-id pub-id-type="doi">10.1073/pnas.1120790109</pub-id><pub-id pub-id-type="pmid">22307623</pub-id><pub-id pub-id-type="pmcid">PMC3277167</pub-id></element-citation></ref><ref id="b179-ijo-65-01-05660"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qu</surname><given-names>M</given-names></name><name name-style="western"><surname>Mao</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C</given-names></name></person-group><article-title>Inhibition of leucine aminopeptidase 3 suppresses invasion of ovarian cancer cells through down-regulation of fascin and MMP-2/9</article-title><source>Eur J Pharmacol</source><volume>768</volume><fpage>116</fpage><lpage>122</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.10.039</pub-id><pub-id pub-id-type="pmid">26526349</pub-id></element-citation></ref><ref id="b180-ijo-65-01-05660"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Luo</surname><given-names>A</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ou</surname><given-names>X</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Sevoflurane induces ferroptosis of glioma cells through activating the ATF4-CHAC1 pathway</article-title><source>Front Oncol</source><volume>12</volume><fpage>859621</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fonc.2022.859621</pub-id><pub-id pub-id-type="pmid">35372041</pub-id><pub-id pub-id-type="pmcid">PMC8969566</pub-id></element-citation></ref><ref id="b181-ijo-65-01-05660"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>YF</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XZ</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>LS</given-names></name><name name-style="western"><surname>Peng</surname><given-names>HH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Cai</surname><given-names>LM</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>TC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>XD</given-names></name></person-group><article-title>Prognostic impact of pretherapeutic gamma-glutamyltransferase on patients with nasopharyngeal carcinoma</article-title><source>PLoS One</source><volume>12</volume><fpage>e0172345</fpage><year>2017</year><pub-id pub-id-type="doi">10.1371/journal.pone.0172345</pub-id><pub-id pub-id-type="pmid">28241022</pub-id><pub-id pub-id-type="pmcid">PMC5328260</pub-id></element-citation></ref><ref id="b182-ijo-65-01-05660"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mujawar</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Suchitra</surname><given-names>G</given-names></name><name name-style="western"><surname>Kosandal</surname><given-names>KA</given-names></name><name name-style="western"><surname>Choudhari</surname><given-names>S</given-names></name><name name-style="western"><surname>Inamdar</surname><given-names>NA</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>KB</given-names></name></person-group><article-title>Evaluation of salivary gamma-glutamyl transpeptidase as a biomarker in oral squamous cell carcinoma and precancerous lesions</article-title><source>J Oral Maxillofac Pathol</source><volume>24</volume><fpage>584</fpage><year>2020</year><pub-id pub-id-type="doi">10.4103/jomfp.JOMFP_73_20</pub-id><pub-id pub-id-type="pmid">33967513</pub-id><pub-id pub-id-type="pmcid">PMC8083403</pub-id></element-citation></ref><ref id="b183-ijo-65-01-05660"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizushima</surname><given-names>T</given-names></name><name name-style="western"><surname>Ohnishi</surname><given-names>S</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hatanaka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hatanaka</surname><given-names>KC</given-names></name><name name-style="western"><surname>Hosono</surname><given-names>H</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>Y</given-names></name><name name-style="western"><surname>Natsuizaka</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamiya</surname><given-names>M</given-names></name><name name-style="western"><surname>Ono</surname><given-names>S</given-names></name><etal/></person-group><article-title>Fluorescent imaging of superficial head and neck squamous cell carcinoma using a &#947;-glutamyltranspeptidase-activated targeting agent: A pilot study</article-title><source>BMC Cancer</source><volume>16</volume><fpage>411</fpage><year>2016</year><pub-id pub-id-type="doi">10.1186/s12885-016-2421-z</pub-id><pub-id pub-id-type="pmid">27387955</pub-id><pub-id pub-id-type="pmcid">PMC4936014</pub-id></element-citation></ref><ref id="b184-ijo-65-01-05660"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Han</surname><given-names>KD</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CH</given-names></name></person-group><article-title>Determining the association between repeatedly elevated serum gamma-glutamyltransferase levels and risk of respiratory cancer: A nationwide population-based cohort study</article-title><source>Cancer Med</source><volume>10</volume><fpage>1366</fpage><lpage>1376</lpage><year>2021</year><pub-id pub-id-type="doi">10.1002/cam4.3735</pub-id><pub-id pub-id-type="pmid">33638317</pub-id><pub-id pub-id-type="pmcid">PMC7925999</pub-id></element-citation></ref><ref id="b185-ijo-65-01-05660"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Ding</surname><given-names>M</given-names></name><name name-style="western"><surname>Lin</surname><given-names>T</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Miao</surname><given-names>E</given-names></name><etal/></person-group><article-title>A machine learning-based approach to predicting the malignant and metastasis of thyroid cancer</article-title><source>Front Oncol</source><volume>12</volume><fpage>938292</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fonc.2022.938292</pub-id><pub-id pub-id-type="pmid">36601485</pub-id><pub-id pub-id-type="pmcid">PMC9806162</pub-id></element-citation></ref><ref id="b186-ijo-65-01-05660"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foddis</surname><given-names>R</given-names></name><name name-style="western"><surname>Franzini</surname><given-names>M</given-names></name><name name-style="western"><surname>Bonotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Marino</surname><given-names>R</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>R</given-names></name><name name-style="western"><surname>Fallahi</surname><given-names>P</given-names></name><name name-style="western"><surname>Chiappino</surname><given-names>D</given-names></name><name name-style="western"><surname>Emdin</surname><given-names>M</given-names></name><name name-style="western"><surname>Paolicchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Cristaudo</surname><given-names>A</given-names></name></person-group><article-title>Big and free fractions of gamma-glutamyltransferase: New diagnostic biomarkers for malignant mesothelioma?</article-title><source>Diagnostics (Basel)</source><volume>12</volume><fpage>311</fpage><year>2022</year><pub-id pub-id-type="doi">10.3390/diagnostics12020311</pub-id><pub-id pub-id-type="pmid">35204402</pub-id><pub-id pub-id-type="pmcid">PMC8870979</pub-id></element-citation></ref><ref id="b187-ijo-65-01-05660"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XP</given-names></name><name name-style="western"><surname>Li</surname><given-names>XH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Lin</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kang</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>PS</given-names></name></person-group><article-title>Prognostic value of pretreatment serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio and gamma glutamyltransferase (GGT) in patients with esophageal squamous cell carcinoma</article-title><source>BMC Cancer</source><volume>17</volume><fpage>544</fpage><year>2017</year><pub-id pub-id-type="doi">10.1186/s12885-017-3523-y</pub-id><pub-id pub-id-type="pmid">28806937</pub-id><pub-id pub-id-type="pmcid">PMC5556356</pub-id></element-citation></ref><ref id="b188-ijo-65-01-05660"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DH</given-names></name><name name-style="western"><surname>Han</surname><given-names>KD</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H</given-names></name><name name-style="western"><surname>Shin</surname><given-names>CM</given-names></name><name name-style="western"><surname>Park</surname><given-names>YS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N</given-names></name></person-group><article-title>Elevated serum gamma-glutamyltransferase is associated with an increased risk of oesophageal carcinoma in a cohort of 8,388,256 Korean subjects</article-title><source>PLoS One</source><volume>12</volume><fpage>e0177053</fpage><year>2017</year><pub-id pub-id-type="doi">10.1371/journal.pone.0177053</pub-id><pub-id pub-id-type="pmid">28475598</pub-id><pub-id pub-id-type="pmcid">PMC5419599</pub-id></element-citation></ref><ref id="b189-ijo-65-01-05660"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lou</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Bi</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prognostic value and predication model of microvascular invasion in patients with intrahepatic cholangiocarcinoma: A multicenter study from China</article-title><source>BMC Cancer</source><volume>21</volume><fpage>1299</fpage><year>2021</year><pub-id pub-id-type="doi">10.1186/s12885-021-09035-5</pub-id><pub-id pub-id-type="pmid">34863147</pub-id><pub-id pub-id-type="pmcid">PMC8645153</pub-id></element-citation></ref><ref id="b190-ijo-65-01-05660"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catalano</surname><given-names>M</given-names></name><name name-style="western"><surname>Roviello</surname><given-names>G</given-names></name><name name-style="western"><surname>Aprile</surname><given-names>G</given-names></name><name name-style="western"><surname>Ramello</surname><given-names>M</given-names></name><name name-style="western"><surname>Conca</surname><given-names>R</given-names></name><name name-style="western"><surname>Petrioli</surname><given-names>R</given-names></name><name name-style="western"><surname>Perrone</surname><given-names>G</given-names></name><name name-style="western"><surname>Ianza</surname><given-names>A</given-names></name><name name-style="western"><surname>Mini</surname><given-names>E</given-names></name></person-group><article-title>Prognostic value of alkaline phosphatase and gamma-glutamyl transferase in patients with metastatic pancreatic cancer</article-title><source>Future Oncol</source><volume>19</volume><fpage>937</fpage><lpage>946</lpage><year>2023</year><pub-id pub-id-type="doi">10.2217/fon-2023-0137</pub-id><pub-id pub-id-type="pmid">37232154</pub-id></element-citation></ref><ref id="b191-ijo-65-01-05660"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name></person-group><article-title>Circulating gamma-glutamyl transpeptidase and risk of pancreatic cancer: A prospective cohort study in the UK Biobank</article-title><source>Cancer Med</source><volume>12</volume><fpage>7877</fpage><lpage>7887</lpage><year>2023</year><pub-id pub-id-type="doi">10.1002/cam4.5556</pub-id><pub-id pub-id-type="pmid">36583230</pub-id><pub-id pub-id-type="pmcid">PMC10134379</pub-id></element-citation></ref><ref id="b192-ijo-65-01-05660"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>SW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Han</surname><given-names>K</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JM</given-names></name><name name-style="western"><surname>Park</surname><given-names>S</given-names></name><name name-style="western"><surname>Soh</surname><given-names>H</given-names></name><name name-style="western"><surname>Kang</surname><given-names>EA</given-names></name><name name-style="western"><surname>Chun</surname><given-names>J</given-names></name><name name-style="western"><surname>Im</surname><given-names>JP</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name></person-group><article-title>Risk of gastrointestinal cancer in patients with an elevated level of gamma-glutamyltransferase: A nationwide population-based study</article-title><source>PLoS One</source><volume>16</volume><fpage>e0245052</fpage><year>2021</year><pub-id pub-id-type="doi">10.1371/journal.pone.0245052</pub-id><pub-id pub-id-type="pmid">33544706</pub-id><pub-id pub-id-type="pmcid">PMC7864398</pub-id></element-citation></ref><ref id="b193-ijo-65-01-05660"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name></person-group><article-title>Prognostic significance of serum uric acid and gamma-glutamyltransferase in patients with advanced gastric cancer</article-title><source>Dis Markers</source><volume>2019</volume><fpage>1415421</fpage><year>2019</year><pub-id pub-id-type="doi">10.1155/2019/1415421</pub-id><pub-id pub-id-type="pmid">31885729</pub-id><pub-id pub-id-type="pmcid">PMC6918938</pub-id></element-citation></ref><ref id="b194-ijo-65-01-05660"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>TC</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CL</given-names></name><name name-style="western"><surname>Kao</surname><given-names>JH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HY</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>YC</given-names></name><name name-style="western"><surname>Yu</surname><given-names>LY</given-names></name><name name-style="western"><surname>Hu</surname><given-names>KC</given-names></name></person-group><article-title>Relationship between serum gamma-glutamyl transferase level and colorectal adenoma</article-title><source>PLoS One</source><volume>15</volume><fpage>e0240445</fpage><year>2020</year><pub-id pub-id-type="doi">10.1371/journal.pone.0240445</pub-id><pub-id pub-id-type="pmid">33048943</pub-id><pub-id pub-id-type="pmcid">PMC7553303</pub-id></element-citation></ref><ref id="b195-ijo-65-01-05660"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>LH</given-names></name><name name-style="western"><surname>Xu</surname><given-names>LZ</given-names></name><name name-style="western"><surname>Huang</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Pan</surname><given-names>HH</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>QY</given-names></name><name name-style="western"><surname>Lu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YP</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>YB</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Comprehensive analysis of immune ferroptosis gene in renal clear cell carcinoma: Prognosis and influence of tumor microenvironment</article-title><source>Am J Transl Res</source><volume>14</volume><fpage>5982</fpage><lpage>6010</lpage><year>2022</year><pub-id pub-id-type="pmid">36247256</pub-id><pub-id pub-id-type="pmcid">PMC9556489</pub-id></element-citation></ref><ref id="b196-ijo-65-01-05660"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horie</surname><given-names>K</given-names></name><name name-style="western"><surname>Kawakami</surname><given-names>K</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Arai</surname><given-names>T</given-names></name><name name-style="western"><surname>Suzui</surname><given-names>N</given-names></name><name name-style="western"><surname>Miyazaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Koie</surname><given-names>T</given-names></name><name name-style="western"><surname>Mizutani</surname><given-names>K</given-names></name><name name-style="western"><surname>Ito</surname><given-names>M</given-names></name></person-group><article-title>Serum exosomal gamma-glutamyltransferase activity increased in patients with renal cell carcinoma with advanced clinicopathological features</article-title><source>Oncology</source><volume>98</volume><fpage>734</fpage><lpage>742</lpage><year>2020</year><pub-id pub-id-type="doi">10.1159/000508688</pub-id><pub-id pub-id-type="pmid">32726790</pub-id></element-citation></ref><ref id="b197-ijo-65-01-05660"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pankevi&#269;i&#363;t&#279;-Bukauskien&#279;</surname><given-names>M</given-names></name><name name-style="western"><surname>Mikalayeva</surname><given-names>V</given-names></name><name name-style="western"><surname>&#381;vikas</surname><given-names>V</given-names></name><name name-style="western"><surname>Skeberdis</surname><given-names>VA</given-names></name><name name-style="western"><surname>Bordel</surname><given-names>S</given-names></name></person-group><article-title>Multi-omics analysis revealed increased de novo synthesis of serine and lower activity of the methionine cycle in breast cancer cell lines</article-title><source>Molecules</source><volume>28</volume><fpage>4535</fpage><year>2023</year><pub-id pub-id-type="doi">10.3390/molecules28114535</pub-id><pub-id pub-id-type="pmid">37299011</pub-id><pub-id pub-id-type="pmcid">PMC10254915</pub-id></element-citation></ref><ref id="b198-ijo-65-01-05660"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seol</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SI</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>IS</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>J</given-names></name><name name-style="western"><surname>Jo</surname><given-names>H</given-names></name><name name-style="western"><surname>Han</surname><given-names>KD</given-names></name><name name-style="western"><surname>Song</surname><given-names>YS</given-names></name></person-group><article-title>Enhanced susceptibility to breast cancer in Korean women with elevated serum gamma-glutamyltransferase levels: A nationwide population-based cohort study</article-title><source>Front Oncol</source><volume>11</volume><fpage>668624</fpage><year>2021</year><pub-id pub-id-type="doi">10.3389/fonc.2021.668624</pub-id><pub-id pub-id-type="pmid">34123839</pub-id><pub-id pub-id-type="pmcid">PMC8191736</pub-id></element-citation></ref><ref id="b199-ijo-65-01-05660"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name></person-group><article-title>Selective tracking of ovarian-cancer-specific &#947;-glutamyltranspeptidase using a ratiometric two-photon fluorescent probe</article-title><source>J Mater Chem B</source><volume>6</volume><fpage>7439</fpage><lpage>7443</lpage><year>2018</year><pub-id pub-id-type="doi">10.1039/C8TB01735B</pub-id><pub-id pub-id-type="pmid">32254745</pub-id></element-citation></ref><ref id="b200-ijo-65-01-05660"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwameis</surname><given-names>R</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>C</given-names></name><name name-style="western"><surname>Brodowicz</surname><given-names>T</given-names></name><name name-style="western"><surname>Petru</surname><given-names>E</given-names></name><name name-style="western"><surname>Hefler-Frischmuth</surname><given-names>K</given-names></name><name name-style="western"><surname>Staudigl</surname><given-names>C</given-names></name><name name-style="western"><surname>Reinthaller</surname><given-names>A</given-names></name><name name-style="western"><surname>Heinze</surname><given-names>G</given-names></name><name name-style="western"><surname>Polterauer</surname><given-names>S</given-names></name><name name-style="western"><surname>Polterauer</surname><given-names>M</given-names></name></person-group><article-title>Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma</article-title><source>Sci Rep</source><volume>6</volume><fpage>33757</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/srep33757</pub-id><pub-id pub-id-type="pmid">27646551</pub-id><pub-id pub-id-type="pmcid">PMC5028736</pub-id></element-citation></ref><ref id="b201-ijo-65-01-05660"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polterauer</surname><given-names>S</given-names></name><name name-style="western"><surname>Hofstetter</surname><given-names>G</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>C</given-names></name><name name-style="western"><surname>Rahhal</surname><given-names>J</given-names></name><name name-style="western"><surname>Mailath-Pokorny</surname><given-names>M</given-names></name><name name-style="western"><surname>Kohl</surname><given-names>M</given-names></name><name name-style="western"><surname>Concin</surname><given-names>N</given-names></name><name name-style="western"><surname>Tempfer</surname><given-names>C</given-names></name><name name-style="western"><surname>Marth</surname><given-names>C</given-names></name><name name-style="western"><surname>Reinthaller</surname><given-names>A</given-names></name></person-group><article-title>Relevance of gamma-glutamyltransferase-a marker for apoptotic balance-in predicting tumor stage and prognosis in cervical cancer</article-title><source>Gynecol Oncol</source><volume>122</volume><fpage>590</fpage><lpage>594</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.ygyno.2011.05.027</pub-id><pub-id pub-id-type="pmid">21664662</pub-id></element-citation></ref><ref id="b202-ijo-65-01-05660"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawakami</surname><given-names>K</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Arai</surname><given-names>T</given-names></name><name name-style="western"><surname>Horie</surname><given-names>K</given-names></name><name name-style="western"><surname>Kameyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Masunaga</surname><given-names>K</given-names></name><name name-style="western"><surname>Kasuya</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer</article-title><source>BMC Cancer</source><volume>17</volume><fpage>316</fpage><year>2017</year><pub-id pub-id-type="doi">10.1186/s12885-017-3301-x</pub-id><pub-id pub-id-type="pmid">28476099</pub-id><pub-id pub-id-type="pmcid">PMC5420129</pub-id></element-citation></ref><ref id="b203-ijo-65-01-05660"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S</given-names></name><name name-style="western"><surname>Pang</surname><given-names>S</given-names></name></person-group><article-title>Preoperative serum gamma-glutamyltransferase as a prognostic biomarker in patients undergoing radical cystectomy for bladder cancer</article-title><source>Front Oncol</source><volume>11</volume><fpage>648904</fpage><year>2021</year><pub-id pub-id-type="doi">10.3389/fonc.2021.648904</pub-id><pub-id pub-id-type="pmid">34026623</pub-id><pub-id pub-id-type="pmcid">PMC8138052</pub-id></element-citation></ref><ref id="b204-ijo-65-01-05660"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takemura</surname><given-names>K</given-names></name><name name-style="western"><surname>Fukushima</surname><given-names>H</given-names></name><name name-style="western"><surname>Ito</surname><given-names>M</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></name><name name-style="western"><surname>Tobisu</surname><given-names>KI</given-names></name><name name-style="western"><surname>Koga</surname><given-names>F</given-names></name></person-group><article-title>Prognostic significance of serum &#947;-glutamyltransferase in patients with advanced urothelial carcinoma</article-title><source>Urol Oncol</source><volume>37</volume><fpage>108</fpage><lpage>115</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.urolonc.2018.11.002</pub-id><pub-id pub-id-type="pmid">30478012</pub-id></element-citation></ref><ref id="b205-ijo-65-01-05660"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J</given-names></name></person-group><article-title>Construction and validation of a novel ferroptosis-related prognostic model for acute myeloid leukemia</article-title><source>Front Genet</source><volume>12</volume><fpage>708699</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fgene.2021.708699</pub-id><pub-id pub-id-type="pmid">35111195</pub-id><pub-id pub-id-type="pmcid">PMC8803125</pub-id></element-citation></ref><ref id="b206-ijo-65-01-05660"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>B</given-names></name><name name-style="western"><surname>Tabuchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wada</surname><given-names>K</given-names></name><name name-style="western"><surname>Hiratake</surname><given-names>J</given-names></name></person-group><article-title>Synthesis and evaluation of the inhibitory activity of the four stereoisomers of the potent and selective human &#947;-glutamyl transpeptidase inhibitor GGsTop</article-title><source>Bioorg Med Chem Lett</source><volume>27</volume><fpage>4920</fpage><lpage>4924</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.bmcl.2017.09.017</pub-id><pub-id pub-id-type="pmid">28985998</pub-id></element-citation></ref><ref id="b207-ijo-65-01-05660"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>L</given-names></name><name name-style="western"><surname>Hiratake</surname><given-names>J</given-names></name><name name-style="western"><surname>Kamiyama</surname><given-names>A</given-names></name><name name-style="western"><surname>Sakata</surname><given-names>K</given-names></name></person-group><article-title>Design, synthesis, and evaluation of gamma-phosphono diester analogues of glutamate as highly potent inhibitors and active site probes of gamma-glutamyl transpeptidase</article-title><source>Biochemistry</source><volume>46</volume><fpage>1432</fpage><lpage>1447</lpage><year>2007</year><pub-id pub-id-type="doi">10.1021/bi061890j</pub-id><pub-id pub-id-type="pmid">17260973</pub-id></element-citation></ref><ref id="b208-ijo-65-01-05660"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>JB</given-names></name><name name-style="western"><surname>West</surname><given-names>MB</given-names></name><name name-style="western"><surname>Cook</surname><given-names>PF</given-names></name><name name-style="western"><surname>Hanigan</surname><given-names>MH</given-names></name></person-group><article-title>A novel, species-specific class of uncompetitive inhibitors of gamma-glutamyl transpeptidase</article-title><source>J Biol Chem</source><volume>284</volume><fpage>9059</fpage><lpage>9065</lpage><year>2009</year><pub-id pub-id-type="doi">10.1074/jbc.M809608200</pub-id><pub-id pub-id-type="pmid">19203993</pub-id><pub-id pub-id-type="pmcid">PMC2666554</pub-id></element-citation></ref><ref id="b209-ijo-65-01-05660"><label>209</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>X</given-names></name><name name-style="western"><surname>Dai</surname><given-names>T</given-names></name><name name-style="western"><surname>Chi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Dong</surname><given-names>D</given-names></name></person-group><article-title>Naringin alleviates acetaminophen-induced acute liver injury by activating Nrf2 via CHAC2 upregulation</article-title><source>Environ Toxicol</source><volume>37</volume><fpage>1332</fpage><lpage>1342</lpage><year>2022</year><pub-id pub-id-type="doi">10.1002/tox.23487</pub-id><pub-id pub-id-type="pmid">35179299</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="f1-ijo-65-01-05660" orientation="portrait"><label>Figure 1</label><caption><p>Role of GSH-degrading enzymes in mammals. The classical GSH degradation pathway occurs extracellularly. Intracellular GSH, GSSG and GS-X are released from cells into the extracellular space via MRP1 transporter. GGT, located on the plasma membrane, hydrolyzes them to Cys-Gly and Glu, serving as the initial step in extracellular GSH degradation. Cys-Gly undergoes catalysis to Gly and Cys by DPEP1 or minopeptidase N. ChaC1 and ChaC2 hydrolyze GSH to Cys-Gly and Glu or their cyclized form of 5-oxo-proline directly in the cell. Among these, 5-oxo-proline is hydrolyzed to Glu by 5-oxop-rolinase. Cys-Gly, induced by cytoplasmic Cys-Gly peptidase LAP or CNDP2, is hydrolyzed to Gly and Cys, completing the degradation of GSH. ChaC1, glutathione-specific &#947;-glutamylcyclotransferase 1; CNDP2, carnosine dipeptidase 2; DPEP1, M19 metallopeptidase dipeptidase 1; GCL, glutamate cysteine ligase; GGT, &#947;-glutamyl transpeptidase; GlyT1-2, glycine transporter 1 and 2; GS, glutathione synthetase; LAP, leucyl aminopeptidase; MRP1, multidrug resistance protein 1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijo-65-01-05660-g00.jpg"/></fig><fig position="float" id="f2-ijo-65-01-05660" orientation="portrait"><label>Figure 2</label><caption><p>Ribbon drawing of the human GGT1 heterodimer. The heavy and light chain subunits are shown in green and red, respectively. The binding site is displayed in pink. The GGT heterodimer has a stacked &#945;&#946;&#946;&#945;-core. Image obtained from US Data Center for the Global Protein Data Bank, Sequence Annotations in 3D: 4Z9O (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://rcsb.org/" ext-link-type="uri">rcsb.org/</ext-link>) GGT, &#947;-glutamyl transpeptidase.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijo-65-01-05660-g01.jpg"/></fig><fig position="float" id="f3-ijo-65-01-05660" orientation="portrait"><label>Figure 3</label><caption><p>Regulation of GGT. The regulation and expression of GGT remain incompletely characterized. GGT mRNA transcription is co-triggered by multiple potential cis-reactive elements, similar to rat GGT promoters. The proximal region of the GGT promoter contains the binding sites for TRE (often called AP-1 binding elements), AP-2, and Sp1. Ras protein and its downstream oxidative stress effectors, such as ERK1/2, p38MAPK, PI3K/AKT and JNK signaling pathways, serve a key role in upregulating GGT. The P13K/AKT, ERK1/2 and p38MAPK signaling pathways activate Nrf2 via EpRE and sMaf. Nrf2 then transfers from cytoplasm to the nucleus, forming heterodimers with other proteins to bind to EpRE, participating in the upregulation of GP5 activity. Activated H-Ras is also implicated in inducing GP2 activation via downstream ERK1/2, p38MAPK and JNK. Inflammatory conditions activate the NF-&#954;B pathway, initiating downstream TNF-&#945; transcription and transfer to the 536 bp site of the nuclear GGT proximal promoter. The site contains a p50, TNF-&#945; and Sp1 binding site, thereby promoting GGT expression. AP2, activator protein 2; ERK1/2, extracellular signal-regulated kinase 1/2; EpRE, electrophile response element; GGT, &#947;-glutamyl transpeptidase; GP2, GGT promoter 2; sMaf, small musculoaponeurotic fibrosarcoma; Sp1, specific protein 1; TRE, cis-regulatory element. Drawn with Figdraw (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://figdraw.com" ext-link-type="uri">figdraw.com</ext-link>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijo-65-01-05660-g02.jpg"/></fig><fig position="float" id="f4-ijo-65-01-05660" orientation="portrait"><label>Figure 4</label><caption><p>Ribbon drawing of human ChaC glutathione specific &#947;-glutamylcyclotransferase 1 protein. Very high confident areas are shown in dark blue, Confident areas are shown in light blue, Low confident areas are shown in yellow; very low confident areas are shown in red. The binding site is shown in green. Figure obtained from UniProt, 2018 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://uniprot.org/" ext-link-type="uri">uniprot.org/</ext-link>). ChaC, glutathione-specific &#947;-glutamylcyclotransferase.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijo-65-01-05660-g03.jpg"/></fig><fig position="float" id="f5-ijo-65-01-05660" orientation="portrait"><label>Figure 5</label><caption><p>Regulation of ChaC1. Oxidative and ER stress, and viral infection induce PERK/eIF2&#945;/ATF4/ATF3/CHOP cascade activation via UPR. ATF3 may primarily regulate basal ChaC1 expression via ATF/CRE, while ATF4 may mainly regulate stress-induced ChaC1 expression via ATF/CRE and ACM. In response to ER stress, C/EBP-&#946; recruits ATF4 to the ChaC1 promoter, but the precise C/EBP-&#946; response element on the ChaC1 promoter remains unclear. CARE serves a secondary role in regulating human ChaC1 transcription. Amino acid starvation induces ChaC1 expression, activating ATF4 via the GCN2/eIF2a/ATF4/ATF3 pathway. ACM, a novel-248 ATF/CRE modifier; ATF/CRE, activating transcription factor/cAMP response element; CARE, conserved-209 CEBP-ATF response element; C/EBP-&#946;, CCAAT/enhancer binding protein &#946;; CHOP, C/EBP homologous protein; eIF2&#945;, eukaryotic initiation factor-2&#945;; ER, endoplasmic reticulum; GCN2, general control nonderepressible 2; PERK, protein kinase R-like ER kinase; UPR, unfolded protein response. Figure constructed using Figdraw (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://figdraw.com" ext-link-type="uri">figdraw.com</ext-link>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijo-65-01-05660-g04.jpg"/></fig><fig position="float" id="f6-ijo-65-01-05660" orientation="portrait"><label>Figure 6</label><caption><p>Functions of glutathione-degrading enzymes in tumors. The functions of GGT and ChaC1/ChaC2 include regulating oxidative and ER stress and programmed cell death, promoting inflammation and cell drug resistance. ChaC1, glutathione-specific &#947;-glutamylcyclotransferase 1; ER, endoplasmic reticulum; GGT, &#947;-glutamyl transpeptidase. Figure constructed with Figdraw (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://figdraw.com" ext-link-type="uri">figdraw.com</ext-link>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijo-65-01-05660-g05.jpg"/></fig><table-wrap position="float" id="tI-ijo-65-01-05660" orientation="portrait"><label>Table I</label><caption><p>GGT-homologous sequences.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Gene<xref rid="tfn1-ijo-65-01-05660" ref-type="table-fn">a</xref></th><th valign="top" align="center" rowspan="1" colspan="1">Previous names</th><th valign="top" align="center" rowspan="1" colspan="1">Functional protein</th><th valign="top" align="center" rowspan="1" colspan="1">Abnormal expression</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">GGT1</td><td valign="top" align="left" rowspan="1" colspan="1">Gene 6; GGT type I</td><td valign="top" align="left" rowspan="1" colspan="1">Functional protein</td><td valign="top" align="left" rowspan="1" colspan="1">Dysregulated in various tumors</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGT2</td><td valign="top" align="left" rowspan="1" colspan="1">Clone F15; Gene 3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="L10396">L10396</ext-link>); GGT type II</td><td valign="top" align="left" rowspan="1" colspan="1">Inactive propeptide, 94% homologous to part of GGT1</td><td valign="top" align="left" rowspan="1" colspan="1">Low expression in glioblastoma multiforme</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGT3P</td><td valign="top" align="left" rowspan="1" colspan="1">Clone F11; GGT3</td><td valign="top" align="left" rowspan="1" colspan="1">Pseudogene</td><td valign="top" align="left" rowspan="1" colspan="1">Not reported</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGT4P</td><td valign="top" align="left" rowspan="1" colspan="1">Gene 12 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="L10398">L10398</ext-link>); clone F30</td><td valign="top" align="left" rowspan="1" colspan="1">Pseudogene</td><td valign="top" align="left" rowspan="1" colspan="1">Not reported</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGT5</td><td valign="top" align="left" rowspan="1" colspan="1">GGL, &#947;-glutamyl leukotrienase; GGTLA1/GGT-rel; GGT5 precursor; GGTLA1</td><td valign="top" align="left" rowspan="1" colspan="1">Functional protein, 40% homologous to GGT1, exhibits &lt;1/46 activity of GGT1 in hydrolyzing GSH, GSSG and leukotriene C4</td><td valign="top" align="left" rowspan="1" colspan="1">High expression of GGT5 is beneficial to the prognosis of hepatocellular carcinoma</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGT6</td><td valign="top" align="left" rowspan="1" colspan="1">Rat GGT6 homolog</td><td valign="top" align="left" rowspan="1" colspan="1">Not characterized</td><td valign="top" align="left" rowspan="1" colspan="1">Overexpressed in low-grade glioma</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGT7</td><td valign="top" align="left" rowspan="1" colspan="1">GGTL3, GGT4, GGTL5; GC20M032896</td><td valign="top" align="left" rowspan="1" colspan="1">Not characterized</td><td valign="top" align="left" rowspan="1" colspan="1">Low expression in gastric cancer; high expression may lead to poor overall survival in hepatocellular carcinoma; GGT7 polymorphic loci rs6119534 and rs11546155 are associated with risk of pancreatic disease</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGT8P</td><td valign="top" align="center" rowspan="1" colspan="1">/</td><td valign="top" align="left" rowspan="1" colspan="1">Pseudogene</td><td valign="top" align="left" rowspan="1" colspan="1">Not reported</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGTLC1</td><td valign="top" align="left" rowspan="1" colspan="1">GGTL6; GGTLA4; GGTLA4</td><td valign="top" align="left" rowspan="1" colspan="1">Encode only the light chain part of GGT</td><td valign="top" align="left" rowspan="1" colspan="1">Not reported</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGTLC2</td><td valign="top" align="left" rowspan="1" colspan="1">Gene 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="L10394">L10394</ext-link>); GGTL4; GGTL4</td><td valign="top" align="left" rowspan="1" colspan="1">Encode only the light chain part of GGT</td><td valign="top" align="left" rowspan="1" colspan="1">Not reported</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGTLC3</td><td valign="top" align="left" rowspan="1" colspan="1">&#947;-glutamyl transferase light chain 3; LOC728226</td><td valign="top" align="left" rowspan="1" colspan="1">May encode only the light chain of GGT</td><td valign="top" align="left" rowspan="1" colspan="1">Not reported</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGTLC4P</td><td valign="top" align="left" rowspan="1" colspan="1">&#947;-glutamyl transferase light chain 4 pseudogene</td><td valign="top" align="left" rowspan="1" colspan="1">Pseudogene</td><td valign="top" align="left" rowspan="1" colspan="1">Not reported</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GGTLC5P</td><td valign="top" align="left" rowspan="1" colspan="1">&#947;-glutamyl transferase light chain 5 pseudogene</td><td valign="top" align="left" rowspan="1" colspan="1">Pseudogene</td><td valign="top" align="left" rowspan="1" colspan="1">Not reported</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ijo-65-01-05660"><label>a</label><p>Heisterkamp <italic toggle="yes">et al</italic> (2008) combed a summary of the human &#947;-glutamyl transferase gene family (<xref rid="b27-ijo-65-01-05660" ref-type="bibr">27</xref>). GGT, &#947;-glutamyl transpeptidase; GGTLA, &#947;-glutamyl transferase-like activity.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tII-ijo-65-01-05660" orientation="portrait"><label>Table II</label><caption><p>Tumors with altered expression of GGT and ChaC1/ChaC2.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">First author/s (year)</th><th valign="top" align="center" rowspan="1" colspan="1">Tumor</th><th valign="top" align="center" rowspan="1" colspan="1">Expression</th><th valign="top" align="center" rowspan="1" colspan="1">(Refs.)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Chen, <italic toggle="yes">et al</italic>, 2023; Hayashima, <italic toggle="yes">et al</italic>, 2022; Chen, <italic toggle="yes">et al</italic>, 2017; Xu, <italic toggle="yes">et al</italic>, 2022</td><td valign="top" align="left" rowspan="1" colspan="1">Glioma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased ChaC1; increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b69-ijo-65-01-05660" ref-type="bibr">69</xref>,<xref rid="b85-ijo-65-01-05660" ref-type="bibr">85</xref>,<xref rid="b154-ijo-65-01-05660" ref-type="bibr">154</xref>,<xref rid="b180-ijo-65-01-05660" ref-type="bibr">180</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wen, <italic toggle="yes">et al</italic>, 2017</td><td valign="top" align="left" rowspan="1" colspan="1">Nasopharyngeal carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b181-ijo-65-01-05660" ref-type="bibr">181</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wang, <italic toggle="yes">et al</italic>, 2022; Mujawar, <italic toggle="yes">et al</italic>, 2020</td><td valign="top" align="left" rowspan="1" colspan="1">Oral squamous cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Decreased ChaC1; increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b140-ijo-65-01-05660" ref-type="bibr">140</xref>,<xref rid="b182-ijo-65-01-05660" ref-type="bibr">182</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mizushima, <italic toggle="yes">et al</italic>, 2016</td><td valign="top" align="left" rowspan="1" colspan="1">Head and neck squamous cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b183-ijo-65-01-05660" ref-type="bibr">183</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lee, <italic toggle="yes">et al</italic>, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">Laryngeal cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b184-ijo-65-01-05660" ref-type="bibr">184</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gu, <italic toggle="yes">et al</italic>, 2022</td><td valign="top" align="left" rowspan="1" colspan="1">Thyroid cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b185-ijo-65-01-05660" ref-type="bibr">185</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Foddis, <italic toggle="yes">et al</italic>, 2022</td><td valign="top" align="left" rowspan="1" colspan="1">Malignant pleural mesothelioma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b186-ijo-65-01-05660" ref-type="bibr">186</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Peng, <italic toggle="yes">et al</italic>, 2023; Lee, <italic toggle="yes">et al</italic>, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">Lung cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT and ChaC2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b81-ijo-65-01-05660" ref-type="bibr">81</xref>,<xref rid="b184-ijo-65-01-05660" ref-type="bibr">184</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Huang <italic toggle="yes">et al</italic>, 2017; Choi, <italic toggle="yes">et al</italic>, 2017</td><td valign="top" align="left" rowspan="1" colspan="1">Esophagus cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b187-ijo-65-01-05660" ref-type="bibr">187</xref>,<xref rid="b188-ijo-65-01-05660" ref-type="bibr">188</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tian, <italic toggle="yes">et al</italic>, 2021; Tian, <italic toggle="yes">et al</italic>, 2022</td><td valign="top" align="left" rowspan="1" colspan="1">Hepatocellular carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT and ChaC2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b32-ijo-65-01-05660" ref-type="bibr">32</xref>,<xref rid="b82-ijo-65-01-05660" ref-type="bibr">82</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chen, <italic toggle="yes">et al</italic>, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">Intrahepatic cholangiocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b189-ijo-65-01-05660" ref-type="bibr">189</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Catalano, <italic toggle="yes">et al</italic>, 2023; Liao, <italic toggle="yes">et al</italic>, 2023</td><td valign="top" align="left" rowspan="1" colspan="1">Pancreatic cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Increase GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b190-ijo-65-01-05660" ref-type="bibr">190</xref>,<xref rid="b191-ijo-65-01-05660" ref-type="bibr">191</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wu, <italic toggle="yes">et al</italic>, 2021; Zhang, <italic toggle="yes">et al</italic>, 2022; Tseng, <italic toggle="yes">et al</italic>, 2021; Liu, <italic toggle="yes">et al</italic>, 2017 Ogawa, <italic toggle="yes">et al</italic>, 2019; Hong, <italic toggle="yes">et al</italic>, 2021; Yang, <italic toggle="yes">et al</italic>, 2019</td><td valign="top" align="left" rowspan="1" colspan="1">Gastric cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Decreased ChaC1 and ChaC2; increased GGT and ChaC1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b62-ijo-65-01-05660" ref-type="bibr">62</xref>,<xref rid="b63-ijo-65-01-05660" ref-type="bibr">63</xref>,<xref rid="b71-ijo-65-01-05660" ref-type="bibr">71</xref>,<xref rid="b79-ijo-65-01-05660" ref-type="bibr">79</xref>, <xref rid="b131-ijo-65-01-05660" ref-type="bibr">131</xref>,<xref rid="b192-ijo-65-01-05660" ref-type="bibr">192</xref>,<xref rid="b193-ijo-65-01-05660" ref-type="bibr">193</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Xiao <italic toggle="yes">et al</italic>, 2022</td><td valign="top" align="left" rowspan="1" colspan="1">Stomach adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Decreased ChaC1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b72-ijo-65-01-05660" ref-type="bibr">72</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Liu, <italic toggle="yes">et al</italic>, 2017; Hong, <italic toggle="yes">et al</italic>, 2021; Hong, <italic toggle="yes">et al</italic>, 2020</td><td valign="top" align="left" rowspan="1" colspan="1">Colorectal cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Decreased ChaC2; increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b79-ijo-65-01-05660" ref-type="bibr">79</xref>,<xref rid="b192-ijo-65-01-05660" ref-type="bibr">192</xref>,<xref rid="b194-ijo-65-01-05660" ref-type="bibr">194</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Li <italic toggle="yes">et al</italic>, 2021; Yang, 2022; Horie, <italic toggle="yes">et al</italic>, 2020</td><td valign="top" align="left" rowspan="1" colspan="1">Renal clear cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Decreased ChaC1; increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b70-ijo-65-01-05660" ref-type="bibr">70</xref>,<xref rid="b195-ijo-65-01-05660" ref-type="bibr">195</xref>,<xref rid="b196-ijo-65-01-05660" ref-type="bibr">196</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nguyen, <italic toggle="yes">et al</italic>, 2019; Chand, <italic toggle="yes">et al</italic>, 2022; Mehta, <italic toggle="yes">et al</italic>, 2022; Goebel, <italic toggle="yes">et al</italic>, 2012; Mehta <italic toggle="yes">et al</italic>, 2022; Pankevi&#269;i&#363;t&#279;-Bukauskien&#279;, <italic toggle="yes">et al</italic>, 2023; Seol, <italic toggle="yes">et al</italic>, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">Breast cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT and ChaC1 and 2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b20-ijo-65-01-05660" ref-type="bibr">20</xref>,<xref rid="b50-ijo-65-01-05660" ref-type="bibr">50</xref>,<xref rid="b74-ijo-65-01-05660" ref-type="bibr">74</xref>, <xref rid="b77-ijo-65-01-05660" ref-type="bibr">77</xref>, <xref rid="b151-ijo-65-01-05660" ref-type="bibr">151</xref>,<xref rid="b197-ijo-65-01-05660" ref-type="bibr">197</xref>,<xref rid="b198-ijo-65-01-05660" ref-type="bibr">198</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Goebel <italic toggle="yes">et al</italic>, 2012; Shi1 <italic toggle="yes">et al</italic>, 2018</td><td valign="top" align="left" rowspan="1" colspan="1">Ovarian cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT and ChaC1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b77-ijo-65-01-05660" ref-type="bibr">77</xref>,<xref rid="b199-ijo-65-01-05660" ref-type="bibr">199</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Liu, <italic toggle="yes">et al</italic>, 2022</td><td valign="top" align="left" rowspan="1" colspan="1">Uterine corpus endometrial carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased ChaC1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b73-ijo-65-01-05660" ref-type="bibr">73</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Schwameis, <italic toggle="yes">et al</italic>, 2016</td><td valign="top" align="left" rowspan="1" colspan="1">Uterine leiomyosarcoma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b200-ijo-65-01-05660" ref-type="bibr">200</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Polterauer, <italic toggle="yes">et al</italic>, 2011</td><td valign="top" align="left" rowspan="1" colspan="1">Cervical cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b201-ijo-65-01-05660" ref-type="bibr">201</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">He, <italic toggle="yes">et al</italic>, 2021; Kawakami, <italic toggle="yes">et al</italic>, 2017</td><td valign="top" align="left" rowspan="1" colspan="1">Prostate cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Decreased ChaC1; increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b65-ijo-65-01-05660" ref-type="bibr">65</xref>,<xref rid="b202-ijo-65-01-05660" ref-type="bibr">202</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Su <italic toggle="yes">et al</italic>, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">Bladder cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b203-ijo-65-01-05660" ref-type="bibr">203</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Takemura, <italic toggle="yes">et al</italic>, 2019</td><td valign="top" align="left" rowspan="1" colspan="1">Urothelial carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased GGT</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b204-ijo-65-01-05660" ref-type="bibr">204</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Liu, <italic toggle="yes">et al</italic>, 2022</td><td valign="top" align="left" rowspan="1" colspan="1">Cutaneous melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased ChaC1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b76-ijo-65-01-05660" ref-type="bibr">76</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Liu, <italic toggle="yes">et al</italic>, 2019; Jin, <italic toggle="yes">et al</italic>, 2021;</td><td valign="top" align="left" rowspan="1" colspan="1">Uveal melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased ChaC1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b75-ijo-65-01-05660" ref-type="bibr">75</xref>,<xref rid="b150-ijo-65-01-05660" ref-type="bibr">150</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Song <italic toggle="yes">et al</italic>, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">Acute myeloid leukemia</td><td valign="top" align="left" rowspan="1" colspan="1">Decreased ChaC1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b205-ijo-65-01-05660" ref-type="bibr">205</xref>)</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-ijo-65-01-05660"><p>GGT, &#947;-glutamyl transpeptidase; ChaC1, glutathione-specific &#947;-glutamylcyclotransferase 1.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tIII-ijo-65-01-05660" orientation="portrait"><label>Table III</label><caption><p>List of the classical and promising therapeutics affecting GGT or ChaC1/ChaC2.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">First author (year)</th><th valign="top" align="left" rowspan="1" colspan="1">Functional category</th><th valign="top" align="left" rowspan="1" colspan="1">Therapy</th><th valign="top" align="left" rowspan="1" colspan="1">Source</th><th valign="top" align="left" rowspan="1" colspan="1">Mechanism/pathways</th><th valign="top" align="center" rowspan="1" colspan="1">(Refs.)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Lyons, <italic toggle="yes">et a</italic>l, 1990</td><td valign="top" align="left" rowspan="1" colspan="1">GGT inhibitor</td><td valign="top" align="left" rowspan="1" colspan="1">Glutamine analogues (acivicin, 6-diazo-5-oxo-norleucine and azaserine)</td><td valign="top" align="left" rowspan="1" colspan="1">Fermentation products of <italic toggle="yes">Streptomyces</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Glutamine analogs are competitive inhibitors that directly modify active site nucleophiles. Due to neurotoxicity, they are no longer used in the clinic</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b161-ijo-65-01-05660" ref-type="bibr">161</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Han, <italic toggle="yes">et al</italic>, 2007; Watanabe, <italic toggle="yes">et al</italic>, 2017</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">GGsTop</td><td valign="top" align="left" rowspan="1" colspan="1">Chemical synthesis</td><td valign="top" align="left" rowspan="1" colspan="1">A phosphonate-basedpotent, non-toxic, highly selective and irreversible GGT inhibitor. Human GGT recognizes the negative charge of GGsTop instead of the C-terminal carboxy group of glutathione by a positively charged critical residue located in the Cys-Gly binding site</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b206-ijo-65-01-05660" ref-type="bibr">206</xref>,<xref rid="b207-ijo-65-01-05660" ref-type="bibr">207</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">King, <italic toggle="yes">et al</italic>, 2009</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">OU749</td><td valign="top" align="left" rowspan="1" colspan="1">Chemical synthesis</td><td valign="top" align="left" rowspan="1" colspan="1">Species-specifically non-competitively inhibiting human GGT. OU749 binds to the covalent E-&#947;-glutamyl complex, the F form of the enzyme</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b208-ijo-65-01-05660" ref-type="bibr">208</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Azouz, <italic toggle="yes">et al</italic>, 2020</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Amlodipine</td><td valign="top" align="left" rowspan="1" colspan="1">Chemical synthesis; fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative</td><td valign="top" align="left" rowspan="1" colspan="1">Currently unclear</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b164-ijo-65-01-05660" ref-type="bibr">164</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Brancaccio, <italic toggle="yes">et al</italic>, 2019</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ovothiols</td><td valign="top" align="left" rowspan="1" colspan="1">Marine metazoans</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibit membrane-bound GGT of human cells non-competitively and reduce proliferation in GGT-positive cell lines with simultaneous occurrence of a non-protective/cytotoxic form of autophagy, indicating inhibition of GGT activity is likely involved in the modulation of autophagic mechanisms</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b105-ijo-65-01-05660" ref-type="bibr">105</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Joo, <italic toggle="yes">et al</italic>, 2012</td><td valign="top" align="left" rowspan="1" colspan="1">ChaC1 activator</td><td valign="top" align="left" rowspan="1" colspan="1">Nisin</td><td valign="top" align="left" rowspan="1" colspan="1">Bacterium <italic toggle="yes">Lactococcus lactis</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Currently unclear</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b68-ijo-65-01-05660" ref-type="bibr">68</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stevens, <italic toggle="yes">et al</italic>, 2019</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Atovaquone</td><td valign="top" align="left" rowspan="1" colspan="1">Chemical synthesis of hydroxynaphthoquinone or analog of ubiquinone</td><td valign="top" align="left" rowspan="1" colspan="1">Increased EIF2&#945;/ATF4/ChaC1 pathway activity</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b158-ijo-65-01-05660" ref-type="bibr">158</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tomonobu, <italic toggle="yes">et al</italic>, 2020</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Xylitol</td><td valign="top" align="left" rowspan="1" colspan="1">Fruits and vegetables</td><td valign="top" align="left" rowspan="1" colspan="1">Induction of CHAC1 by xylitol triggers endoplasmic reticulum stress</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b100-ijo-65-01-05660" ref-type="bibr">100</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wang, <italic toggle="yes">et al</italic>, 2019</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Artesunate</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Artemisia apiacea</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Increased EIF2&#945;/ATF4/ChaC1 pathway activity</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b67-ijo-65-01-05660" ref-type="bibr">67</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wang, <italic toggle="yes">et al</italic>, 2021</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Dihydroartemisinin</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Artemisia apiacea</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Increased EIF2&#945;/ATF4/ChaC1 pathway activity</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b66-ijo-65-01-05660" ref-type="bibr">66</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wang, <italic toggle="yes">et al</italic>, 2022</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Glaucocalyxin A</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Rabdosia japonica</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Increased EIF2&#945;/ATF4/ChaC1 pathway activity</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b140-ijo-65-01-05660" ref-type="bibr">140</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Guan, <italic toggle="yes">et al</italic>, 2020</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Tanshinone IIA</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Salvia miltiorrhiza Bunge</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Currently unclear</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b162-ijo-65-01-05660" ref-type="bibr">162</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chen, <italic toggle="yes">et al</italic>, 2021</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Omega-3 fatty acids docosahexaenoic acid or eicosapentaenoic acid</td><td valign="top" align="left" rowspan="1" colspan="1">Marine metazoans</td><td valign="top" align="left" rowspan="1" colspan="1">Increased EIF2&#945;/ATF4/ChaC1 pathway activity</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b138-ijo-65-01-05660" ref-type="bibr">138</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tseng, <italic toggle="yes">et al</italic>, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">Negatively regulating CHAC1 expression factor</td><td valign="top" align="left" rowspan="1" colspan="1">Metformin</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Galega officinalis</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Regulating the Loc100506691-miR-26a-5p-miR-330-5p-ChaC1 axis signaling induces cell cycle arrest in G2/M phase, inhibiting cancer cell proliferation</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b71-ijo-65-01-05660" ref-type="bibr">71</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Zhai <italic toggle="yes">et al</italic>, 2022</td><td valign="top" align="left" rowspan="1" colspan="1">ChaC2 activator</td><td valign="top" align="left" rowspan="1" colspan="1">Naringin</td><td valign="top" align="left" rowspan="1" colspan="1">Citrus fruit</td><td valign="top" align="left" rowspan="1" colspan="1">Upregulating CHAC2 via activation of the Nrf2 signaling pathway</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="b209-ijo-65-01-05660" ref-type="bibr">209</xref>)</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-ijo-65-01-05660"><p>GGT, &#947;-glutamyl transpeptidase; ChaC1, glutathione-specific &#947;-glutamylcyclotransferase 1; EIF2&#945;, eukaryotic initiation factor-2&#945;; ATF4, activating transcription factor 4; miR, microRNA; GGsTop, 2-amino-4-[(3-(carboxymethyl)phenoxy)(methoyl)phosphoryl]butanoic acid.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>